PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 3/4 RANDOMIZ ED, DOUBLE -BLIND, DO SE-RANGING STUDY OF THE 
SAFETY AND EFFICACY OF DEXMEDETOMIDINE ( DEX) USED WITH 
PROPOFOL (PRO) AS NE EDED FOR PROCEDURAL SEDATION OF PEDIATRI C 
SUBJECTS ≥1 MONTH TO <17 YEARS OF AGE UN DERGOING MRI SCANS
Investigation al Product Number: PF- 00914730
Investigational Product Name: Dexmedetomidine hy drochloride
United States (US) Investigational New 
Drug (IND) Number:32,934
European Clinical Trials Database 
(EudraCT) Number:N/A
Protocol Number: C0801039
Phase: 3 / 4
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or dis close it to others (except where required by applicable law ) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
prom ptly notified.
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Cha nges and 
Rationale
Original protocol 27 August 2019 Not applicable (N/A)
Amendment 1 21April 2020 General grammatical and 
formatting revisions & 
typographical error 
corrections
Protocol Summary  section: 
updated as appropriate to be 
consistent with the revis ions 
described below
Schedule of Activities (SOA) 
section: updated as 
appropriate to be consistent 
with the revisions described 
below .
Section
1.Introductio n: 
revised to provide
clarification around prop ofol 
appro valin the US vs Japan
.
Section 1.2.1. S tudy DEX 
10-16: revised to remove
trailing zeroes 
related to 
DEX dosing.
Section 1.2.2.2. Dose 
Selection: revised to: clarif y
that 
age cohort s are based on 
age on Day  1;remove
trailing zeroes related to 
DEX dosing .
Section 1.3.1.1. Safety  Data 
from Pedi a
tric ICU Sedation 
Studies: revised to remove 
trailing zeroes related to
DEX dosing .
Section 2.Study  Objectives 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 3and Endpoints: revised to: 
remove safet y endpo int for 
clinically  significant 
hemody namic changes from 
Basel ine; addsafety endpoint 
for time ou tside of the stable 
range for hemod ynamic 
parameters; clarif ythat 
incidences of listed adverse
even ts are for protocol -
specified events;add
paradoxical agitation reaction 
as a safety  endpoint .
Section 3. Study Design:
revised to provide allowance 
for Sc r
eening and Day  1 
Visit s tooccur o n different 
days.
Section 3.2 .Approximate 
Number of Subjects: revised 
to:remove the number of 
sites; clarif ythat age cohorts 
are based on age on Day  1.
Section 4.1 .Inclusion 
Criteria a t Screening :revised 
to: provide separate 
Screening and Day 1 
Inclusion Criteria ; clarif y
that age isbased on age on 
Day 1; require that ASA 
assessment is p erformed by
medic ally qualified personnel 
and reviewed b y PI;permit 
conditional use of a pre -
exist
ing IV forstudy  drug 
administrat ion.
Section 4.2. Inclusion 
Criteria on Day
 1: revised to 
addthis section to confirm 
subject continued to mee t 
Screening inclusion criteria .
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 4Section 4.3. Exclusion 
Criteria at Screening , revised 
to:separate the exclusion 
criteria into separate
Screening 
andDay 1 
Exclusion Criteria; modif y
weight c riterion for global 
details to be done at 
Screening; clarifynon-
interventional/observational 
procedures are permitted 
during MRI ; change 
“allergy ”to
“hypersensitivity ”to DEX ,
PROor components
;remove
the acu teMI exclusion ; add 
medication asa factor that 
may increase su bject risk .
Section 4.4 .Exclusion 
Criteria on Day
 1: revisedto 
add this section and move 
selected Screening exclusion 
criteria here .
Section 5.1. Allocation to 
Treatment: revised to add
DEX total loading dose in 
mLs to the unblinded IRT 
confirmation report.
Section 5.4.2 . Preparation 
and Dispensing: revised to 
clarify thestudy  drug 
preparation and dispensation 
responsibilities ofthe
unblinded site pharmacist .
Section 5.5. Investigational 
P
roduct Administration: 
revised to
:remove the
requirement for a new IV to 
be placed; clarif yage cohorts 
are based on age on Day  1; 
remov etrailing zeroes f rom 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 5the dosing tables .
Section 5.6. Rescue Propofol 
Medication: revised to
: 
clarify the propofol 
maintenance dosing 
requirements; provide
clarification around propofol 
approval in the US vs Japan.
Secti on 5.10.2. Permitted 
Concomitant Treatments: 
revised to c larifygas 
induction procedure
requirements .
Section 5.10.3. Prohibited 
Concomitant Treatments: 
r
evised to: clarif yother 
alpha-2 agonist/antagonist 
use; clarify 
interventional/ non-
interventional/observational 
procedures during scan and 
post-scan recovery .
Section 6.1. Screening: 
revised to: provide separate 
Screening Visit
requirements ; allow 12- lead
ECG to b
eperform ed in lieu 
of rh ythm strip ; remove 
pregn ancy  test from 
Screening .
Section 6.2. Day 1 Period 1 
(MRI  scan): 
revised to: 
separate Day 1 assessments 
intopre-and post -
random ization timeframes; 
addcaveat regarding weigh t 
and temperature if 
Screening/Day  1 are the 
sameday; allow for urine or 
whole- blood pr egnancy  test; 
clarify  Baseline values are 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 6those obtained within
approximately  5 minutes 
before the DEX loading 
dose; 
remove requirement for 
placement of a new IV.
Section 6.3. Day 1 Period 2
(Post-MRI  Recovery ): 
revised to: clarify  Baseline 
values are th ose obtained 
within approximately  5 
minutes before the DEX 
loading dose ;remove the 
PSSS as sessments from this 
period; 
modifythe PAED
collecti on timepoint
requirements .
Section 6.5. Subject
W
ithdrawal/ Early  
Termination :  revised to add
a discontinuation
requirement for subjects who 
have a medical procedure 
performed during the MRI  
scan.
Section 6.5.1. Adverse 
Events Requiring Subject 
Withdrawal 
from Treatment: 
revised to add
discontinuation requirement 
for subjects who have a 
medical procedure performed 
during the MRI scan.
Secti on 7. Assessments: 
revised to: add“as 
appropriate” to assent 
collection; remove
requirement for placement of 
a new IV; allow for urine or 
whole- blood pregnancy  test; 
clarify the 12- lead ECG and 
blood pressure at Screening
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 7requirements .
Section 7.1. Pregnancy  
Testi ng: revised to clarify
that 
urine or whole blood 
pregnancy test will be done 
on Day  1.
Section 8.4.1.1. Changes in 
Blood Pressure and He art 
Rate: revised to cla
rify 
Baseline values are th ose 
obtained 
within
approximately  5 minutes 
before the DEX loading 
dose.
Secti on 8.5. Medical De vice 
Complaint Reporting 
Requirements: re vised 
to 
limit medical device 
reporting to sites in Japan
using propofol pre -filled 
syringe s.
Section 9.1. Sample Size 
Determin
ation: re vised to
remove trailing zeroes 
related to DEX d osing.
Section 9.2.5. Japanese 
P
opula tion Set: revised to 
adda new anal ysis 
population set for Japanese 
subjec ts.
Section 9.5 .Safety  Analy sis: 
revised to:clarif yBaseline 
values are th ose obtained 
within approximately  5 
minutes before the DEX 
loading dose ;add 
paradoxical agitat ion reaction
and 
clarif y text regarding
protocol -specified adverse 
events summarized for each 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 8age cohort and each dose 
level ; remove textregarding 
separate tabulations of 
specific AEs .
Appendix 1. Abbreviations: 
revised to update per 
protocol text revisions.
Appen dix 4. Modified 
Aldrete Score: revised to add
reference.
Appendix 5. Pediatric 
Anesthesia Emergence 
Delirium Scal e(PAED): 
revised toaddreference .
Appendix 6. Pediatric 
Sedation State Scale (P SSS): 
revised to addreference .
Appendix 9. Propofol Pre -
filled Syringe Medical 
Device Reporting in Japan; 
revised to addappendix.
Amendment 2 11March 2021 Protocol Summary  section: 
updated as appropriate to be 
consistent with the rev isions 
described below .
Schedule of Activities:
updated as appropriate to be 
consistent with the revisions 
described below .
Section 1. I ntroduction: 
revised to remove text 
identify ing th eUS and Japan 
as part icipating countri es; 
clarify  PRO is not approved
for procedural s
edation inthe 
pediatric population and is
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 9investigational in this st udy.
Section 1.4 Safety  Summary : 
updated the SRSD language
and clarif iedthat the 
propo folUSPImay be 
referenced for a dditional 
safet y information a nd 
countries may also reference 
their local package insert for 
country -specific information.
Section 2 Study  Objectives
and Endpoints: revis edthe 
primary  efficacy  endpoint to
clarifythe comparis on is in 
the combined age coho rts;
corrected the safet y endp oint
to include subjects who 
require intervention to 
complete the MRI ;changed 
the pr otocol -specified AE
term 
“systolic hy potension ”
to “hypotension”.
Section 3.2 App roximate 
Number of Subjects: revised 
toremove text identify ing
participating countries .
Section 4.3 Exclusion 
Criteria at Scr eening :
modified excl usion criterion 
#2to clarify that medications 
orvaccine sapproved for 
emergency  authorizati on are
notconsidered 
investigational and arenot
included in th e
30-day 
restriction
; revised exclusion
criterion #2 2to include ECG 
findings diagnostic of AV 
conduction block or 
sustained cardiac arrh ythmia ; 
eliminated “acute febrile 
illness ”from exclusion
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 10criterion #26to limit the
exclusion to fever .
Section 5.6 Rescue Propofol 
Medications: clarif ied
requir ements for propofol 
bolus dosing and 
maintenance dose increases
and decrease s; clarify  PRO is 
not approved fo
r procedural 
sedation in the pediatric 
population andis
investigational in this st udy.
Section 5.10 Concomitant 
Treatments: revised to
extend collection of
concomitant treatments 
through the Day  29 Lon
g-
term Follow -
upVisit.
Section 5.10.1 Required 
Treatments
: revise dthe 
maintenance IVfluid 
requirements to require a
minimum mL/hrrate pe r
formula but also permittin g a
maximum rate of 100 mL/hr .
Section 6.2 Day  1 Period 1 
(MRI  scan): added 
c
larification that serum 
qualit ative or quantitati ve 
hCG preg nancy  testsarenot 
permitted ; clarified vital 
signscollection and
timepoint capture .
Section 6.3 Day 1 Period 2 
(Post -
MRI Recover y): 
clarified vital signs collection 
andtimepoin tcapture .
Section 6.4.2 Day  29 Long -
term Foll ow-up Visit: added
collection of concomitant 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 11treatments .
Secti on 6.5.1 Adverse Ev ents
Requiring S ubject 
Withdrawa l from 
Treatmen t: 
changed t he AE te rm
“systolic hy potens ion”to
“hypotension”.
Section 7 Assessm ents: 
revised to extend collection 
of concomit ant treatments
through the Day  29 Long-
term Follow -
upVisit ; added 
clarification thatserum 
qualitative or quantitati ve 
hCG pregnancy  testsarenot 
permitted;clarif ied
requirem entfor 12 -lead E CG 
vs rhy thm str i
pinclud ing 
chan gessuggestive of AV 
conducti on block or 
sustained cardiac arrh ythmia ;
addedinstruction on
rounding height/weight 
values to 1 dec imal plac e; 
clarifiedBP cuff size must be 
appropr i ate forarm or leg
girth .
Section 7.1 Pregnancy  
Testing: added clarifi cation 
that serum qualitative or 
quanti tativehCG pregnancy  
testsarenot perm itted.
Section 8.1 Requirements: 
updated the requirem entsfor 
recording saf etyevents on 
the CRF to be consi stent with 
the current Pfizer protocol 
template.
Section 8.1.4 Time Period for
Collecting AE/SAE
Information: added 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 12concomitant t reatment data 
to be collected at the Day 29 
Long-term Follow -up vis it.
Section 8.4.1.1 Changes in 
Blood Pressure and Heart 
Rate: clarified text to sp ecify
AE criter iarefer to
measureme nts exceeding the 
specified limits within the 
indicated time p eriods ;
clarified brad ycardia AE
definition based on 2
consecuti ve measurements at 
least 
1minute apart to ensure
a minimum duration of 
decreased HR ;changed the 
AE term 
“systolic 
hypotension” to 
“hypotension ”; clarified 
hypotension AE definition 
based on 2 consecutive 
measurement s at least 5 
minutes 
apart to ensure a 
minimum duration of 
decreased SBP and/or 
require sintervent ion;
clarified h ypertension AE
definitio n based on 
measurements at leas
t 5 
minutes apar t.
Section 8.4.1.3 Changes in 
Respiratory  Rate, EtC O2and 
SpO 2:
clarified brad ypnea
AEdefin
ition based on 
measurements at least 1
minutes apar t.
Section 8.4.5.1: Medication 
Err
ors: modified the sponsor 
notification timeframe 
requirement to 24 hours.
Section 9.3.3 Ana lysis of 
Other Secondary  Endpoin ts:
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 13added text when censored
time would be used to calculate emergence time.
 
 
Section 9.5 Safety Analysis: 
corrected the safety endpointto include subjects who require intervention to complete the MRI; changed the AE term “systolichypotension” to “hypotension”.
Appendix 5: Pediatric
Anesthesia Emergence Delirium Scale (PAED): additional reference added.
General grammatical and 
formatting revisions & typographical error corrections.CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 14TABLE OF CONTENTS
LIST OF TABLES ...................................................................................................................18
LIST OF FIGURES .................................................................................................................18
APPENDI CES .........................................................................................................................19
PROTOCOL  SUMMARY .......................................................................................................20
SCHEDUL E OF ACTIVITI ES................................................................................................29
1.INTRODUCTION ...............................................................................................................33
1.1.Mechanism of Action and Indication ......................................................................33
1.2.Approval History  and PREA ...................................................................................33
1.2.1. Study  DEX 10
-16 .......................................................................................34
1.2.1.1. S tudy DEX 10- 16 Study  Results ...............................................35
1.2.2.
DEX Expert Advisory Committee ..............................................................35
1.2.2.1. Imaging Procedures ...................................................................36
1.2.2.2. Dose Selection ...........................................................................36
1.2.2.3. Concomitant Sedative Drugs .....................................................39
1.2.2.4. Summary  of Study  Design ........................................................39
1.3.Safet y Data ..............................................................................................................39
1.3.1. Clinical Trial Safety Data Base ..................................................................39
1.3.1.1. Safet y Data from Pediatric I CU Sedation Studies .................... 39
1.3.1.2. Safet y Data from Pediatric Procedural Sedation Study  
DEX 10 -16.........................................................................................41
1.4.Safet y Summary ................................ ................................ ................................ ......42
2.STUDY OBJECTIVES AN D ENDPOINTS .......................................................................43
3.STUDY DESIGN ................................ ................................ ................................ ................. 44
3.1.Approximate Duration of Subject Participation ......................................................45
3.2.Approximate Number of Subjects ...........................................................................45
4.SUBJECT ELIGIBILITY CRITERIA .................................................................................46
4.1.Inclusion Criteria at Screening ................................................................................47
4.2.Inclusion Crite ria on Day  1
.....................................................................................48
4.3.Exclusion Criteria at Screening ...............................................................................48
4.4.Exclusion Criteria on Day  1
....................................................................................51
4.5.Lifesty le Requirements ...........................................................................................51
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 154.5.1. Contraception ..............................................................................................51
4.6.Sponsor’s Qualified Medical Personnel ..................................................................52
5.STUDY TREATME NTS .....................................................................................................53
5.1.
Allocation to Treatment ..........................................................................................53
5.2.Breaking the Blind ..................................................................................................54
5.3.
Subject Compliance .................................................................................................54
5.4.Investigational Product Supplies .............................................................................54
5.4.1. Dosage Form(s) and Packaging ..................................................................54
5.4.2. Preparation and Dispensing ........................................................................55
5.5.Investigational Product Administration ..................................................................55
5.6.Rescue Pro
pofol Medication ...................................................................................56
5.7.Investi
gational Product Storage ..............................................................................57
5.8.Investigational Product Accountabilit y
...................................................................58
5.8.1.
Destruction of Investigational Product Supplies ........................................58
5.9.Prior Treatments ......................................................................................................58
5.10. Concom itant Treatments .......................................................................................58
5.10.1. Required Treatments .................................................................................58
5.10.2. Permitted Concomitant Treatments ..........................................................59
5.10.3.
Prohibited Concomitant Treatments.........................................................59
6.
STUDY PROCEDURES .....................................................................................................60
6.1.Screening .................................................................................................................60
6.1.1. Screen Fail Subject .....................................................................................62
6.2.Day 1 Period 1 (MRI scan)
.....................................................................................62
6.3.Day 1 Period 2 (Post
-MRI Recovery ) .....................................................................64
6.4.Follow -
up ................................................................................................................65
6.4.1. Day 2 Follow -
up .........................................................................................65
6.4.2. Day 29 Long -term Follow -
up.....................................................................65
6.5.Subject Withdrawal / Early  Termination ................................................................66
6.5.1.
Adverse Events Requiring Subject Withdrawal from Tr eatment ...............67
6.5.2. Adverse Events Requiring Assessment for Subject Withdrawal from 
Treatment .........................................................................................................68
7.
ASSESSMENTS ................................ ................................ ................................ .................. 68
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 167.1.Pregnancy  Testing ...................................................................................................72
7.2.Rater Qualifications .................................................................................................72
8.ADVERSE EVENT REPOR TING......................................................................................72
8.1.Requirements ...........................................................................................................72
8.1.1.
Additional Details On Recording Adverse Events on the CRF..................74
8.1.2. Eliciting Adverse Event Information ..........................................................74
8.1.3. Withdrawal From the Study  Due to Adverse Events (see also the 
Subject W ithdrawal / Early  Termination section) ...........................................74
8.1.4.
Time Period for Collecting AE/SAE Information......................................74
8.1.4.1. Reporting SAEs to Pfizer Safety ...............................................75
8.1.4.2. Recording Non
-serious AEs and SAEs on the CRF .................75
8.1.5. Causality  Assessment .................................................................................75
8.1.6.
Sponsor’s Reporting Requirements to Regulatory  Authorities ..................75
8.2.
Definitions...............................................................................................................76
8.2.1. Adverse Events ...........................................................................................76
8.2.2. Abnormal Test Findings .............................................................................76
8.2.3. Serious Adverse Events ..............................................................................77
8.2.4. Hospitalization ............................................................................................78
8.3.Severity  Assessment ................................................................................................79
8.4.Special Situations ....................................................................................................80
8.4.1. Protocol -
Specified Adverse Eve nts............................................................80
8.4.1.1.
Changes in Blood Pressure and Heart Rate...............................80
8.4.1.2.
Paradoxical Agitation Reactions ...............................................82
8.4.1.3. Changes in Respiratory  Rate, EtCO 2and SpO 2........................82
8.4.2. Protocol -
Specified Serious Adverse Events ...............................................83
8.4.3. Potential Cases of Drug -
Induced Liver Injury................................ ............ 83
8.4.4. Exposure to the I nvestigational Product During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................85
8.4.4.1. Exposure During Pregnancy ......................................................85
8.4.4.2. Exposure During Breastfeeding ................................................87
8.4.4.3. Occupational Exposure .............................................................87
8.4.5. Medication Errors .......................................................................................87
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 178.4.5.1. Medication Errors......................................................................87
8.5. Medical Device Complaint Reporting Requirements .............................................88
9. DATA ANALYSIS/STAT ISTICAL METHODS...............................................................88
9.1. Sample Size Determination.....................................................................................889.2. Analysis Populations ...............................................................................................89
9.2.1. Safety Analysis Set.....................................................................................899.2.2. Full Analysis Set (FAS)..............................................................................899.2.3. Efficacy Evaluable Population (EEP).........................................................89
9.2.4. Per Protocol Population (PPP)....................................................................909.2.5. Japanese Population Set (JPS)....................................................................90
9.3. Efficacy Analysis ....................................................................................................90
9.3.1. Analysis of the Primary Endpoint...............................................................909.3.2. Analysis of the Ke y Secondary  Endpoint...................................................90
9.3.3. Analysis of Other Secondary Endpoints.....................................................90
9.5. Safety Analysis........................................................................................................91
9.6. Interim Analysis ......................................................................................................929.7. Data Monitoring Committee ...................................................................................92
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................9311. DATA HANDLING AND RECORD KEEPING .............................................................93
11.1. Case Report Forms/Electronic Data Record .........................................................9311.2. Record Retention...................................................................................................94
12. ETHICS...................................................................................................................... ........94
12.1. Institutional Review Board/Ethics Committee......................................................9412.2. Ethical Conduct of the Study ................................................................................9512.3. Subject Information and Consent..........................................................................9512.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................9 6
13. DEFINITION OF END OF TRIAL...................................................................................9714. SPONSOR DISCONTI NUATION CRITERIA ................................................................97
15. PUBLICATION OF STUDY RESULTS ..........................................................................97CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 1815.1. Communication of Results by  Pfizer ....................................................................97
15.2. Publications by  Investigators ................................................................................98
16.REFERENCES ................................................................................................................100
LIST OF TABLES
Table 1. Report ed DEX PK Parameters in Pediatric ICU Patients and Pediatric 
Procedural Sedation Patients
..............................................................................107
Table 2. Demographic s of Input Dataset by  Age Group ..................................................108
Table 3. Dose levels for Subjects >2 years of age ............................................................108
Table 4
.Dose level s for Subjects ≥1 month to ≤2 years of age ........................................108
Table 5. Dexmedetomidine PK Parameters for Simulated Data by  Dose and Age 
Group
..................................................................................................................112
LIST OF FIGURES
Figure 1 .
Simulated Plasma Dexmedetomidine Concentration vs Time Profiles in 
Different Age Groups following Low Dose Infusion .........................................109
Figure 2. Simulated Plasma Dexmedetomidine Concentration vs Time Profiles in 
Different Age Groups following Me
dium Dose Infusion...................................110
Figure 3. Simulated Plasma Dexmedetomidine Concentration vs Time Profiles in 
Different Age Groups following High Dose Infusion ........................................111
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 19APPENDICES
Appendix 1. Abbreviations ....................................................................................................103Appendix 2. Simulated Pharmacokinetic Profiles of Dexmedetomidine in Pediatric 
Subjects Undergoing Procedural Sedation .........................................................106
Appendix 4. Modified Aldrete Score.....................................................................................114
Appendix 5. Pediatric Anesthesia Emergence Delirium Scale (PAED)................................115Appendix 6. Pediatric Sedation State Scale (PSSS) ..............................................................116Appendix 7. HR and RR Centile Chart Cut-offs for Children from Birth to 18 Years of 
Age......................................................................................................................117
Appendix 8. Normal Vital Signs According to Age..............................................................118Appendix 9. Propofol Pre-filled Syringe Medical Device Reporting in Japan......................119CCI
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 20PROTOCOL SUMMARY
Background & Rationale
Dexmedetomidine (DEX) is a highly selective α2-adrenergic agonist that is being 
investigated for use in procedural sedation in pediatric subjects undergoing magnetic resonance imaging (MRI) requiring moderate to  deep sedation.  DEX is currently approved 
for sedation of initially intubated and mechanically ventilated adults during treatment in an intensive care setting and for procedural sedation of adults.
The present study is being conducted by Pfizer, Inc under the Pediatric Research Equity Act 
(PREA) and is a Phase 3/4 randomized, double-blind, dose-ranging study of the safety and efficacy of DEX used with propofol (PRO) for procedural sedation of pediatric subjects ≥1 month to <17 years of age undergoing MRI scans.
Objectives
•The primary efficacy objective is to assess the efficacy of DEX for pediatric 
procedural sedation as measured by the percent of subjects at the high dose level versus the low dose level in the combined age cohorts who do not require concomitant PRO to achieve adequate sedation.
•The key secondary objective is to assess the efficacy of DEX for pediatric procedural 
sedation as measured by the percent of subjects at the high dose level versus the low dose level in each age cohort who do not require concomitant PRO to achieve adequate sedation.
•Other secondary efficacy objectives include:
•Explore the efficacy of DEX at the middle dose level compared to the high dose 
level and the low dose level in both the overall sample and in each age cohort as measured by the percent of subjects who do not require concomitant PRO to achieve adequate sedation.
•Explore the efficacy of DEX by examining the percent of time at the target 
sedation score, time to first PRO use, emergence time from sedation, proportion 
of subjects at each dose level receiving PRO and amount of PRO required.
 
C
C
I
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 21•The safety objective is to assess the safety of DEX used for procedural sedation of 
pediatric subjects undergoing an MRI scan.
Endpoints
•Primary Efficacy: Percent of sub jects at the DEX high dose level versus the low dose 
level in the combined age cohorts who do not require concomitant PRO to complete the MRI.
•Key Secondary Efficacy: Percent of subjects at the DEX high dose level versus the 
low dose level in each age cohort who do not require concomitant PRO to complete the MRI.
•Secondary Efficacy: 
•Percent of subjects at the DEX middle dose level compared to the high dose level 
and the low dose level in both the overall sample and in each age cohort who do not require concomitant PRO to complete the MRI.
•Percent of time at the target sedation rating scale score (Pediatric Sedation State 
Scale [PSSS] rating of 2) after the administration of the DEX loading dose and during the DEX maintenance infusion. 
•The amount of time from the start of the DEX loading dose infusion to the time of 
the first PRO bolus administration.
•Emergence time (defined as the time from the end of the MRI scan to when the 
subject meets a Modified Aldrete Score ≥9).
•The proportion of subjects at each dose level who receive PRO.
•Total amount (mg/kg) and weight and time adjusted amount (per kg per minute 
basis) of concomitant PRO required to successfully complete the MRI scan.
 
•Safety:
•Incidence, seriousness, causality and severity of treatment-emergent adverse 
events.C
CI
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 22Percent of subjects who complete dthe MRI  scan and re quire dartificial 
ventilation or interventio n to restore baseline or normal hemody namic status .
Mean change from baselin
e in sy stolic blood pressure (SBP) , diastoli c blood 
pressure (DBP), mean arterial pressure (MAP), heart rate (HR ) and re spirator y 
rate(RR).
Time outside of the stable range for he mody namic paramet ers of SBP and HR.
Incidence of protocol -specified respirat ory adverse events of brad ypnea, h ypoxia 
andapnea.
Incidence of protocol -
specified cardiac adver se events of hypotensi on, 
hypertension and brady cardia.
Incidence of protocol -speci fied adv
erse event of paradoxical agitation reaction.
Incidence of protocol -specified adverse ev ents of brady pnea, h ypoxia, apnea, 
hypotension, hy pertensio n,bradycardia and para doxical agitat ion reaction 
requiring intervention.
Incidence of DEX withdrawal -related adverse events after discontinuation of 
DEX infus ion.
Study Design
This is a random ized, double -blind, dose -ranging study  of the efficacy  and safe ty of DEX
when used wit h PRO as neede d, for procedural sedation of pediatric subjects ≥1 month to 
<17years of age undergoing MRI scans .  The sponsor, subject and i nvestigat or wil l be
blinded to the dose of DEX.
This study  include s a Screening, Day 1, Day  2 Follow -upand D ay 29 Long -term Foll ow-up 
Visit.  The Day  1 Visit is comprised of a Period 1 (MRI  scan) Phase and Period 2 (Po st-MRI  
Recov ery) Phase.  The Day  2 Visit is a 24-hour Fo llow-up, and the Day  29 V isitis a 28 -day 
Follow-up. 
A sufficient number o f subjec ts wil l be screened to ran domize approximately  120 subjects 
(40 subjects per dose level):
Age Cohort Low Dose Group Middle Dose Gro up High Dose Group
≥1 month to <2 years 20 20 20
≥2 years to <17 years 20 20 20
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 23All eligible subjects will receive double -blind treatment where one of 3 dose levels of DEX 
will be administered.  Following completion of required procedur esbefore randomization at 
the Day  1Visit , subjects meeting entry  criteria will be randomly  assigned to a L ow, Middle 
or High dose level group (actual dose dependent on age) in a 1:1:1 ratio.  
Treatment will be initiated just prior to the start of the MRI  scan a nd wi ll continue during 
Period 1 (M RI scan). Subjects will first receive a DEX loading dose administered over 
10
minutes.  Following completion of the loading dose, the maintenance infusion of DEX 
will be started. The subject’s level of sedation will be asses sed using the PSSS a t 5-minute
intervals throughout the drug infusion.  If an adequate level of sedation is not achieved as 
assessed b y the investigator (eg, if the subject moves) within 5 minutes after the DEX 
maintenance infusion ha s been started, c oncom itant PRO may  be giv
en to ensu re that an
adequate sedation level is achieved and maintained for completion of the scan.  Sedation with 
DEX and if required, concomitant PRO, shall continue through completion of the MRI  scan, 
to maintai n the subject at an ad equate sedation leve l per principal investigator (PI)
clinical 
judgment.  The target sedation level is indic ated by a PSSS score of 2.  Subjects will also be 
administered supplemental intravenous (IV) fluids throughout the DEX infusio n at a 
maintenance rat eper Sectio n 5.10.1 Required Treatments.  The use, t ype and rate of 
maintenance fluid administration following discontinuation of the DEX infusion will be at 
site discreti on.
The investigationa
lproduct infusion(s) s hould not be discontin ued until confirmati on that the 
MRI  is complete has been received and DEX must be discontinued prior to the subject being 
transferred to the post -procedural recovery  area.  Period 2 (post -MRI recovery ) begins at the 
conclusion of t he MRI scan.
Investigational Produc t Administ ration
The study  will be conducted using the manufactured strength of DEX 200 mcg/2 mL, diluted 
to a concentration directed by  the Investigational Product Manual (I P Man ual) based on each 
subje ct’s treatment group assignment.
Subjects e nrolled in to the study  will be randomized to receive one of three DEX dosing 
regimens (Low, Middle, or High), each consisting of an IV loading dose that is immediately  
followed b y an IV mai ntenance infusion that will continue for t he duration of the MRI  scan.
The loading and maintenance infusion doses will be given at the stable, pre -defined doses as 
described below and may not be modified, but the infusion may  be discontinued if clinicall y 
indicated.  The loadin gdose will be admin istered over 10 minutes:
Blinded dose levels for subjects ≥1 month to <2 years of age on Day  1:
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose level 0.5 mcg/kg 0.5 mcg/kg/hour
Middle dose leve l 1mcg/kg 1mcg/kg/hour
High dose le vel 1.5mcg/kg 1.5 mcg/kg /hour
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 24Blinded dose levels for subjects ≥2 y ears to <17 years of age on Day  1:
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose level 0.5 mcg/kg 0.5 mcg/kg/hour
Middle dose level 1.2 mcg/kg 1mcg/kg/hour
High dose le vel 2mcg/kg 1.5 mcg/kg/h our
Rescu e Propofol Administration
Once the DEX loading dose has been administered and the maintenance dose started, if an 
adequate level of sedation is not achieved within 5 mi nutes after the start o fthe D EX 
maintenanc e infusion, concomitant P RO may  be given per clinical judgment to ensure that an 
adequate level of sedation is achieved to start the scan.  The target sedation level is indicated 
by a PSSS score of 2. 
Concomitant PRO should be administ ered as needed throu gh complet ion of the scan to 
mainta in adequat e subject sedation per PI clinical jud gment.  If it is needed, concomitant 
PRO should be administered first as a bolus of 0.5 mg/kg (500 mcg/kg) over approximately  
1minute followed by  the sta rt of a PRO mainten ance infus ion at 50 mcg/k g/min.  Additional 
bolus doses of PRO 0.5 mg/kg may  be giv en as needed for subject movement/wakening .  
Following each additional PRO bolus, there must be asimultaneous increase in the PRO 
maintenance infusion ra te in a 25 or 50 mcg/kg /min i ncrement .  However, s ubsequent 
increase sin the PRO ma intena nce infusion rate may  bemade in 25or 50 mcg/kg /min 
increments without a corresponding PRO bolus .  The PRO m a intenance infusion may also b e 
decreased in 25 or 50 mc g/kg/min increments as neede d to maintain adequate subject 
sedation, or it may  be discontinued if clinicall y indicated.   
PRO is not approved for procedural sedation inthe pediatric population ,so in this study  the 
use of PRO is considered investigational .
Statistical Methods: 
Sample Size
The primary  comparison will be the percent of subjects who do not r equire supple mental 
PRO in the hi gh dose group vs. the low dose gr oup i n both age cohorts combined.  The 
younger age cohort will be comprised of subjects aged ≥ 1 month to <2 y ears of age and the 
older age cohort will include subjects ≥2 to <17 years of age .  The primar y efficacy analysis 
population is the Full Analy sis Set (F AS) defined as all randomized subjects who receive any  
amount of DEX, and for the primar y and key  secondary  anal yses, subjects who do not 
complete the MR I scan will be consi dered failur es, ie, will be counted as receiving 
supplemental PRO.  Assuming that the percent of subjects not requiring PRO are 15% and 
60% in the low and high dose groups respectivel y, a sample s ize of 40 per dos e group would 
provide a 99% power for a 2-s ided test wi th alpha=0.05.  The key secondary comparison is 
the percent of subjects who do not require supplemental PRO in each of the 2 age cohorts.  
Assuming that the pe rcentage of subjects not requiring supplem ental PRO in the older a ge 
cohort is 17% an d 63% for th e low and hig h dose gro ups respec tively , and the percent of 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 25subjects not requiring PRO in the y ounger age cohort is 13% and 57% for the low and high 
dose group s respectivel y, and assu ming that equal nu mber of subjects will b eenrolled in 
each a ge cohort, t he power = 87 % for the older age cohort and 86% for the younger age 
cohort.  Within the older age cohort, it is planned to enroll approximately  4subjects per dose 
group for subjects ≥ 12 to <17 y ears of age, since it is expected that these subj ects would 
require minimum sedation .  Fort y subjects will be enrolled per each dose level, and 
20subjects for each dose group for age cohorts ≥1 month to <2 y earsand ≥2 years to 
<17years.
Anal ysis Populations:
Safety Analysis Set
The safet y analysis set consists of all randomiz ed subject s who rece ived any amount of DEX.  
Participants will be anal yzed according to the intervention they received.  In the event a 
subject re ceives a loading and/or maintenance dose that is different from the dose group to 
which they  were randomized, the subjec t will be analy zed in the dose level group that 
corresponds to the lowest dose received .  All safety  analy ses will be performed on the s afety 
analysis set.
Full Analysis Set (FAS)
All randomized subjects who receive an y amount of DEX will form the FAS.  Participants
will be anal yzed according to the intervention to which they  were randomized.  This will be 
the primary  population for effica cy anal ysis.
Efficacy Ev aluable Population (EEP)
All randomized s ubjects who receive an y amount of DEX and complete the MRI  scan w ill 
form the EEP.
Per Protocol Population (PPP)
All subjects included in the FAS and have no major protocol deviations will form the PPP.  
The details of the major protocol violation criteria will be documented in a separat e 
document pr ior to the end of the study .
Japanese Popu lation Set (JPS)
All randomized Japanese subjects who receive any amount of DEX will form th e JPS .  The
JPS will be used for ef ficacy  endpoints, demographic and baseline characteristic and safet y 
endpo ints.  Participants wil l be ana lyzed according to t he intervention to which they  are 
randomized for efficacy  and will be anal yzed according to the intervention they receive for 
safet y
.
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 26Endpoint Analyses :
Primary Efficacy Endpoint Analysis
The DEX high vs low dose group will be compared by Mantel -Haenszel tes t, and by  
calculating the odds ratio and 95% confidence intervals on the percent of subjects not 
requirin g supplemental PRO.  A llage cohorts will be combined.  The primary  anal ysis will 
be performed ba sed on the FAS.  The sa me analy sis will be repeated onthe EEP and PPP.
Analysis of Key Secondary Efficacy Endpoint
The method of analy sis for the primary  endp oint will be repeated fo rthe key  secondary  
endpoint for each age cohort based on the FAS.  The s ame anal ysis will be re peated on the 
EEP and PPP.
Anal
yses of Other Secondary Efficacy Endpoints
The method of analy sis for the primary  endpoint will be repeat ed for the secondary  endpoints 
comparing the low dose to the medium dose and the medi um dose to t he high dose, overall 
and withi n each age cohort ba sedon the FAS, EEP and PPP. 
The total amount and the weight and time adjusted amount (per kg per minute) 
of PRO use 
will be summ arized for each dose group with descriptive statistics (N, mean , standard 
deviation [SD], median, minimum, Q1, Q3, and maximum ). The weight -and time -adjusted 
difference between treatment groups (high dose and low dose, and medium do se and low 
dose and hi ghdose versus medium dose) will be assessed using two -way anal ysis of vari ance 
(ANOVA) when assum ption of normal distribution isreasonable or b
y nonparametric tests 
when this assumption is not met.  
Emergence time (defined as the time from the end of th e MRI scan to when the subject meets 
a Modified Aldrete Score ≥ 9) will be summarized and compared between dose groups using 
Kaplan Meier methodology .Subjects who are withdraw nor discharged from the r ecovery  
area without r eaching an Aldrete score ≥9, will be considered as having censored time
computed from 
the end of the MRI  scan to the time of the la st vital signs assessment .  Zero 
minute will be used as the censored time if no vital signs are taken dur ing the post-MRI
recover yperio d.
Additionally , the dif ference between dose levels in percent of time at the target s edation 
rating scale sco re (PSSS rating of 2) following the administration of the DEX loading dose 
and during the DEX maintenance infusion will be asse ssed using the Wilc oxon test.  
Time (min utes) from the onset of the DEX 
infusion to the first dose of PR O will be 
summarized usi ng the Kaplan- Meier method.  Subjects that do not receive any  additional 
PRO will be considered as having a censored time.  The censored time to t he first dose of 
PRO f or additional sedation will be c omputed as the length of time fr om the onset of the 
DEX infusion up to the time the DEX infusion is stopped.
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 27Efficacy analyses will be conducted for all age cohorts combined and by each age cohort.
 
 
 
 
Analysis of Safety Endpoints
All safety analyses will be performed on the safety analysis set.
Descriptive statistics (quantitative variables: arithmetic mean, SD, median, minimum, and 
maximum, categorical and ordinal variables: proportion of subjects) will be calculated for quantitative safety data as well as for the change from baseline, when appropriate.  Data analyses will be presented by dose level, overall and within each age cohort.
TEAEs will be analyzed by dose level, overall, and for each age cohort according to the 
Medical Dictionary for Regulatory Activities system organ class and preferred term.  Additionally, the proportion of subjects with protocol-specified adverse events of bradypnea, hypoxia, apnea, hypotension, hypertension, bradycardia and paradoxical agitation reactionand the proportion of subjects with such events requiring intervention will be summarized for each age cohort and each dose level.  Pre-specified criteria will be used to identify the protocol-defined adverse events mentioned above.
The proportion of subjects who completed the MRI scan and required artificial ventilation or 
intervention to restore baseline or normal hemodynamic status will also be summarized.  The incidence of individual adverse events during MRI sedation will be descriptively summarized for each dose level, including the total adverse events.
The types of individual interventions and the total number of interventions will be
descriptively summarized at each dose level and for each age cohort (ie, airwayrepositioning, bag-mask intervention, deepening of sedation, fluid bolus, jaw thrust,continuous positive airway pressure (CPAP), increased oxygen, intubation, etc). 
Vital sign measurements and hemodynamic and respiratory parameters will be summarized 
descriptively by dose level and age cohort.
Prior and concomitant medications will be summarized according to WHODRUG 
Dictionary.  The number and percentage of subjects who used prior medications (by preferred term) will be tabulated by dose level and age cohort.  The number and percentage of subjects who used concomitant medications will be similarly tabulated.  CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 28DEX withdrawal sy mptoms, such as agitation/anxiety , rebound tach ycardia and rebound 
hypertension will be summarized by each do se level and age cohor t.  A descriptive summary  
will be performed for the incide nce of DEX withdrawal -related AEs after discontinuation of 
the DEX infusion.
Descriptive anal yses will be performed for the Pediatri c Anesthesia Emergence Delirium 
Scale (PAED) total score for dose l evel and by  age cohort.
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 29SCHEDULE OF ACTIVITIES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each pro cedure and assessment required for compliance with the 
protocol. The investigator may schedule visits (unplanned visits) in addition to those listed on the schedule of activities tab le, to in 
order to conduct evaluations or assessments required to protect the well-being of the subject.  
Study Visit Identifier Screen Day 1 (Day of MRI scan) Day 2 Follow-up Day 29 Long-term Follow-up
Study Visit Scheduling/Window Screening 
(up to 3 days before-
randomization)aPeriod 1  
(MRI scan) Period 2 
(Post-MRI Recovery)b24-Hour
(±2 hours)c28-Day 
(+3 days)
Informed consent X
Subject Number assigned X
Demography X
Medical history X
Inclusion/Exclusion criteria X X
Physical examinationdX
Contraception checkeX X
Vital signsfXXX
EtCO 2gX
Rhythm stri p (12-lead ECG if needed)hX
Laboratory: Pregnancy testiX
Randomization X
Peripheral IV placementjX
MRI scanjX
Cardiac telemetryhXX
PSSSkX
StudytreatmentlX
Propofol (as needed)lX
Supplemental IV fluidslX
Modified Aldrete Score and PAEDmX
AEs/SAEsnX →→ → X
Prior/Concomitant TreatmentsoX →→ → X
Abbreviations: → = continues; AE = adverse event; ECG = electrocardiogram; EtCO 2 = end-tidal carbon dioxide; IV = intravenous; MRI = magnetic 
resonance imaging; PAED = Pediatric Anesthesia Emergence Delirium Scale; PSSS = Pediatric Sedation State Scale; SAE = serious ad verse event
a. Signed informed consent and age-appropriate assent must be obtained prior to conducting any tests, assessments or procedures.   All Screening tests, 
assessments and procedure results must be received and reviewed by study site personnel prior to randomization.  All inclusion criteria must be met and CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 30Study Visit Identifier Screen Day 1 (Day of MRI scan) Day 2 Follow -up Day 29 Long -term  Follow -up
Study Visit Sc heduling/Window Screening 
(up to 3 days bef ore-
randomization)aPeriod 1  
(MRI scan) Period 2 
(Post -MRI Recovery)b24-Hour
(2 hours)c28-Day 
(+3 days)
all exclusion criteri amust not be me t. The Scr eening Visit may occur on or up to 3 d ays before Day 1.
b.Subjects must be monitored per protocol requirements for a minimum of 1 hour; this must occur in a post-procedure recovery area such as a post -
anesthesia care unit (PACU), recovery room or other hosp ital area w here the required monitorin g canbe achieved.   After 1 hour, subjects will meet 
criteria to leave this area when the subject attains a minimum Mo dified Aldrete Score of 9, is tolerating oral fluids and if applicable, a ny institution -
specific dis charge criteria have been met.
c.The Day 2 Follow-up visit will be completed 24 hours (±2 hours) after discontinuation of dexmedetomidine (DEX).  Contact with the subject or 
parent/legal guardian may be done via a phone call.
d.Physical examination will includ e evaluation of general appearance, he ad, ears, eyes, no se, mouth, throat, neck, lungs, heart, abdomen, musculoskeletal, 
extremities, skin, lymph node and a neurological assessment.   
e.The investigator must assess and document in the source if th e subject i s biologically c apable of having/fathering children and if the subject is sexually 
active, continues to be sexually active or has become sexually active.  I f yes, their method of contraception and confirmation of its consistent a nd correct 
use m ust also be documented in t he source documents.
f.Vitalsigns will in clude height (or length), weight, temperature, heart rate, respiratory rate, saturation of periphera l oxygen (SpO 2) and blood pressure 
including mean arterial pressure (MAP) .  Measurements should be o btained w ith the subject in a supine p ositi on as much as possible.  
Height will only be measured atScreening.  
Weight will only be measured at Screening and Day 1 Period 1 before randomization . If Screening and Day 1 occur on the same day, th e weight do es 
not need to be repeated. 
Height and w eight values w ill be rounded to 1 decimal place (the nearest tenth) for calculations and documentation . If thesecond number to the righ t 
of the decimal point (the hundredths) is4 or les s, rem ove all numbers to the right of the t enths place . If the hundred thsnumber is 5 or greater, add 1 
to thenumberin the tenths place, and then remove all numbers to the right of the tenths pla ce.
Body  temperat ure will be measured at Screening , at Day 1 Period 1 prior to randomi zation and durin g Day 1 Per iod 2 both when the subject arrives 
in the post -proce dure recovery area and w hen they meet the criteria to leave this area.   If Screening and Day 1 occur on thesame day, the 
temperature does not need t obe repeated at Day 1 Peri od1 prior to ra
ndomization but would need to be obtained on Day 1 Period 2 in addition to 
Screening .
Blood pressure, MAP, heart rate, respiratory rat e and SpO 2will be measured at Screen ing, within approximately 5 minutes before the loading dose 
and then every 5 (±1) minutes once the loading dose has started until the end of the MRI scan.  The m easurements obtained just before t he loading 
dose w ill be considered the Ba seline values for an alysis purposes .
On Day 1 Pe riod 2, blood p ressure including MAP, hea rtrate, respira tory rate and SpO 2will be measured upon arrival in the post-procedure recovery 
area and then every 5 (±1) min utes for the fi rst 15 minutes, and every 15 (±5) minutes for at least 1 hour until the su bject attains a minimum 
PF-00914730
C0801039
Final Protocol Amendment 2,11March 2021
PFIZER CONFIDENTIAL
Page 31Study Visit Identifier Screen Day 1 (Day of MRI scan) Day 2 Follow -up Day 29 Long -term  Follow -up
Study Visit Sc heduling/Window Screening 
(up to 3 days bef ore-
randomization)aPeriod 1  
(MRI scan) Period 2 
(Post -MRI Recovery)b24-Hour
(2 hours)c28-Day 
(+3 days)
Modified Aldrete Score of 9, is t olerating oral fluids and a ny instit ution- specific discharge cr iteria as applicable have been met.  
Heart rat e, respiratory rate and S pO 2,as well as blood pressure w here available ,will also be m onitored betw eenscheduled readings either per site
equipme nt monitoring standards or more frequently as deemed clinically necessary from t he start of the stud y treatment loading dos e through the 
post-MRI recovery period.  If heart rate decreases >20% from Baselin e and is outside the normal rang e, a blood pre ssure measurement includi ng 
MAP should be repeated a t appro ximately 2 -minute interval s until the heart rate returns to the normal ra nge.  If systo lic blood pressure decreases 
≥30% fro m Baseline and is outside t he normal range, a blood pressur e measurement including MAP should be checked approximately 1 minu te later.  
If the systolic blood pressure remains out side the normal range, meas urements shoul d be repeated at approximately 2 -minu te intervals until the 
systolic blood pressure returns to the normal range.  Normal ranges are pro vided in Appendix 8, Normal Rang es by Age (Nelson Textbook of 
Pediatrics, 20thEd, 2016) .  Baseline values are those obtained at Day 1 Period 1 within approx imately 5 minutes prior to the start of the DEX loading 
dose.
g.Nasal can nula capnography will be us ed to monitor EtCO 2conce ntration s fromthe start of the study treatment loading dose through the MRI scan.  
EtCO 2data will not be collected on a CRF.
h.A 2-minute rhythm strip will be obtained at Screening, and a 12 -lead ECG w illbe performed if clinically significant abno rmalities are noted.  I f a site 
does not have the capability toobtain a hard copy rhythm strip , the 12 -lead ECG m ay be performed in lieu of the rhythm strip. Subjects w ith a kno wn 
history of cardiac disease will be required to have a 12 -lead ECG performed atScreening.  Cardiac telemetry mo nitoring is required beginn ing just prior
to the start of the study treatment loading dose and continuing through the post -MRI recover y period.  
i.For all female subjects of chi ld-bearing potential, a uri ne dipsti ck or whole -blood qualitativ e human chorionic gonadotropin (hCG) pregna ncy test that 
can be performed at the bedside will be perfor med on Day 1Period 1 .  Serum qualitative or quanti tative hCG pregnancy testsarenot permitted. A 
negative pregnancy result i s required befor e the subje ct may be randomized . Subjects w ith an indeterminate or positive test result may not randomize in 
the study.  Please refer to Section 7.1Pregnancy Testing for details.
j.DEX must be adm inistered t hrough a peripheral IV line that is not a central cat heter such as a subclavian or peripherall y inserted centr al catheter (PICC) 
line.  The MRI scan may comme nce once the subject has achieved an adequate sedation level in the inv estigator’s clinical judgme nt.  The target sedation 
level is indicated by a Pedi atric Sedation State Scale (PSSS) score o f 2.  During sub ject sedation, facili ties for maintenance o f a patent airw ay, provision 
of artificial ventilation, administratio n of su pplem ental oxygen and cardi ovascular resuscitation must be i mmediately available .  Sitepersonnel trained i n 
the use of r esuscitative dru gs and emergency equi pment and skilled in a irway management must be available at all times during subject sedati on.
k.ThePSSS sedation ratings will be recorded as part of the anest hesia log on Day 1 Period 1within approximatel y 5 minutes prior to the start of the study 
treatme nt loading dose infusi on, immediately follow ing completion of the loading dose infusion, and at 5 (±1) minute intervals throu ghout the duration of 
the study t reatment infusion an d MR I scan.    
l.After all Screening and D ay 1 assessments have been completed and reviewed, subject has b een confirmed as meeting entry criteria and has been 
randomiz ed, study treatment will be ad ministe red as a 2-stage intravenous infu sion to be started j ust prior to the start of t he MRI scan.  Immediately prio r 
to the scan, a load ing dose of dexmedetom idine (DEX) will be administered over a period of 10 minutes.  The n a contin uous maintenance dos e infus ion 
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 32Study Visit Identifier Screen Day 1 (Day of MRI scan) Day 2 Follow-up Day 29 Long-term Follow-up
Study Visit Scheduling/Window Screening 
(up to 3 days before-
randomization)aPeriod 1  
(MRI scan) Period 2 
(Post-MRI Recovery)b24-Hour
(±2 hours)c28-Day 
(+3 days)
of DEX will be started that will continue for the duration of the scan.  Concomitant PRO may be administered starting 5 minutes f ollowing the start of the
DEX maintenance infusion to ensure that an adequate level of sedation is achieved prior to and throughout the scan.  Subjects wil l also be required to
receive supplemental IV fluids during the administration of DEX.  The use, type and rate of maintenance fluid administration fol lowing discontinuation 
of DEX will be at site discretion.  Please refer to Section 5 , Study Tr eatment, for details.
m. The Modified Aldrete Score will be performed on arrival at the post-procedure recovery area and every 15 (±5) minutes until t he subject meets criteria to 
leave that area.  The PAED will be performed after the subject awakens following arrival at the post-procedure recovery area and  every 15 (±5) minutes 
until the subject meets criteria to leave that area. If any total score on the PAED is 10 or greater, the subject should be evalu ated for emergence delirium, 
treated as appropriate and the PAED assessment frequency should be increased to every 5 (±1) minutes until the PAED score is be low 10 or the subject 
leaves that area.  
n. Adverse events (AEs) and serious adverse events (SAEs) will be collected from the time the informed consent is obtained throug h the Day 29 Long-term 
Follow-up Visit or final visit prior to the Da y 29 Long-term Follow-up Visit as appropriate. See Section 8.1.4 , Time Period for Collecting AE/SAE 
Information, for further details.  The Day 29 Long-term Follow-up Visit is a tele phone contact visit to elicit contraception and AE/SAE information only.  
SAE information must be reported to Pfizer per Section 8.1.4.1 Reporting SAEs to Pfizer Safety.  
o. Prior medications and non-pharmacologic therapies will be collected for the 4-week period before randomization.  Concomitant t reatments and 
non-pharmacologic therapies will be collected from randomization t hrough the Day 29 Long-term Follow-up Visit as described in Section 5 , Study 
Treatments.CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 331.INTRODU CTION
The present stud y is bein g con ducted by  Pfizer, Inc under the Pediatric Research Equity  Act 
(PREA) an d is a Phase 3/4 random ized, double -blind, d ose-ranging stud y of the safet y and 
eff
icacy of dexmedetomidine (DEX) used wi th propofol (PRO) for proced ural seda tion of 
pediatric subj ects ≥1 month to <17 y ears of age undergoing magnetic resonance imaging 
(MRI) scans .
  PRO is not approved for procedural s edation in the pediatric population ,so in this study  the 
use of PRO is consi dered investigational
.
1.1. M echanism of Action and Indication
DEX is a highl y selective α2 -adrenergic agonist that is being investig ated for use in 
procedural seda tion in pediatric subjects undergoing M RI requiring moderate to deep 
sedation.  DEX is currently  approved for sed ation of initially  intubated and mechanica lly
ventilated adults during treatment in an intensive care setting an d for procedural sedation of 
adults.
The effects of DEX are mediated via adrenoreceptors in both the central and peripheral 
nervous s ystems.  Ow ing to the wide distribution of adrenergic receptors, DEX has effects 
across multiple organ s ystems and in some cases, multiple effects on a si
ngle organ s ystem.  
For example, DEX has a dual effect on the cardiov ascular s ystem.  Upon administ ration DEX 
hasa transient peripheral effect mediated th rough its stimulation of α2 -receptors on vascular 
smooth muscle causing an increase in blood pressur e and a reflex decrease in heart rate.  In 
the heart, the dominant ef fect of DEX is to induce bra dycardia ─ mediat ed through vagal 
stimulation and a decreas e in tach ycardia as DEX blocks the cardio acceler ator nerves.  In 
children, large doses of dexmedetom idine have been shown to cause peripheral 
vasoconstriction, leading t o transient sy stemic h ypertension, whereas l ow doses can cause 
central s ympathol ysis, leading to s ystemic h ypotension.1-4
The sedative and anxiolytic effects result pri marily  from activity  in the locus ceruleus of the 
brain stem where stimulation of the α2-
adrenergic receptors inhibits norepinephrine release, 
resulting in increased firing of inhibitory  neurons.  I n the dorsal horn of the spinal cord, DEX 
modulates the re lease of substance P which produces its analgesic effects.5  The 
α2-
adrenergic agonist action of DEX results in mild to moderate analgesia, sedation, 
anxioly sis, diuresis, peripheral and central effects on the cardiovascular s ystem, and mild 
inhibition of insulin release and platelet aggregation.6
In health y subjects, DEX caused dose -dependent decreases in s ystolic blood pressure (SBP) 
and diastolic blood pressure (DBP) and a slowed heart rate but did not alter re spiratory  rate 
or oxygen saturation at rec ommended dosages.6,7,8
1.2.Approval History and PREA
In December 1999, Precedex (devel oped b y Hospira Inc.) received regulatory approval in the 
United States for sedation of initially  intubated and mechanically  ventilated a dults in an 
intensive care unit (I CU) setting for up to 24 hours.  I n October 2008 DEX was approved for 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 34use in non- intubated adults requiring sedation prior to a nd/or during surgical and other 
procedures.  
In 2007 the FDA issued a Pediatric Written Request (PWR) 
in ICU sedation.  In response, 
6 studies were conducted, and the results submitted to the FDA.  In March 2013, fo llowing 
2amendments (December 2010 and A ugust 2011), the FDA granted Pediatric Exclusivity  for 
Precedex, based on the fulfillment of the requirements of the PWR.  However, based on the 
FDA’s assessment of insufficient proof of efficacy  and safet y, they d id not accept the results 
of the PWR studi es as adequate to support the approval of an indication for Precedex in 
pediatric ICU sedation.
In 2008 following the approval of DEX for procedural sedation in adults, a PREA request 
was issued to conduct a clinic al study  in pediatric subjects receiving D EX for procedural 
sedation.  In response, study  DEX 10- 16, entitled Phase IV, Open Label, Safet y Study 
Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure -Type 
Sedation was conducted to fulfill the PREA requirement.  The objective of the DEX 
10-16 study  was to evaluate safety ; this study  was not intended to support an in dication for 
the use of DEX in pediatric procedural sedation (PPS).  The DEX 10
-16 study  ultimately did 
not fulfill the PREA requirement, and FDA advised consult ation with clinical experts in PPS to 
inform the design of a new study  and ensure that the study  reflected the way  DEX was used in
clinical practice (ie, with regard todose selection and rationale, types of proced
ures, and use of 
concomitant sedative drug s).
1.2.1. Study DEX 10 -16
DEX 10-16 was an open -labeled, single -arm, multi -center study designed to evaluate the 
safety of DEX in pediatric subjects ages ≥28 weeks to<17 yearsold who required 
non-intubated moderate to deep sedatio n (NI -MDS) for procedures lasting at least 30 minutes 
and falling in to 1 of the following 3 procedural groups:
Non-invasive
diagnostic/therapeutic procedures including ultrasound (U/S),
computed tomograph y (CT) scans, MRI,cardiac catheterization or transthoracic 
echocardiogram (TTE).
Minimall y invasive diagnostic/therapeutic procedures such as procedures performed 
under U/S or CTguidance (eg, U/S or CT- guided solid organ biops y), and routine 
myocardial biopsies in cardiac transplant recipients.
Surgical procedures including small surgical procedures (eg , excisions, biopsies) and 
dental procedures (eg,extractions, pulpectom y, pediatric rehabilitation dental 
procedures, 
fillings, and crowns).
Dosing of DEX was based on age: subjects aged ≥28 weeks’ gestational age to <1 month 
postnatal (n=1) received a 0. 1 microgram/kilogram (mcg/kg) loading dose over 10 minutes and a 
0.05 -0.2 mcg/kg/hour infusion; subjects aged 1 month to <17 y ears (n=90) received a 1mcg/kg 
loading dose over 10 minutes and a 0.2 - 2mcg/kg/hour infusion.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 35Although DEX 10 -16 was initi ally designed to assess safety  only , based on feedback from the 
FDA, the study  was revised to incorporate assessments of efficac y.
Theprimary  efficacy  endpoint of DEX 10-16 was the rate of successful sedation.  This was a 
composite endpoint consisting of the following 3 criteria, all of which had to be satisfied for a 
sedation to be considered asuccess:
Subject had adequate level of sedation (University of Michigan Sedation Scale 
[UMSS] score of 1 to 3 or a Neonatal Pain, Agitation and Sedation Scale [N -PASS] 
score of -5 to -2) at least 80% of the time the subject was given the stud y drug.
Subject successfull y completed the proced ure without rescue medication 
(midazolam).
Subject did not need artificial ventilation or intervention to restore baseline or normal 
hemody namic 
status.
Theprimary  safet y endpoint of DEX 10 -16 was the incidence of treatment- emergent adverse 
events (TEAEs) .
The study  enrolled 91 subjects, of whom 90 subjects were included in the safet y evaluable 
population and 78 in t he efficacy  evaluable population.
1.2.1.1. Study DEX 10 -16 Study Results
DEX 10 -16 demonstrated that DEX was generally  safe and well tolerated in pedia tric
subjects who were undergoing procedural sedation.  The most common TEAE was 
respiratory  depression (62%) whic
h was pre -defined in the protocol as the presence of either 
absolute or relative thresholds for respiratory  rate and saturation of peripheral oxy gen (SpO2) 
changes.  None of the events of respiratory  depression required medical intervention or 
resulted in a subject discontinuing from the stud y.  The other common TEAEs were 
hypotension (37%) and brady cardia (4.4%).9
Based on the 3 criteria comprising the primary  efficacy  endpoint, the study  failed to 
demonstrate efficacy .  The majority  of subjects in all 3 procedural groups required rescue 
midazolam for adequate sedation.  Only  2 subjects met the criteri afor successful sedation; 
both were in the non -invasive procedure group.  Notably , the need for rescue sedation and 
incidence of AEs increased with increasingl y invasive/painful procedures.  More subjects in 
the non- invasive procedures group (primarily subjec ts undergoing imaging studies) were 
adequatel y sedated compared to subjects in the minimally  invasive or surgical procedures 
groups.
1.2.2. DEX Expert Advisory Committee
In preparation for the current protocol, Pfizer assembled a team of 5 nationally  and 
internationally  recognized Clinical Experts in the field of pediatric sedation and met with 
them for advice in designing a study based on current clinical practice for the use of DEX for 
PPS.  As a result of that meeting and subsequent communication with the A dvisory  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 36Committee, the procedures for stud y, dose ra nge and concomitant sedation drugs for this 
study  were determined.
1.2.2.1. Imaging Procedures 
The Clinical Experts recommended that Pfizer include only  MRI/non-invasive imaging 
procedures for this study  because a ppr oximately  80% of DEX used in pediatric procedura l 
sedation is for imaging procedures.  The predominant use of DEX for sedation for imaging 
procedures (MRI in particular) is also strongl y supported b y the the literature.10,11,12
1.2.2.2. Dose Selection
Pharmacokinetic (PK) data from adults undergoing procedural sedation with DEX is not 
available and only limited PK data is available for pediatric subjects.13  Additionally , no 
PK/Pharmacod ynamic (PD) model has been established to guide dose selection in pediatric 
subjects undergoing procedural sedation with DEX. In the absence of PK and model ing data 
to guide dose selection for this study , the selecti on of the DEX dosing regimens was based on 
consideration of the following:
1.The
recommended DEX dose for procedural sedation in adults.
2.The dosing experience and results of the previous pediatric procedural sedation
study  DEX 10-16.
3.The available PKdata inadult and pediatric ICU subjects, as well as simulated 
PK profiles of DEX at the projected doses in pediatric procedural sedation subjects 
based on a population PK model developed from the ICU pe diatric subjects 
(Appendix 2).
4.
The published literature in similar patient populations undergoing similar non -
invasive imaging procedures.
5.Reports of dose -related effects of DEX on required concomitant anesthesia.
6.Clinical exper tadvisor recommendations.
The doses selected for this study  are shown below:
Blinded dosing for subjects ≥1 month to <2 years of age on Day 1
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose level 0.5 mcg/kg 0.5 mcg/kg/hour
Middle dose level 1mcg/kg 1mcg/kg/hour 
High dose level 1.5 mcg/kg 1.5 mcg/kg/hour
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 37Blinded dosing for subjects ≥2 years to <17 years of age on Day 1
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose level 0.5 mcg/kg 0.5 mcg/kg/hour
Middle dose le vel 1.2 mcg/kg 1mcg/kg /hour   
High dose level 2mcg/kg 1.5 mcg/kg/hour
Lower loading doses were selected for subjects <2 y ears old compared to subjects from 2 to 
<17 y ears of age because of a potential increased risk of respiratory  insuffi ciency  leadi ng to 
hypoxia and brad ycardia in newborns and infants treated with high dose s of DEX.14
The clinical expert advisory  board unanimousl y agreed that the dosing regimen used in the 
DEX 10 -16 study  does n ot reflect current clinical usage.  The DEX doses used in children in 
practice today  are higher than the doses administered in the DEX 10 -16 stu dy and higher than 
the doses specified for adults in the current label.
Since the approval of DEX for adult pro cedural seda tion in 2008, there have been numerous 
publications on the use of DEX for PPS, chiefl y for non -invasive procedures such as MRI, 
CT, n uclear medicine studies, and electroencephalograms (EEG).  A review of this literature 
reveals that the range o floading an d maintenance doses used in pediatric subjects is 
frequentl y higher than the recommended adult dose.  In addition, there has been a p rogressive 
increase in the doses used over time.
Mason et al. reported on 747 consecutive pediatric patients who received D EX for MRI 
sedation.15  Bet ween April 2005 and April 2007 the loading dose of DEX was increased from 
2 to 3 mcg/kg, and the maintenance infusion rate increased from 1 mcg/kg/hour to 1.5 to 
2mcg/kg/ hour.  During this time the success rate of sedation with DEX alone increased from 
91.8% to 97.6% of patients being able to complete the imaging stud y.  Similarly, Siddappa et 
al reported on the successful use of high -
dose DEX (2 mcg/kg loading dose followe d by 
1mcg/kg /hour infusion) for sedation during MRI.11  The safety profile of DEX at these 
higher doses was found to be acceptable and was characterized in multiple studies by  a 
modest decrease in heart rate an dblood pressu
re that typically  did not require intervention.14
Co-administration of DEX with other sedatives such as ketamine, midazolam, or PRO is also 
common; about 67% of cases in the recent analy sis of the D EX database b ySulton et al. 
utilized concomitant sedatives such as midazolam or ketamine.10  In addition, DEX has been 
reported to exert a dose- sparing effect on the requirement for concomitant opioids and 
sedat ives.16,17  The reduced need for concomitant sedatives is significant, given increasing 
concerns regarding pote ntial neurotoxic effects of anesthetics in developing chi
ldren.18,19
The doses selected for this study  were based on the combined information from the above 
sources and input from clinical experts.  The selected doses range f rom a minimall y effective 
low dose to maximum doses, which are representative of current clinical us age. 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 38It is anticipated that the proportion of subjects adequately  sedated at the lowest dose level 
(0.5 mcg/kg loading dose and 0.5 mcg/kg/hour maintenance dose) will be low.  As reported by  
Berkenbosch et al., initial use of a 0.5 mcg/kg induction and 0. 5 mcg/kg/hour maintenance dose 
regimen failed to achieve adequate sedation and prevent patient movement in most children 
undergoing MRI  scans, leading subse quently  to the use of higher DEX doses.20  The middle 
dose level chosen for this study  is comparable to the approved dose for adult procedural 
sedation and the dose utilized in the original Hospira pediatric tria l(DEX 10 -16),in which 
approximately  30% of subjects undergoing MRI  did not require supplemental midazolam.  The 
high doses were chosen to be more representative of current practice, and it is expected that up 
to 70 -80% of subjects who receive this dose l evel will not require supplemental ane sthetic to 
achieve adequate sedation.15  Across the dose range to be studied, it is anticipated that 
increasing dose levels of DEX will beassociated with a decreasing requir ement for a
concomitant sedative, and with an increasing proportion of subjects who are able to complete 
the procedure with DEX alone.
Although there are very limited PKdata available for DEX used for procedural sedation, the 
PK of DEX has been well chara cterized in ad ults and in pediatric ICUsubjects.  DEX 
undergoes extensive hepatic metabolism to inactive metabolites, with 85% undergoing 
glucuronidation by  UDP -glucuron yltransferase (UGT) and 15% by cytochrome P450 2A6.  
In adults, following intravenous (IV) administr ation, DEX exhibits arapid distribution phase 
with a distribution half-life (t½) of approximatel y 6
minutes; a terminal elimination t ½ of 
approximatel y 2hours; a steady -state volume of distribution (Vdss ) of approximately  118 L, 
and an esti mated clearanc e of approximatel y 39 L/hour.  In adults, DEX exhibits linear PK in 
the dosage range of 0.2 to 0.7 mc g/kg/hour when administered by IVinfusion for up to 
24hours.21
,22
Based on the results from 5 clinical studies (W98 -266, CHOP, DEX 08 -01, DEX 08 -09,and 
DEX 11 -01) in pediatric ICU subjects ranging in age from 1 month to 17 years, the median 
weight -adjusted DEX clearance values were between 0.79 and 1.32 L /hour/kg and 
the 
median weight -adjusted volume of distribution (Vd) values, between 2.09 and 3.64 L/kg.  
DEX exhibits linear PKacross the dosage range of 0.2 to 2mcg/kg/hour studied in pediatric 
ICU subjects when administered by IV infusion for up to 24hours.  Hence, the exposure of 
DEX in this study  is expected to be dose- proportional within the proposed DEX dosage range
of 0.5 to 2mcg/kg/hour in PPS subjects.
1.2.2.2.1. Loading Dose Infusion Duration
The Precedex United States Package Insert (USPI) recommends a loading dose of 1 mcg/kg 
infused over 10 minutes for adults (DEX is not approved for pediatric use).  The pediatric 
ICU sedation studies used a 10- minute interval for infusion of the DEX loading dose.  
However, there are some literature reports of PPS s
tudies that infused the DEX loading dose 
over ≤5 minutes.  Some members of our clinical expert advisory  committee also use an 
infusion rate of ≤5 minutes for PPS.  This practice of shortening the duration of the loading 
dose infusion is employ ed primarily at tertiary  care hospitals and by  very experienced 
providers with specialized interest and/or training in using DEX for PPS.  However, while 
there is little published data on the safet y and tolerability of different infusion duration times, 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 39a shorter duration may  be associated with increase d AEs.  Therefore, this study  will use the 
more conservative 10 -minute infusion interval for the DEX loading dose, which is consistent 
with the current USPI as recommended for adults.  
1.2.2.3. Concomitant Sedative Drugs
The Clinical Experts emphasized that in pra ctice, DEX is usually  used in combination with 
other sedatives and analgesics (ie, midazolam, PRO, ketamine, morphine, or fentan yl).10
For an MRI to be successful the subject must remain motionless during image c apture and 
therefore in young children deep sedation is necessary.  While multiple sedative drug 
regimens have been used to achieve deep sedation for MRI studies, PRO has become a
commonly  used drug because it has a short induction and recovery  time and ca n be titrated 
easily  to the required sedation level.23,24  In this study , PRO will be used as a rescue sedative 
in subjects who are not sufficientl y sedated b y DEX alone.
1.2.2.4. Summary of Study Design
This study  design is based on the comments received in the FDA’s complete response letter 
(CRL ) of August 2016 and the recommendations of the Clinical Expert advisory  committee.  
The study  is designed to meet the post -marketing study  requirements (PMR 1772 -1) to fulfill 
the PREA requirements and to investigate the safety  and efficacy  of DEX for pediatric 
procedural sedation.
This clinical trial will be a randomized, double- blind, fixed dose -ranging study  of the 
efficacy  and safet yof DEX, when used with PRO administered as needed, fo r procedural 
sedation of pediatric subjects ≥1 month to <17 y ears of age undergoing diagnostic magnetic 
resonance imaging (MRI) scans.
1.3.Safety Data
1.3.1. Clinical Trial Safety Data Base
The legacy  Hospira clinical safety  data base for DEX pediatric studies contai ns safet y 
information on 319 pediatric subjects participating in 6 studies conducted on the use of DEX 
for ICU pediatric sedation and 90 subjects receiving DEX for PPS in DEX 10 -16.
1.3.1.1. Safety Data from Pediatric ICU Sedation Studies
In support of the Pediatr ic Written Request for DEX for the indication of sedation in initially  
intubated and mechanically  ventilated pediatric ICU (PI CU) subjects, Hospira completed 
6pediatric clinical studies with a total of 319 subjects aged 28 weeks to <17 y r.  In these 
studi es, the loading dose was given over 10 minutes and the maintenance doses were as 
follows: 
28 weeks gestational age to <1 month chronological age: loading dose of 
0.05 - 0.2 mcg/kg and maintenance dose of 0.05 -0.2 mcg/kg/hour.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 401 month to ≤16 y ears of age: loading dose of 0.25 - 0.5 mcg/kg and maintenance dose 
of 0.2 - 0.5 mcg/kg/hour.
1 month to ≤16 y ears of age: loading dose 0.5 - 1 mcg/kg and maintenance dose of 
0.5 - 2 mcg/kg/hour .
Adverse events occurring between the start of the DEX infusion and up t
o 24 hours after its 
discontinuation (study  end) were considered TEAEs.  Among the 319 pediatric subjects in 
the integrated safet y population, 203(63.3%) had 1 or more TEAEs, 2.5% had severe TEAEs, 
and 50 subjects (15.7%) had one or more drug -related T EAEs .  Nine subjects (2.8%) had 1 or 
more treatment emergent serious adverse events (SAEs); 4 subjects had treatment -emergent 
SAEs that were considered drug -related.  Thirteen subjects (4.1%) had TEAEs leading to 
discontinuation; the incidence of an y singl e TEAE leading to discontinuation was low, 
ranging from 0.3 to 0.6%.  No single TEAE led to discontinuation in more than two subjects, 
and no subjects died as a result of a TEAE.
Most TEAEs in the PI CU sedation studies were mild in severity  (2.5% were cons idered 
severe). No subject had a TEAE resulting in death.  The incidences of discontinuations due to 
TEAEs was low (4.1%), and no single TEAE leading to discontinuation occurred in more 
than two subjects.  The incidence of treatment- emergent SAEs leading t o discontinuation was 
also low (1.3%), and none of the treatment -emergent SAE leading to discontinuation 
occurred in more than one subject.
The most common TEAEs were h ypertension (43 subjects, 13.5%), h ypergly cemia 
(36subjects, 11.6%, with no hy pergl ycem ia considered related to drug), h ypotension 
(32subjects, 10.1%), h ypokalemia (28 subjects, 8.8%), p yrexia (26 subjects 8.2%), and 
vomiting (16 subjects, 5.0%). 
Based on the known mechanism of action of DEX and its adverse event profile in adults, 
certain adverse events were considered “adverse events of special interest”.  These adverse 
events included brad ycardia, tach ycardia, h ypotension, diastolic hy potension, and systolic 
hypertension.  The majority  of AEs of special interest did not require medical i ntervention, 
which was defined as any  action taken in response to the AE and included decreasing the 
infusion rate of DEX, re -positioning the patient and/or treatment with fluids, medications, or 
procedures.  The Incidence of AEs of Special Interest and th e incidence of these events 
requiring medical intervention are shown below:
The Incidence of AEs of Special Interest vs. Incidence of AEs of Special Interest 
Receiving Medical Attention in an Integrated Pediatric Population During ICU 
Sedation < 24 Hours
Adver se event Subjects with AEs of 
special interest 
N=319
n (%)Subjects receiving medical 
intervention
N=319
n (%)
Brad ycardia 11 (3.4) 3 (0.9)
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 41Adver se event Subjects with AEs of 
special interest 
N=319
n (%)Subjects receiving medical 
intervention
N=319
n (%)
Tach ycardia 12 (3.8) 1 (0.3)
Hypertension 43 (13.5) 14 (4.4)
Hypotension 34 (10.7) 11 (3.4)
The change s invital signs (blood pressure [BP] and heart rate [HR]) across the PI CU 
sedation studies were predictable given DEX’s mechanism of action and were generall y 
manageable.  Additionally, DEX had no clinicall y meaningful effect on hematology  or se rum 
chemis try analytes.
Overall, considering the underlying medical condition of the pediatric subjects upon 
enrollment (subjects had to be intubated and mechanicall y ventilated to qualify for the 
studies), DEX appeared to be generally  safe and well -tolera ted in the sedation of initially  
intubated and mechanically  ventilated PICU subjects.  The TEAEs that occurred were 
generall y consistent with the known AE profile of DEX in the adult population.25  
1.3.1.2. Safety Data from Pediat ric Procedural Sedation Study DEX 10 -16
As discussed in Section 1.2.1.1, study  DEX 10 - 16 demonstrated that DEX was generall y safe 
and consistent with the known safet y profile of DEX in adults.26  Adverse event s of special 
interest were AEs of brady cardia, tachy cardia, h ypotension, hy pertension, hy poxia and 
respiratory  depression based on protocol
-defined vital signs limits.  The frequency  of 
subjects ex periencing a TEAE and TEAE of special interest in subjects undergoing 
non-invasive diagnostic/therapeutic procedures were 32 (69.6%) and 30 (65.2%).  With few 
exceptions, all TEAEs were TEAEs of special interest.  The commonly  reported treatment
-
related TE AEs (reported in ≥2 subjects) were h ypotension in 30 subjec ts (33.3%), respiratory  
depression in 19 subjects (21.1%), brad ycardia in 3 subjects (3.3%), and vomiting, BP 
systolic decreased, headache and h ypoxia in 2 subjects each (2.2%).
The increased frequ ency of TEAEs of brady pnea and hy potension was noted with more 
invasive procedures, and with increased use of rescue sedation and analgesia.  As noted b y 
Jooste et al, the high incidence (62%) of the protocol -defined decrease in respiratory  rate of 
>30% fr om b aseline, was not viewed as being clinically  significant and represents a normal 
decrease in the respiratory rate of a child who is well- sedated in pediatric subjects 
undergoing procedural sedation.  All of the AEs reported were in calml y sedated childr en 
compared w ith that of a child in a relatively  anxious pre -sedation state.9  There were 2 events 
of a >10% decrease in the saturation of peripheral oxy gen(SpO 2
)from baseline that resolved 
quickly , and none of thesubjects in DEX 10- 16 required mechanical ventilation either during 
or post study  drug infusion.  
There was 1 treatment -emergent SAE of s yncope reported in this study.  This event was 
reported.  The SAE of syncope was assessed as probably not related to DEX and resolved 
without treatment.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 421.4.Safety Summary
Based on the safety  data from the pediatric I CU s edation studies, the DEX 10- 16 study  in 
PPS, and the published literature, DEX is generally  safe and well tolerated in pediatric 
subjects.  The most common TEAEs - hypotension, respiratory  depression, and brady cardia, 
are well understood based on the drugs mechanism of action, are generally  mild, and 
generall y resolve without medical intervention. 
More detailed information about the known and expected benefi ts and risks and reasonabl y 
expected AEs of DEX may be found in the Investigator Brochure (IB), which is the single
reference safet y document ( SRSD )for this stud y.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PRO may  be found in the United States package insert [(USPI ], which is the 
SRSD for this study . Individual countries may  also reference their local package insert for 
additional country -specific information on PRO .  
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 432. STUDY OBJECTIVES AND ENDPOINTS
Primary Efficacy Objective: Primary Efficacy Endpoint:
• Assess efficacy of DEX for pediatric procedural 
sedation as measured by the percent of subjects at the 
high dose level versus the low dose level in the 
combined age cohorts who do not require concomitant PRO to achieve adequate sedation.• Percent of subjects at the DEX high dose level versus 
the low dose level in the combined age cohorts who 
do not require concomitant PRO to complete the 
MRI.
Key Secondary Efficacy Objective: Key Secondary Efficacy Endpoint:
•Assess the efficacy of DEX for pediatric procedural 
sedation as measured by the percent of subjects at the high dose level versus the low dose level in each age cohort who do not require concomitant PRO to achieve adequate sedation.• Percent of subjects at the DEX high dose level versus 
the low dose level in each age cohort who do not require concomitant PRO to complete the MRI.  
Secondary Efficacy Objective(s): Secondary Efficacy Endpoint(s):
•Explore the efficacy of DEX at the middle dose level 
compared to the high dose level and the low dose level in both the overall sample and in each age cohort as measured by the percent of subjects who do not require 
concomitant PRO to achieve adequate sedation.
•Explore the efficacy of DEX by examining the percent 
of time at the target sedation score, time to first PRO 
use, emergence time from sedation, proportion of 
subjects at each dose level receiving PRO and amount of PRO required.• Percent of subjects at the DEX middle dose level 
compared to the high dose level and the low dose level in both the overall sample and in each age cohort who do not require concomitant PRO to 
complete the MRI.
• Percent of time at the target sedation rating scale 
score (Pediatric Sedation State Scale [PSSS] rating of 
2) after the administration of the DEX loading dose 
and during the DEX maintenance infusion . 
• The amount of time from the start of the DEX 
loading dose infusion to the time of the first PRO bolus administration.
• Emergence time (defined as the time from the end of 
the MRI scan to when the subject meets a Modified Aldrete Score ≥9).
• The proportion of subjects at each DEX dose level 
who receive PRO.
• Total amount (mg/kg) and weight and time adjusted 
amount (per kg per minute basis) of concomitant PRO required to successfully complete the MRI scan.
 
 
 
Safety Objective: Safety Endpoints:
•Assess the safety of DEX used for procedural sedation 
of pediatric subjects undergoing an MRI scan.• Incidence, seriousness, causality and severity of 
treatment-emergent adverse events.
• Percent of subjects who completed the MRI scan and 
required artificial ventilation or intervention to restore baseline or normal hemodynamic status.CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 44 Mean change from baseline in SBP, DBP, mean 
arterial pressure (M AP), HR and re spiratory rate 
(RR).
 Time outside of the stable range for hemodynamic 
parameters of SBP and HR.
 Incidence of protocol -specified respiratory adverse 
events of bradypnea, hypoxia and apnea.
 Incide nce of protocol -specified cardiac adverse 
events of hypotension, hype rtension and bra dycardia.
 Incidence of protocol -specified adverse event of 
paradoxical agitation r eaction .
 Incidence of protocol-specified adverse events of 
bradypnea, hypoxia, apnea, hypotension, 
hypertension , bradyc ardia and para doxical agitation 
reaction requiring intervention.
 Incidence of DEX withdrawal -related adverse events 
after discontinuation of DEX infusion .
Safety Assessments  Exposure to study drug (total dose of study drug 
received and the duration of studydrug infusi on).
 Adverse Events (AEs).
 Cardiac telemetry.
 Vital signs (HR, blood pressure [DBP, SBP and 
MAP], RR, temperature, SpO 2), end -tidal carbon 
dioxide (EtCO 2) and body weight.
 Prior and concomitant medications.
 Pedia tric Anesthesia Emergence D elirium Scale 
(PAED).
3.STUDY DESIGN
This is arandomized, double -blind, dose -ranging study  of the efficacy  and safet y of DEX, 
when used with PR O as needed, for procedural sedation of pediatric subjects ≥1 month to 
<17 y ears of a ge undergoing MRI scans.  The sponsor, subje ct and investigator will be
blinded to the dose of DEX.
This study  includes a 
Screening, Day  1, Day  2 Follow -up and Day  29 Long -term Follow -up 
Visit.  The Day  1 Visit is comprised of a Period 1(MRI  scan) Phase and a Period 2 (Post -
MRI  Recovery ) Phase.  The Day 2 Visit is a 24- hour Follow -up, and the Day  29 Visit is a 28-
dayFollow -up.  
All eligible subjects will receive double -blind treatmen twhere one of 3 dose levels of DEX 
will be administered.  Following completion of required procedures be fore randomi zation at 
the Day  1 Visit, subjects meeting entry  criteria will be ra ndomly  assigned to a L ow, Middle 
or High dose level group (actual dose dependent on age) in a 1:1:1 ratio.  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 45Treatment will be initiated just prior to the start of the MRI  scan and will continue during 
Period 1 (MRI  scan). Subjects will first receive a DEX loading dose administered over 
10minutes.  Following co mpletion of the loading dose, the maintenance infus ion of DEX 
will be started. The subject’s level of sedation will beassessed using the Pediatric Sedation 
State Scale (PSSS) at 5- minute intervals throughout the drug infusion and MRI  scan.  If an 
adequat e level of se dation is not achieved as assessed by  the investigator (eg, if the subject 
moves) within 5 minutes after the DEX mai ntenance infusion has been started, concomitant 
PRO may  be given to ensure that an adequate sedation level is achieved and main tained for 
completion of the scan.  The target seda tion level is indicated by  a PSSS score of 2 (ie, 
patient is quiet
[asleep or awake], not moving during procedure, has no frown [or brow 
furrow] indicating pain or anxiety  and no verbalization of any  compl aint).27  
Once the subject has achieved an adequate sedation level per principal inv estigator ( PI)
clinical j udgment, the MRI  scan can commence.  Sedation with DEX and if required, 
concomitant PRO, shall continu e through com pletion of the MRI  scan to maintain the subject 
at 
an adequate sedation level per PI clinical judgment.
Subjects wil l also be adm inistered supplemental IV fluids throughout the DEX infusion at a 
maintenance rate per Section 5.10.1 Required Treatments.  Please refer to the Investigational 
Product Manual (IP Ma nual) for the list of per
mitted IV fluids that may  be used.  The use, 
type and rate of maintenance fluid administration followi ng discontinu ation of the DEX 
infusion will be at the site’s discretion.
During subject sedation, facilities for maintenance of a patent airway, provision of artificial 
ventilation, administration of supplemen tal oxy gen and cardiovascular resuscitation mus t be 
immediat ely available.  Site pers onnel trained in the use of resuscitative drugs and 
emergency  equipment and skilled in airw ay management must be ava ilable at all times 
during subject sedation.
The DEX infusion should not be discontinued until confirm ation that th e MRI  is complete 
has be en received and DEX must be discontinued prior to the subject being transferred to the 
post-procedural re covery area.  Period 2 (post -MRI recovery ) begins at the conclusion of the 
MRI  scan.
The study  will be conducted u
sing the manu factured strength of DEX 200 mcg/2 mL, diluted 
to a concentration directed by  the Investigational Product Manual (I PManual) based on each 
subject’s treatment group assignment. 
3.1.Approximate Duration of Subject Participation
Subjects will parti cipate in the study  for ~4 weeks.  
3.2. Ap proximate Number of Subjects
A sufficient number of subjects will be screened to randomiz e approximately 120subject s 
(40subjects per dose level) who will participate in the study .  The numbers of 
enrolled 
subjects are not pre -specified for each participating country .  Enrollment is competitive and 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 46willdepend on the capabil ities of each site.  S ubjects who withdraw from the study  will not 
be replaced. 
Age Cohort Low Dose Group Middle Dose Group High Dose Group
≥1 month to <2 y ears 20 20 20
≥2 years to <17 years 20 20 20
Age Cohort ≥1 month to <2 y ears:
This age cohort should have an even distribution of subjects between the ages of 
1month to <2 y ears on Day  1 within each dose group: 
Approximately  10 subject s aged ≥1 month to <1 year in each dose group.    
Approximately  10subje cts aged ≥1 year to <2 y ears in each dose group.  
Age Cohort ≥2 y ears to <17 y ears:
This age cohort should have an even distribution of subjects between the ages of 
2years to <12 years on Day  1 within eachdose group:  
Approximately  8subjects aged ≥2 years to <6 years in each dose grou p.
Approximately  8subjects aged ≥6 years to <12 years in each dose gro up.
Approximately  4, but no more than 5subjects aged ≥12 y ears to <17 years in
each dose group.
All a
ge cohorts can be enrolled in parallel. 
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subj ects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom parti cipation in the study  is 
considered appropriate.  All relevant medical a nd nonmedical conditions should be taken into 
consideration when de ciding whether a particular subject is suitable for this protocol.  
Female subjects of non -childbearing potential mu st meet at least 1 of the following criteria:
a.Are pre -menarche;
b.Achieved postmenopausal status, defined as follows: cessation of regular me nses for 
at leas t 12consecutive mon
ths with no alternative pathological or phy siological 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 47cause; status may  be confir med with a serum f ollicle-stimulating hormone (FSH) 
level confirming the postmenopausal state;
c.Have undergone a documented hy sterectomy  and/or bilateral oo phorectomy ; 
d.Have me dically  confirmed ovarian failure. 
All other female subjects who have experienced menarche (including female subjects with 
tubal ligations) are consider ed to be of childbearing potential.
Subject eligibility  should be r eviewed and documented by  an appropr iate member of the 
investigator’s stud y team before subjects are included in the study .  
4.1.Inclusion Criteria at Screening
Subjects must meet all 
the following inclusion criteria to be eligible for enrollment into the 
study:
1.Evidence of a personally  signed and dated informed consent document indicating 
that the subject or a parent(s) /legal guardian has b een informed of all pertinent 
aspects of the stud y.  Assent will also be obtained where age -appropriate and 
according to 
state regulat ions.
2.Willing and able to comply  with scheduled visits, treatment plan, laboratory 
tests, and other stud y procedures.
3.Male or female subject ≥1 month and <17 y ears of age onDay 1.
4.American Societ y of Anesthesiologists (ASA) Physical Status I
,II or III . This 
assessment is to be performed by a medically  qualified person and reviewed by  
thePI.
5.
Requires non- intubated, spon taneous breathing, moderate to deep sedation 
(NI-MDS) for a magnetic resonance imaging (MRI ) study  with an intensivist, 
anest hesiologist or other proceduralist i n attendance.
6. Duration of the MRI scan is expected to take at least 20 minut es but no more 
than 3 hours to complete.
7.Subjects must be willing and able to undergo placement of a peripheral IV 
catheter inserted specifical ly for this study .Existing IV catheters being used for 
another purpose (eg , administration of fluids, I V ant ibiotics etc. ) must be used
with the Sponsor provided Y -connector and 3 -port connector. Existing IV tubing 
must not be used.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 484.2.Inclu sion Criteria o n Day 1
Subjects must meet all the f ollowing inclusion criteria to be eligible for enrollment into the 
study :
1. A ll Screening incl usion criter iacontinue to appl y as appropriate .
4.3. Exclusion Criteria at Screening
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1.Investigator site staff members directl y involved in the conduct of the study and 
their fa mily members, site st aff members otherwise supervised b y the
investigator, or subjects who are Pfizer emplo yees, inc luding their family  
members, directl y involved in the conduct of the study .
2.Participation in other studies involving investigational drug(s) within 30 day s
prior to study  entry  and/or during study  participation .  This includes 
investigational medicinal products and investigational vaccines received outside 
of a clinical study such as corona virus disease 2019 ( COVID -19) va ccine sthat 
do not have emergency  use authoriza tion. Approved orEmergency  Use 
Authorized medicinalproducts and vaccines are 
not considered investigational 
and do not fa ll into this category .
3.Other acute or chr onic medical or ps ychiatric condition including recent (within 
thepast y ear) or active suic idal ideation or behavior or laboratory  abnormality  
that may  increase the risk associated with study  participation or investigational 
product a dministr ation or may  interfere with the interpr etation of stud y results 
and, in the jud gment of the investigator, would make the subject i nappropriate 
for entry  into this study .
4.Female su bjects of childbearing potential who are sexually  active who have not
been usin g a highly  effective method of contra ception as outlined in this protocol 
during the 2 weeks prior to r andomization.
5.Fertile mal e subjects and female subjects of childbearing potential who are 
sexually  active and are unwilling or unable to use a highl y effective method of 
contraception as out lined in this protocol for the durati on of the study  and for at 
least 28 day s after the las t dose of inves tigational product. 
6.Weight at Scr eening is less than the 10th percentile of weight for age and sex or 
is greater than the 95th percentile of weight f or age and sex 
(97th percen tilein 
Japan )based on sponsor -provide dgrowth charts.
7.Previous participation in this study  or concurrent partic ipation in any  other 
interventional non -observat ional study .
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 498.Planned medical pr ocedure during the MRI sc anor post -MRI recovery  period.
Non-interventional/o bservational procedures are not exclusionary .
9.Crani ofacial anomal y that could make it difficult to effectivel y establish a mask 
airway  for positive pressure ventilation if needed.
10.Require s endotracheal intu bation or laryngeal mask airway  (LMA).
11.Neurologica l or ps ychiatric condition that in the opinion of t he Investigator could 
confound reliable assessmen t of sedation score.  Examples include but are n ot 
limited to cerebra l pals y, autism, s
evere mental reta rdation, etc .
12.Other central nervous s ystem (CNS) dis ease including an uncontro lled seizure 
disorder, an y seizure activity  within 1 week of Day  1, known history  of or 
anticipated potential for increase d intracranial pressu re, and/or known 
psychiatric illnes s that could confound a normal response to sedatives .  History  
of single child hood febrile seizure is n ot exclusionary .
13.Known Ty pe I diabetes mellitus ( DM), or insulin dependent Ty pe II DM.
14.Known hist ory of significant re nal or liv er disea se.
15.Uncorrected h ypothyroidis m or hy perthy roidism or subjects whose t hyroid 
function and medica t
ion regimen have been st able less than 1 month prior to 
Day 1.
16.Known hype rsensitivity  to DEX or PROor an y of the Diprivan®Injectable 
emulsio n components .
17.Known allergy  to eggs, egg produc ts, soy beans or soy bean products.
18.Subjec ts for whom PRO, opiates, benzodiazepines, DEX or o ther alph a -2 
agonists are cont raindicated.
19.Received ge neral anesthesia within 7 day s prior to the planned start of the
investiga tional product administration.
20.Received treatment with an alpha -2 agonist or antagonist within 14 day s prior to 
the planned star t of the investigational p
roduct administration.
21.Received digoxin in the month prior to the planned start of th e inves tigational
product administration.
22.Known secon d-or third -degree heart block or clinic ally significant abnormal 
findings on the Screening rhythm str ip or electrocardiogram (EC G)diagnostic of 
atrioventricular ( AV) conduction block or sustained cardiac arrhy thmia .
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 5023.Symptom atic cardiac or respiratory  disease that, in the I nvestigator’s opini on, 
might increase the risk to the subject.
24.Requirement for an apnea monitor within the past 3 months, or moderat eto 
severe Sleep A pnea S yndrome bas ed on clinical history  or sleep study .
25.SpO2 <93 % on room air.
26. A temperature (c ore or t ympanic) ≥38.0° Centigrade.
27.Any other medication, condition or factor that, in the Investigator’s opinion ,
might increase the risk to the subject.
28.Any subject that, in the Investigator’s opinion, is exhibiting any  behavior(s) or 
indication(s) that they may  be under the influenc e of alcohol or dr ugs of abuse.
29.Heart rate values at Screening 
according to the respective age groups below 
based on the 10thcentile data from the HR table in Appendix 7, HR and RR 
Centile Chart Cu t
-offs fo r Children from Birth to 18 Years of Ag e (Fleming et al, 
Lancet 2011).  Subject can be reassessed after 5 minutes and can be considered 
for randomization if their heart rate increases above the criteria.
Exclusion Criteria for Heart Rate
Age Hear t Rate
≥1 month to <3 months <123 beats per min ute (bpm)
≥3 months to <6 months <120 bpm
≥6 months to <9 month s <114 bpm
≥9 months to <12 months <109 bpm
≥12 months to <18 months <103 bpm
≥18 months to <24 months <98 bpm
≥2 year to <3 years <92 bpm
≥3 years to <4 years <86 bpm
≥4 years to <6 years <81 bpm
≥6 years to <8 years <74 bpm
≥8 years to <12 years <67 bpm
≥12 y ears to <1 5 years <62 bpm
≥15 y ears to <18 years <58 bpm
30.Systolic blood pressure values at Screening according to the respecti ve age 
groups below based on t he BP data from the table in Appendix 8, Normal Vital 
S
igns According to Age (Ne lson Textbook of Pediatrics 20thEd, 2016).  Subject 
can be reassessed after 5 minutes and can be considered for rando mizatio nif 
their blood pressu re does not meet t he below criteria.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 51Exclusion Criteria for Systolic Blood Pressure
Age SBP
≥1 month to <3 months <65 or >85 millimeters of mercury  (mm Hg)
≥3 months to <6 months <70 or >90 mm Hg
≥6 months to <1 y ear <80 or >100 mm Hg
≥1 year to <3 years <90 or >105 mm Hg
≥3 years to <6 years <95 or >110 mm Hg
≥6 years to <12 years <100 or >120 mm Hg
≥12 y ears to <17 years <110 or >135 mm Hg
4.4. Exclusion Criteria on Day 1
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1. A ll Screening exclusion criteria continue to apply as appropriate .
2.Pregnant female subjects (incl uding those with an indeterminate or po sitive 
pregnancy  test); breast feeding female subjects .
3.Weight on Day 1 before randomization is less than the 10th percentile of weight for 
age and sex or is greater than the 95th percentil e of we ight for age and sex ( 97th 
perce ntile in Japan) based on sponsor -provided growth charts.
4.Exposed to DEX within 48 ho urs prior to the planned start of the investigational 
product administration.
5.Received an IV opioid within one hour, or oral/intra -muscular 
(PO/IM) opioid within 
4 hours pr ior to the planned start of the investigational product administration .
6.Received an y medica tion that has sedative or h ypnotic properties within 4 hours prior 
to the planned start of the investigational product adminis tration.
7.Recei ved an y pre -induction med ication (ie, ketamine, chloral h ydrate, 
benzodiazepines) within 4 hours prior to the planne d start of the investigational 
product administration, other than planned gas induction to be administered via mask 
for placem ent of IV acce ss as described in Section 5.10.2 Permitted Co ncomitan t 
Treatments .
8.Received anti -depressant agents (eg, fluoxetine) during the 48-hour period prior to the 
planned start of the investigat ional product administration.
4.5.Lifestyle Re quirements
4.5.1. Contraception
All fertile male subjects and female subjects wh o are of childbearing potential who are, in the 
opinion of the investigator, sexually  active and at risk for pregnancy  with their part ner(s),
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 52must h ave been using a highl y effective m ethod of contraception consistently  and correctl y 
for at least 2 weeks pr ior to D ay1 and must agree to use a highl y effective method of 
contraception consistently and correctl y for the duration of the activ e treat ment pe riod and 
for at least 28 day s after the last dose of investigational product.  The investigator or his or 
her designee will confirm that the subject has selected an appropriate method of 
contraception from the list of permitted contraception methods (see b elow) .  At time points 
indicated in the Schedule of Activities, the investigator or designee will instruct the subject 
of the need to use highl y effective contraception consistently  and correctly  and document the 
conve rsation, and t he subject’s affirmation, in the subject’s chart.  In addition, the 
investigator or designee will instruct t he subje ctto call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subje ct or 
partner.
Highl y effec tive methods
of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.Established use of hormona l metho ds of c ontraception associated w ith inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal), provide d the subject 
plans to remain on the same treatment throughout the entire study  and has been using 
that hormonal contraceptive for an adequa te period of time to ensu
re effectiveness. 
2.Correctly placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ).  For countries where spermic ide is not available or 
condom plus spermicide is not accepted as highl y effective contraception, this option 
is not appropri ate. 
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (includin g durin g the e ntire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if th is is th e preferred and usual 
lifesty le of the subject. 
All sexually  active male subjects must agree to prevent potential transfer to and ex posure of 
partner(s) to drug thr ough ejaculate b y using a condom consistently  and correctl y, beginning 
with the first dose of investigational product and continuing for at least 28 days after the last 
dose of investigational product.
4.6.Sponsor’s Quali fied Me dical P ersonnel
The contact info rmation for the sponsor's appropriately  qualified medical personnel for the 
study  is docume nted in the study  contact list located in the supporting study documentation .
To facilitate access to appropriatel y qualified medical person nel on study -related medi cal 
questions or problems, subjects are provided with a contact card. The contact card con
tains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 53contact information for the inve stigato r site, and contact details for a contact center in the 
event that the investigator site staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s partic ipation in the study .  The contact numb er can also be used by investigator 
staff if they  are seeking advice on medical que stions o r problems; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the s tudy team are not availab le.  It is therefore intended to augment, but not replace, the 
established communication pa thways between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the study .The co ntact 
number is not inten ded for use b y the subject directly, and if a subject calls that number, he 
or she will be directed back to the investigator site.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmonisation (I CH) 
guideli nes, investi gational product is defined as a pharmaceutical form of an active 
ingredient or pla cebo bei ngtested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or asse mbled ( formulated or
packaged) i n a way  different from the approved form, or when used for an unapproved 
indication , or whe n used to gain further information about an approved use (I CH E6 1.33). 
For this study , the investigational product is Dexmed etomidi ne hy drochloride inj ection, US 
approved PRECEDEX™. 
5.1.Allocation to Treatment
Within the appropriate age stratum, sub jects wi llbe randomized in a 1:1:1 ratio on Study  
Day 1 to the DEX low dose, middle dose or high dose group.  Allocation of subjects to dose
groups will proceed through the use of an interactive response technology  (IRT) sy stem 
(interactive Web -based resp onse [I WR]).
Once the signed informed consent has been provided by  the parent/legal guardian and assent 
(as required b y the Institut ional R eview B oard [IRB]/I ndependent Et hics Committee [I EC]) 
has been provided b y the subject, the blinded site staff will screen 
the subject in the I RT 
system and obtain a single subject identification number (SSID) which will be used to 
identify  the subj ect thr oughout the study .  Subjects wil l be numbered sequentially .  The 
subject must keep that number throughout the study even if he or she transfers to another site.  
A subject who discontinues or is withdrawn from the study  prior to randomization and who 
re-screens at a later time must be as signed a new subject number.  A subject numb er must 
never be reassigned or reused f or an y reason.  The investigator must maintain a log linking 
the subject number to the subject’s name.  The investigator must follow a ll applicable 
privacy  laws in order to protect a subject’s privacy and confidential ity.  Information that 
could identify  asubject will be masked on material received b y the sponsor.
To randomize an eligible subject, the blinded personnel will be required to ente r or se lect 
information including but not limited to the user’s identificati on (ID) and password, the 
protocol numb er, the 
subject number, subject date of birth and the subject’s weight. The 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 54blinded personnel will only  be provided with a randomization num ber whi ch must be 
recorded on the case report form (CRF).  The IRT sy stem wi ll provide them a confirmation 
report c ontainin g the above information, which must be retained in the blinded site file.
The designated unblinded dispenser(s) will receive n otifica tion th at a subject has been 
randomized into the study and will be provided with the subject number, weight, date o f birth 
with age, randomization number, dose group assignment, loading dose per kg in mcg/kg, 
total loading dose in mcg, total loading dose i n mLs, loading dose concentration in mcg/mL, 
loading dose IV rate in mL/hr t o be given over 10 minutes, maintenance dose pe r kg in 
mcg/kg/hr, maintenance dose in mcg/hr, maintenance dose concentration in mcg/mL, 
maintenance dose IV rate in mL /hr (ie , all v alues u sed in determining the in fusion rates), 
number of vials needed and the dispensable unit(s) (DU) or container number( s)to be 
used.   Once subject numbers, randomization numbers and DU or container number(s) have
been assigned, they  cannot be r eassign
ed.This notification must be r etained by  the 
unblinded dispenser in the un blinded site files.
A study  specific IR T manual will be provided that will include I RT contact information and 
details on the use of the IRT sy stem for this study .
A study  specific IP man ual will provide dosing and administration instructions and 
investiga tional product dilution instructions fo r this s tudy.
All manuals will be provided separatel y.
5.2.Breaking the Blind
The investigational product dose is blinded to the sponsor, investi gator a nd subject.
At the initia tion of the study , the investigator site wil l be instructed on the method for 
break ing the blind.  The method will be an electronic process.  Sites must not contact the 
unblinded dispenser for this information.  Blind ing cod es shou
ld be broken only  in 
exceptional circumstances when knowledge of the actual treatment code is absolutely  
essential f orfurther management of the subject.  Investigators are encouraged to discuss with 
a member of the study  team if they  believe that b reaking the blind is necessary . When the 
blinding code is broken, the reaso n must be fully  documented in the sourc e docume nts and 
entered on the CRF.
5.3. Subject Compliance
The investigational product will be administered as a single loading dose infus ion fol lowed 
by a maintenance dose infu sion by  the appropriately  designated stud y staff at the investigator 
site. Subjects will no t be assessed for dosing compliance.
5.4.Investigational Product Supplies
5.4.1. Dosage Form(s) and Packaging
Precedex™ (dexmedetomidine hydroch loride) Injection, Concentrate, will be provided b y
Pfizer I nc. as vials for IV infusion following dilution of the concentr ate.  Precedex I njection, 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 55Concentrate, 200 mcg/2 mL  (100 mcg/mL) vials will be supplied in a 2 mL clear glass flip -
top vial an d seale d with a coated stopper and an a luminum overseal with an aqua flip- off cap. 
Each vial will be packaged in an indiv idual ca rton and labeled according to local regulatory  
requirements. 
Each carton will contain a single vial of study  medication, and each ca rton wi ll be identified 
with a unique DU or container number. Each carton will be packaged with a tamper -resistant
seal. T hesponsor must be notified of any  investigational product in which the 
tamper -resistant seal has been broken and this medicat ion should not be used. Further detail s 
will be detailed in the Investigat ional Product Manual (I P Manual).   The IP is pr esented as a 
sterile, clear, colorless concentrate solution for IV administration.  Each vial contains 200 
mcg of Dexmedetomidine in 2 mL of 0.9% so dium chloride solution.  Each mL  contains 100 
mcg of dexmedetomidine and 9000 mcg of sodium chloride in wate r and must be diluted 
before use.  The solution is preservative -free and contains no additives or chemical 
stabilizers.  Each vial is for single- useonly.  
The intended dose will be diluted to a concentration not to exceed 4 mcg/mL .  Each vial must 
be dil uted as 
described in the I P Manual to achieve the appropriate concentration for each 
subject’s treatment group assignment prior to adm inistration.  Specific instructions for
dilution will be provided separatel y in the IP Manual.  
5.4.2. Preparation and Dispensing
The unblinded dispenser will prepare the investigational product from the carton(s) with the 
unique DU or container number(s) assigned b y the IRT.  The IP will be dispense d on Day  1 
by the unblinded dispense r to the blinded study  staff who will administe r the bl inded loading 
and maintenance doses to the subject.
The site should be instructed to maintain the product in the cartons provi ded, an
d the c artons 
should not be opened until the investigational product is to be diluted for administration.
The numbe r of via lsdispensed will be sufficient for preparing the subject’s dose based on the 
randomization to the low, middle, or high dose l evel. S ee the IP Manual for instructions on 
how to prepare the IP for administration.  The I Ppreparation and dispensation is the 
responsibility  of and requires oversight b y an appropriatel y qualified and experienced 
unblinded site pharmacist as allowed b ylocal,state, and institutional guidan cewho must sign 
the Preparation Records .  For 
this study , third- party  blind will be used to ensure the integrit y 
of the blind.  The I P dose will be administered blinded to the subject by  site staff.  The 
blinded stud y medication m
ust be administered by a site phy sician experienced in delivering 
sedati on and e ither the PI , or a sub -investigator (subI) who meets the criteria for PI and is 
listed on the 1572, must be present. The sponsor, subject a nd investigator will b e blinded to 
the dose of DEX.
5.5.
Investigational Product Administration
Subjects enrolled into the study  will be randomized to receive one of three DEX dosing 
regimens (Low, Middle, or High), each consisti ng of an IV loading dose that is immediately  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 56followed by  an IV maint enance infusion that will continue for the dura tion of th e MRI  scan.  
DEX must be administered through a peripheral IV line that is not a subclavian li ne, 
peripherally  inserted (or pe rcutaneous indwelling) central cathe ter (PI CC) line or othe r type 
of cent ral cathet er.
The loading and maintenance infusion doses will be given at the stable, pre -defined doses as 
described below and may not be modified, but the infusion may  be discontinue d if clinicall y 
indicated.  The loading dose will be admini stered over 10 minutes:
Blinded dose levels for subjects ≥1 month to <2 years of ageon Day  1:
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose le vel 0.5 mcg/kg 0.5 mcg/kg/hour
Middle dose level 1mcg/kg 1mcg/kg/hour   
High dose leve l 1.5 m cg/kg 1.5 mcg/kg/hou r
Blinded dose levels for subjects ≥2 years to <17 years of ageon Day  1:
Dose Level DEX Loading Dose DEX Maintenance Infusion Dose
Low dose level 0.5 mcg/kg 0.5 m cg/kg/hour
Middle dose level 1.2 mcg/kg 1mcg/kg/hour   
High dose l evel 2mcg/kg 1.5 mcg/kg/hour
Refer to the IP Manual for instructions on how to administer the investigational product. 
Investigational product admi nistration details including sta rt time, stop time and IV rate in 
mL/hour will be recorded on the C RF.
5.6.Rescue Propofol Medicat ion
Once the DEX loading dose has been administered and the maintenance dose started, if an 
adequate level of sedation is not achieved within 5 minute s after the start of the DEX 
maintenance infusion, concomitant PRO may  be given per cl inical judgment to e nsure that an 
adequate sedation level is achieved to start the scan.  The target sedation level is indicated by  
a PSSS score of 2 (ie, “Quiet [asleep or awake], not moving during procedure, and no frown 
[or brow furrow] indicatin g pain or a nxiety.  No verbalization of any  complaint.”).27
Concomitant PRO should be administered as needed through completion of th e scan to 
maintain adequate subject sedation per PI clinical judgment.  If it i s neede d, PRO should be 
administered first as a bolus of 0.5 mg/kg (500 mcg/kg) over approximately  1 minute 
followed b y the start of a PRO maintenance infusion at 50 mcg/kg/min.   Additional bolus 
doses of PRO 0.5 mg/kg m ay be given as 
needed for subject mo vement/ wake ning. Following 
each additional PRO bolus , there mus t bea simultaneous increase in the PRO maintenance 
infusion rate in a 25or 50 mcg/kg/min increment .  However, s ubsequent increase s in the 
PRO ma intena nce infusion rate may  bemade in 2 5or 50mcg/kg /min increments without a 
corresponding PRO bolus .  ThePRO maintenance infusion may also be decreased in 25or 50 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 57mcg/kg/min inc rements as needed to maintain adequate subject sedation, or it may be 
dis
continued if clinically  indicated .  
PRO admin
istration details including start time, stop time, bolus doses in mg /kg and 
maintenance dos e rates in mcg/kg/min will be re corded on the CRF.
PRO will be supplied by  each individual study  site.
PRO is not approved for procedural sedati on in the pe diatric populati on,so in this study  the 
use of PRO is considered investigational .
5.7.Inve stigational Product Stora
ge 
The investigat or or an approved representative, eg, pharmacist, will ensure that all 
investigational products including PRO arestored in a secured area wi th controlled access 
under required storage conditions and in accordance with applicable regulato ry requirements.
Invest igational products should be stored in their original containers and in accordance with 
the labels.  
See t he IP manual for storage conditions of the product.
Any storage conditions stated in the SR SD will be superseded b y the storage conditions 
stated on the product label.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a
minim
um, dai ly minimum and m aximum temperatures for all site storage locations (as 
applica ble, inclu ding frozen, refrigerated , and/or room -temperatu re products).  This should 
be captured from the time of investigational product receipt throughout the stud y.  Even for 
continuous
-monit oring systems, a log or site procedure that ensures active eval uation fo r 
excursions should be available.  The int ent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursi on occ urred s ince the last 
evaluation and to provide the site with the capability  to store 
or view the m inimum/maximum 
tempera ture for all non-w orking day s upon return to normal operations.  The operation of the 
temperature monitoring device and storage un it (forexamp le, refrigerator ), as applicable, 
should be regularl y inspected to ensure they are maint ained in working order.  
Any excursions f rom th e product label storage conditions should be reported to Pfizer upon 
discovery .  The site should actively  pursue options for returning t he product to the storage 
conditions described in the labeling
,as soon as possible.  Deviations from the storage 
requir ements, including any  actions taken, must be documented and reported to Pfizer.  
Once an excursion is ident ified, the investigational p roduct must be quarantined and not used 
until Pfizer provides permission touse the investigation al product.  It w ill not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperat ure exc ursion. Use of the investigational product prior to Pfizer approval will be 
c
onsidered a protocol deviation. Specific details re gardin g information the site should report 
for each excursion will be provided to the site.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 58Receipt of materials, door opening and closing, an d other routine handling operations where 
the products are bri
efly out o f the temperature range d escribed in the la belin g are not 
considered excursions.
5.8.Investigational Product Accountability 
The investigator site must mainta in ade quate r ecords documenti ng the receipt, use, loss, or 
other disposition of the investi
gational p roduct supplies.  All inv estigational prod ucts w ill be 
accounted for using a drug accountabilit y form/record.  
5.8.1.
Destruction of Investigational Product Suppl ies 
The sponsor or designee will provide guidance on the destruction of unused investigat ional 
product(eg, at the site).  A ll used and unuse dsupp lies must be inventoried and accounted for 
by the study  monitor.  When notified by  the Sponsor that it is a ppropr iate, a ll used, partial ly 
used, or unused vials may be destro yed according to site -specific sta nda
rd operating 
procedure (SOP) for clinic al supply  destruction after accountability  has been completed by  
the study  monitor.  If destruction is authorized to take plac e at the investi gator site, the 
investigator must ensure that the materials ar edestroy ed in compliance with applicable 
environmen
tal regulations, institutional policy , and any  special instructions provided by  
Pfizer, and all destruction must be ade quatel ydocumented.
5.9.Prior Treatments
The start and stop dates of administration for a ll medicat ions and non
-pharmacologi c 
therapies recei ved bythe subject for the 4 -week period before randomization will be 
recorded on the subject’s CRF.
5.10. Concomitant T reatm ents
All medications an d non- pharmacologic therapies that the subject receives from 
r
andomization through the Day  29 Long -term Follow - up V isit will be recorde d on t he 
appropriate CRF along with the dates of administration and dosages.  Time will also be 
collected for concomitant treatments with a start date on Day  1.  An y questions about 
whether use of a conco mitant med ication or treatment i s pro hibited or perm itted during a 
subject’s study  participation should be discussed with the Pfizer medical repr esent ative.
5.10.1. Required Treatme nts
The following treatments are concomitant treatments or procedures that are requ ired during 
the DEX administration.
Subjects will be administered supplemental IV fluids during the DEX infusion that will be 
administered at a minimu m mainte nance rate in mL/hr per the following formula :  
4 mL /kg/hr for the first 10 kg of we ight; and
2 mL/kg/hr for the nex t 10 kg of weight; and
1 mL/kg/hr for every  additional 1 kg of weight.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 59However, s ites may  limit the IV rate to amaximum of 100 mL /hr for subjects weighi ng ≥60 
kg if appropriate per PI judgment /local practice .Please refer to the I P Manual f or the list of 
permitted IV fluids that may  be used.  The use, type and rate of maintenance fluid 
administrat i
on following discontin uation of the DEX infu sion will be a t site discr etion.
5.10.2. Permitted Concomitant Treatments
The following treatments are concomi tant treatments or procedures that are permitted
throughout stud y participation.
Supplemental oxy gen (O 2) is pe rmitted, bu tif used as proph ylaxis, it sho uldbe 
adminis
tered via na sal cannula at a rate of 1 -3 L/min or via face mask at a rate of at 
least 6 L/min and must n ot interfere with EtCO 2concentration monitoring throughout 
the MRI  scan.  Oxy gen may  also be administered as interv
entional treatment if 
needed.  See Section 8.4.1.3 .
Contrast solution is permitted but must be administere dwhile the DEX and/or PRO 
infusion is paused.  Site -specific standard pro cedures for contrast solution in fusion 
should be followed.
If the Investigator believes th at placement of IV access could provoke anxiety  or 
added discomfort t o the s ubject, they  may utilize one of the following options below 
in an effort to allay  subject anxiety :
Topical or l
ocal anesthe tic; 
Gasinducti on that is adm inistered via mask with ei ther sevoflurane -oxygen, 
sevoflurane -nitrous oxide -oxygen mixtures or nitrou s oxide -oxygen. As soon as 
the patient becomes compliant, intravenous cannulation should occur.  F ollowing 
intravenous ca nnulation, the inhalation agents should be tur ned off and the patient 
should be administered 100% oxy gen.  To wash out these ag ents as fast as 
possibl e, a high fresh gas flow of 100% ox ygen should be administered.  The 
Fract ional Inspiratory  Oxy gen (FIO 2),Fractiona l Inspir atory  (FI), En d Tidal (ET) 
sevoflurane/nitrous oxide should be monitored during this induction process.  
When the ET sevoflurane/nitr ous oxide is below 0.1% and the subject is awake 
and not agitated the inf usion of the DEX loading dose ma ycommence.
5.10.3. P rohib ited Concomitant Treatments
The followin g treatments are concomitant treatments or procedures that are prohib itedfrom 
randomization through the Day  2 Follow -up Visit (24 -Hour Post-Treatment Period) or as 
otherwise specified below.  Subje cts requiring a prohibited treat men t,procedur e or 
medicat ion to control a medical condition should notbe enrolled.
Drugs admi nistere d during the stud y drug infusion tha t may  affect the sedatio n 
assessm entsuch as anestheti cs (other than topica l/local), se datives, h ypnotic s and 
opioids oth erthan DEX or PRO.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 60Prophy lactic use of atropine or other medications to prevent brady cardia are 
prohibited, but th ey ma y be used as interventional treatment if needed.   See 
Section
8.4.1.3 .
Current or recent use of digo xin within the past month.
Subjects receiving anti-depressants (eg, fluoxetine) for chronic therapy prior to 
enrollment in the study  may  be enrolled and continue the us e of the prior 
antidepressant(s); however, these agent s are not to be introduced duri ng th e 48- hour
period prio r to study  drug infusion through the Day  2 Follow -up Visit (24- Hour 
Post-Treatment Perio d). 
Any neuromu scular blocking agents.
Any drug s contrai ndicated with the use of DEX or PRO.
Alpha- 2 agonists /antagonists other than DEX with in 14days prior to study  drug start 
or during stud y drug infusion. (eg, clonidine, guanfacine, etc).
Agents to in
duce sleep (eg, triazolam, diphenhy dramine, etc) during t he study  drug 
infusion other than those listed in Se ction 5.10.2 Permitted Concomitant Treatments.
Insulin administere d for T ype I or T ype IIDM.
Planned medical procedure during the MRI scan orpost-MRI  recovery  period .Non-
intervent i
onal/observa t ional proced ures are not exclus ionary.
6. STUDY PROCEDURES 
6.1.Screening
All subjects must complete the procedures listed below duri ng a Screening Visit onor up to 3 
days before 
Day 1.
The study  will be thoroughl y explained to the subject and the subject’s le gal guardian( s) as 
appropriate. The investiga tor must ens ure that each trial subject, or his/her legal guardian(s), 
is fully  informed about the n
atureand objectives of the tr ialand possible risks associated 
with participation.  If the subje ct wishes to participate i n the study  and the legal guardia n(s) 
desires the subject to participate in the study , an IRB/IEC -approved informe d conse nt form 
willbe signed and dated by the su
bject or legal guardian(s) as appropriate, before an y 
procedures ar e performed t hat are speci fic to this study . The informed consent form must be 
agreed to b y Pfizer and the I RB/IEC and must be in complianc e with ICH Good Cli nical
Practice (GCP), local re gulato
ry requirements, and legal requirements. 
The signed document s will be ret ained at the site and the invest igator or pers on designate d by 
the investigator must document in the source documents that info rmed co nsent was obtained. 
Each subject will be assigned a unique subject number via the IRT s ystem.  The Day 1 Visit
is the dat eof the MRI scan.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 61The following information/a ssessments w ill be collected.  
1.Informed consent/assent.  Signed informed consent /assent must be obtaine dprior to 
conduc ting anytests,assessments or procedures.
2. Subject Number assignment via IRT.
3. Subject dem ograph y: date of birth, sex, ra ce,and ethnic ity.
4.Presenc e of chronic conditions and general medical history  of relevance incl uding 
surgical pr ocedur es.  Start and st op dates should be included if known.
5.Eligibility  assessment.
6.Physical exami nation includ ing the follo wing body  systems: general appea rance, 
head, ears, ey es, nose, mouth, throat, neck, lungs, heart, abdomen, muscul oskelet al, 
extrem ities, skin, ly mph node s, neurol ogical.  The phy sical examination (PE) will be 
conducted b y a ph ysician, trained physician’s assistant or nurse pra ctitioner a s 
acceptable according to local regulation.
7.Contraception check.  The investigato r must assess and docum ent in the source ifthe 
subject is biologicall y capable of havin g/fathering children and if the subject 
c
ontinues to be or has become sex uallyactive. If yes, the ir method of contraception 
and confirmation of its consistent and cor rect us e must als
o be documented in the 
source do cuments.
8.Vital signs measurements, including height (or length as a ppropriate), w eight, 
tempe rature, heart rate, respiratory  rate, SpO 2and blood pressure including MAP.  
Vital signs measurements should be t aken in a supine positi on as much as pos sible.
9.Two-minute rh ythm strip and/or 12 -lead ECG as required.  A 12 -lead EC G will be 
performed if cli nicall y significant abnormalities are noted o n the rh ythm strip. If a site 
does not have the capability  to obtain a hard copy rhythm stri p, the 12 -lead EC G may 
be per formed in lieu of the rhy thm strip. Subjects with a known histo ryof cardiac
disease will be required to have a 12-lead EC G performed.   Rhy thm strips and 12-
lead ECGs must be evaluated for abnormalities by a ph ysician ex perien ced in 
pediatric rhythm in terpretation and hard copies retained.  The investigator is 
respons ible for revi ewing, signin g and dating the in terpr etations.  If a clini cally  
significant observation is noted, please contact the Pfizer Medical Re presentative 
prior to randomization.
10.
Adverse events (AEs)/serious adverse events (SAEs) will be collected fro mthe time 
theinformed consent is obtained.
11.Colle ction of prior t reatment inf ormation. 
The presence of all required inclusion criteria and the absence of a ll exc lusion criteria must 
be recorded in the source documents.  Subjects meeting all of the inclus ion criteria and none 
of the exclusion criter ia will be eli gible t o randomi ze in the study .  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 626.1.1. Screen Fail Subject
A subject who does not mee t one or more inc lusion criteria or meets one or more exclusion 
criteria will be considered a screen failure and the yshould not be randomized .
Screen failure su
bjects may  re-screen at a later date.  If a sub ject chooses to re -screen, a 
second informed con sent mu st be obta ined a nd documented, a new subject number must be 
assigned, and 
allscreening tests and procedures must be repea ted.  All res ults must be 
obtain ed and reviewe d befor e the sub
jectmay be randomized.  Subjects needing to be 
re-screened more than on ce must fi rst be discussed with the Pfizer Medical Representative.
6.2.Day 1 Peri od 1 (MRI scan)
Alltests and pr ocedures desc ribed in Section 6.1and those prior t o randomization listed 
below must be complet ed and all results reviewed before the subject may  be evaluated for 
eligibility  to randomize.  Subj ects who meet all inclusio n criteria and do not meet an y 
exclusion criteria willbe randomly assigned by age to one of three dose groups.  T he 
following will be co mpleted before randomization : 
1.Eligibility  assessment.
2.Temperature and wei ght.If Screening a ndDay 1 occu r onthe same day, the 
temperatu
re and weight do not need to b e repeated before randomization.
3.Laboratory  evaluation: Urine dip stick or whole - blood qua litative hCG pregnancy  test 
that can be performed at the bedside 
for all female subjects of ch ild-bearing pote ntial.
Serum qualit ative or quanti tative hCG pregnancy  tests arenot permi tted.
The following will be com pleted after randomization:
1.Vital signs measurements, incl uding heart rate, respiratory rate, SpO 2 and blood
pressure including MAP sh ould be obtained with the subject in a supine position as 
much as possible.  H eart rate, r espiratory  rate, SpO 2, blood pre ssure and MAP will be 
measured within approxi mately  5 minutes before the load
ing dose to obtain Baseline 
value sand thosevalues will b e documented on the CRF . Heart rate, r espiratory  rate, 
SpO 2, blood pressure and MAP will be measured every  5 (±1) minutes once the 
loading dose has starte d until the end of the MRI  scan and the 
values documented on 
the CRF .  Hea rt rate , respiratory  rate and SpO 2,as well as blood pressure where 
available ,will alsobe monitored between scheduled readings e ither per site
equipment monitoring standards or mor e frequently  as deemed clinically  necessary  
from the sta rt of the study  treatment loading dose throug h the post -MRI reco very 
perio d.  A llvital sign values obtained from amonitoring equipment downl oadneed to
be reviewed for adverse events regardless of their collection frequency . If anyvital 
sign values between the required scheduled re adings meet the criteria fora protocol -
speci fied adverse event , the AE needs to be reported. Nadir valuesforH R, RR and 
SpO 2 vital sign measurements during the course o f the sedati on will also be obtai ned 
from the te lemetry  monit ordata and documented on the CRFs.  Nadi r values for 
systolic BP and MAP during the c ourse of th e sedation wi ll be identified 
programm atically f rom the data entered on the CRF.  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 63If heart rate d ecrea ses >20 % from Baseline and is outsid e the normal range, a blood 
pressure measure ment including MA P should be repeated at appr oxim ately 2 -minut e 
intervals until t he heart rate returns to the normal range.  If s ystolic blood pressure 
decreases ≥30% from Base line and is outside the norm al range , a blood pressure 
measurement including MAP should be check ed approximately  1 minute later. If the 
systolic blood p ressure remains outside the no rmal ran ge,measurements should be 
repeated at approximately 2 -minut e inte rvals until the sy stolic bl ood pres sure returns 
to the normal range.  Normal ra nges are provide din Appendix 8, Normal Range s by 
Age (Nelson Textbook of P ediatric s, 20thEd,2016).  Baseline values are those 
obtained at Da y 1 Pe riod 1 within approximately 5 minut esbefore the start ofthe 
DEX loading dose.
2.EtCO 2will be m onitored from the st art of the study treatment loading do se through 
the MRI  scan. EtCO 2data will notbe collected ona CRF.
3.Continuous cardiac telemetry  monitor ing is required beginning j ust prior to the start 
of th
e study  treatment loadin gdose and conti nuing through the po st-MRI recove ry 
period
.  New or worsening clinically  significant ab normalities not al ready defined in 
Sectio n 8.4.1 , Protocol -Specifie d Adverse Events, will a lso be documente d as adverse 
events on the CRF.  
4.Peripheral IVline ins ertion if needed .  DEX must be administer ed throu gh a 
peripheral IV line that is not a subclavian line, PICC line or other central c atheter .
5.PSSS sedation rati ngs will be obtained pr ior to the study  treatment loading dose, 
immediate ly following admi nistrat ion of the loading dose , and a t 5 (±1) minut e 
intervals throughout the duration of the study  treat ment i nfusion and MRI  scan. 
6. Administrati on of DEX.  Subjects will receive a single blinded IV Loadin g Dose of 
DEX over 10 minu
tesfollowed by  a blinde d IV Ma intenan ce Infusion D oseof DEX
per their age anddose group assignment described in Section 5.5 Investigational 
Product 
Administration.  The infusion rate of the l oading and maintenance d ose IV 
infusions in mL /hour will be provided b y the third-party unblinded dispenser.  The 
sponsor, subjec t and investigator will remain bl inded to the dose assignme nt. Dose 
adjustments of DE X are not permi tted. 
7.Open -label PRO may  be admi nistered if neede d per Section 5.6 Rescue Propofol 
Medicat ion to a chieve and maintain an adeq uate lev el of sedation in th e clinical 
judgment of 
the PI.  The target sedation level is indic ated by a PSSS score of 2.
8.Supp lementa l IV fluids w illbe adm inistered duri ng the DEX infusion at a 
maintenance rate per Section 5.10.1.  Please refer t othe IP Manual for the list of 
permitted IV fluids that may  be used.
9.TheMRI  scan may  commen ce once th e subject h as achieved an adequate level of 
sedation.  An y necessary contr ast solution must be admini stered w hile the DEX 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 64and/or PRO infusion is paused. Site-specific s tandard procedures for con trast 
solution infusion should be foll owed.
10. AE/SAE mon itoring .
11.Collectio n of co ncomitant treatment information.
6.3.Day 1 Period 2 (P ost-MRI Recovery)
Subjects must b
emonito red per protocol req uirements for a minimum of 1 hour; this must 
occur in a post -proce dure recovery  area such 
as a post -anesthesia care unit (PACU) , recovery  
room or other hospital area where the required monitoring can b e achieved.  After 1 hour, 
subjects will meet criteria toleave this area when the subject atta ins a minimum Modified 
Aldrete Score of 9, is tole rating oral fl uids and if a pplicable, anyinstituti on-specific 
discharge criteria have also been met.
1.
Vital sig ns measurements, including t emperat ure, heart rate, res piratory  rate, SpO 2
andblood pressure i ncluding MAP should be obt ain ed w ith the subject i n a sup ine 
position as much aspossib le. Body temperat ure will be measured when the subject 
arrives in t
he pos t-procedure recovery area a nd when they meet the criter iato leave 
this area. Heart rate, resp
iratory  rate, SpO 2, blood pre ssure and MAP will be
measur ed upon arrival in t he post-proced ure rec overy a reaandevery  5 (±1) minutes 
for the first 15 m inutes, and every  15 (±5) minutes until the subject meets the cr it eria 
to leave this ar eadescribed abov e.Thesevalues will be docum ented on the CR F.  
Heart rat e, respirator y rate and SpO 2,as well as blood pressure where 
available , will 
also be monitored be tween sche duled readings either per siteequipment monitori ng
standards or more freque ntly as deemed clinicall y necessary  from t he start of the 
study  treatmen t loading dose t hrough the post -MRI recovery  period.  Allvital sign 
value sobtained from amonito ring equipment download need to be reviewed for 
adverse eve ntsregardless of their collection frequen cy. If anyvital sign values 
between the required schedul ed readings meet the criteria for a protocol -specified 
adverse event , the AE needs to be reported. If heart rate decreases >20% from 
Baseline and is outside the normal range, a bloo d pre ssure measur ement in cluding 
MAP shoul d be repeated at approxi mately2-minu te interval s until the heart rate 
returns to the normal range.  If systolic blood pressure de creases 
≥30% from Baseline 
and is outs ide the normal range, a blood pressure measurement including MAP 
should be checked approximately  1 minute later.  If the s ystolic blood pressure 
remains outside the normal range, measurements sh ould be repeated at appr oximately  
2-minute intervals until the sy stolic blood press ure returns to the normal range.  
Normal ranges are provided in Appendix 8, Norm al Rang es by Age (Nelson 
Textbook of Pediatrics, 20thEd, 2016). Baseline values are tho se obtained at Day  1 
Period 1 
within approximately  5 minutes before the start of the DEX loading dose.
2.Continuous cardiac t elemetry  monitoring is required b
eginning just prior to the sta rt 
of the study  treatment loading dose and con tinuing through the post- MRI recovery  
period.  New or worsening clinically  significant abnormalities n ot already  defined in 
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 65Section 8.4.1 , Protocol-Specified Adverse Events, will also be documented as adverse 
events on the CRF. 
3. Modified Aldrete Score will be performed on arrival at the post-procedure recovery 
area and every 15 (±5) minutes until the subject is deemed suitable for discharge from that area.  Every attempt should be made to collect Modified Aldrete Scores for subjects less than 1 year of age.
4. PAED score will be performed after the subject awakens following arrival at the post-
procedure recovery area and every 15 (±5) minutes until the subject is deemed suitable for discharge from that area.  If any total score on the PAED is 10 or greater, subjects should be evaluated for emergence delirium, treated as appropriate and the PAED assessment frequency should be increased to every 5 (±1) minutes until thePAED score is below 10 or the subject leaves that area.
 
6. AE/SAE monitoring.
7. Collection of concomitant treatment information.
6.4. Follow-up
6.4.1. Day 2 Follow-upThe Day 2 Follow-up visit will be completed 24 hours (±2 hours) following discontinuation 
of DEX.  Contact with the subject or parent/legal guardian may be done via a phone call.
1. AE/SAE monitoring (see the Time Period for Collecting AE/SAE Information 
Section 8.1.4 ).
2. Collection of concomitant treatment information.
6.4.2. Day 29 Long-term Follow-up
The Day 29 Long-term Follow-up contact will be completed at least 28 calendar days, and up 
to 31 calendar days after the last administration of the investigational product.  Contact with the subject or parent/legal guardian will be done via a phone call.
1. AE/SAE monitoring (see the Time Period for Collecting AE/SAE Information 
Section 8.1.4 ).
2. Contraception check (see the Contraception Section 4.5.1 ).
3. Collection of concomitant treatment information.CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 666.5. Subject Withdrawal / Early Term inatio n
Subjec ts may  withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (s ee also the 
Withdrawal From the S tudy Due to Adverse Eve nts (see also the Subject Withdrawal / Earl y 
Term inatio nsection) ) or behavioral reasons, or the inability  of the subject to comply  with the 
protocol -required schedule of stud y visits or procedures at a given s tudy site. 
Subjects who do not co mplete th e MRI  scan wil lbe considered discontin ued subjects.  
Subjects 
who have a medical procedure performed during the MRI scan must be 
discontinued. The Day  1 Period 1 assessments described in Section 6.2 and the Day 1 Period 
2 assessment s described in Section 6.3 should be completed as appro priate.  The Follow -up 
Visits should be completed whenever possible.
Withdrawal of co nsent :
Subjects/parents/legal guardians who reque st to discontinue receip t of study  treatment will 
remain in the study  and must continue to be followed for protocol specif ied follow -up 
procedures.  The onl y exception to t his is when a subject/parent/legal guardian specifically  
withdraws consent for any furthe r contact with him or her or persons previously  authorized 
by the subject to provide this information.  Subjects/pare nts/legal guardians should notify  the 
investigator in writing of the decision to with
draw cons ent from future follow -up, wheneve r 
possible.  The withdrawal of consent should be explained in detail in the medical records b y 
the investigator, as to whether t he withdrawal is only  from further receipt of inve stigational 
product or also from study proce dures and/or post -treatment study  follow -up and entered on 
the a ppropriate CRF page.  In the event that vital status (whether the subject is alive or dead) 
is bei ng measured, publicly  available information should be used to determine vital status 
only as appropriatel y directed in accordanc e with local law.
Lost to fo
llow-up: 
All reasonable efforts must be made to locate subjects to determine and report their ongoi ng 
status.  This includes follow -up with persons a uthorized by  the subject as noted a bove.  Lost 
to follow -up is defined by  the inability  toreach the subje ct/parent/legal guardian after a 
minimum of 2 documented phone calls, faxes, or e- mails as well as l ack of response by  the 
subject to 1 registered mai l letter.  All attempts should be d ocumented in the subject’s 
medical record s.  If it is determined that t hesubject has died, the site will use locally  
permissible methods to obtain the date and cause of d eath.  If the investigator’s use of a third -
party  representative to assist in the fol low-
up portion of the study has been incl uded i n the 
subject’s informed consent, then the investigator may  use a sponsor -retained third -party 
representative to assist site staff with obtaining the subject’s contact inform ation or other 
public vital status data nece ssary  to complete the follow -up portio n of the study.  The sit e 
staff and representative will consult publicly  available sources, such as public health 
registries and databases, in order to obtain updated contact information.  If, after all attemp ts, 
the subject remains lost to follow
-up, then the la s t-known -alive da teas determined b y the 
investigator should be reported and documented in the subject’s medical reco rds.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 67If a subject does not return for a scheduled visit, every  effort should be made to contac t the 
subject.  Study  sites should doc ument 3 attempts to cont act subjects and/or parent(s)/legal 
guardian(s) as appropriate.  All attempts to contact the subject and information received 
during contact attempts must be documented in the subject’s medical record.  The final 
attempt shoul d be a certified letter or use of a courier to the subject and/or parent(s)/legal 
guardian(s) to attempt contact.  In an y circumst ance, every  effort should be made to 
document subj ect outcome, if possible.  The inve stigator should inquire about the reason for 
withdrawa l, and request th atthe subject return for a final visit, if applicable, and follow up 
with the subject regarding an yunresolved adverse events (AEs).
If the subject w ithdraws from the study , and also w ithdraws consent for disclosure of future
infor mation, no further evaluat ions should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use an y data collected before such 
withdrawal of consent.
Subjects who wi thdraw fr om the study  will not be replace d. 
6.5.1. Adverse E vents Requiring S ubject Withdrawal from Treatment
The following adverse events should be assessed as described below to determine if the event 
requires discontinuation of treatment.  Refer to Section 8.4.1.1 fordefinitions of brad ycardia, 
hypotension, hy pertension and paradoxical agitation reaction
.  Subjects experiencing an AE 
that 
requir esa medic al procedure be performed during the MRI scan must be discontinued.
Bradycar diathatis not r espon siveto standard treatment (including gl ycopyrrolate or 
atropine).  The DEX infusion will be discontinued and the subject treated as clinically  
indicated.  Th is adverse event should be reported as an SAE.
Hypote nsion that is not re sponsive to standard treatment (including fluid 
resuscitation and vasopressor/inotropic support).  The DEX infusion will be 
discontinued and the subject treated as clinicall yindicated.  This adverse event sh ould 
be reported as an SAE.
Hypertension that is not res ponsive to s tandard t reatment.  The DEX infusion will be 
discontinued and the subject treated as clinicall y indicated.  This adverse event should 
be reported as an SA E.
Paradoxical agitation reaction occurring during the study  drug infusion period. The 
DEX infusion wi ll bedis
continued and the subject treated as clinically  indicated.  
This adverse event should be reported as an SAE.
Adverse event requiring intubation or LMA (laryngeal mask airway) .  The DEX 
infusion will be disco ntinued and the subj ect trea ted as clini callyindicated.  This 
adverse event should be reported as an SAE.
Second- or third -degree heart block .  The DEX infusion will be discontinued and 
the subject treated as clinically  indicat ed.  Second- degree block adverse events should 
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 68be reported as an SAE if appropriate. All third-degree block adverse events should be 
reported as an SAE. 
6.5.2. Adverse Events Requiring Assessment for Subject Withdrawal from Treatment
The following adverse events should be assessed as described below for the Investigator to 
determine if the event warrants discontinuation of treatment: 
•Decreased respiratory rate in a subject unresponsive to commands.  The 
Investigator should determine if the DEX infusion should be discontinued and if further intervention is needed.  
•Other cardiac events should be assessed and the Investigator should determine if the 
DEX infusion should be discontinued and if further intervention is needed.
7. ASSESSMENTS
Every effort should be made to ensure that the protocol-required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be circumstances outside of the control of the investigator that may make it unfeasible to perform the test. In these cases the investigator will take all steps necessary to ensure the safety and well-being of the subject.  When a protocol-required test cannot be performed, the investigator will document the reason for this and any corrective and preventive actions that he or she has taken to ensure that normal processes are adhered to as soon as possible.  The study team will be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior to initiation of the study.
1.AE/SAE Reporting : adverse events and serious adverse events will be collected 
from the time the informed consent and assent (as appropriate) is obtained through the Day 29 Long-term Follow-up visit or final visit prior to the Day 29 Long-term Follow-up visit as appropriate and will be recorded on the CRF and source documents.  There are 2 Adverse Event CRF pages used in this study: the Adverse Event Report CRF page and the Medication Error Record CRF page.  See Section 8 for further information regarding adverse event reporting.
 
 
 
 
  
CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 693.Concom itant treatment recording : concomi tant medications and 
non-pha rmacologic the rapies will be collected from randomization through the 
Day 29 Long -term Follow - up Visit and will be recorded on the CRF and source 
documents.
4.Contrac eption Check : The investigator must assess and docu ment in the source 
if the subject is biol ogically  capable of having/fat herin g chil drenandif the 
subject co ntinues to be or has become sexually  active.  If yes, their method of 
contraception and confirmat ion of its consistent and correct use must also be 
documented in the source documents.
5.EtCO 2: end tidal carbon dioxide to be monitore d through nasal cannula 
ca
pnograph y.
6.IV line access : peripheral I V access is required for the study  drug infusion.  
DEX mus t be administered through a peripheral IV line that is not a sub clavian 
line, PI CC line or other central catheter.  Existing IV cathe tersbeing used for 
another purpose (eg , administration of fluids, I V ant ibiotics etc. ) must be used
with the Sponsor provided Y -connector and 3 -port connector. Existing IV tubing 
must no t be used. Topical or loca l anesthetics may be used as n eeded for IV 
placemen t. 
7.Laboratory whole -blood qualitative hCG pregnancy test :  a whole -blood 
test may  be performed if it can be done at the bedside . Serum qualitative or 
quanti tative hCG pregnanc y testsarenot permitted. The test must be conducted 
on D ay 1 and a nega tivepregnancy  result is r equired before the subject may be 
randomize dprior to the MR I scan. Sites are expected to provide 
their own 
supplies.  Subjects with an indeterminate or pos itive test result may  not 
randomize in the study .
8.Laboratory urine qualit ativ e hCG pregnancy test: dipstic k test kits will be 
provided b y each individual site and only  kits that have a sensitivity  of at least 25 
milli-international units per milliliter (mIU/mL) will be approved for u se in this 
study . A negative pregnancy  resul t isrequired before the s ubject may be 
randomized.  Subje cts with an indeterminate or positive test result may  not 
randomize in the study .
9.Modified Aldrete Score : a validated observational medical scoring s ystem that 
allows verbal prompts f or the measurem ent of recovery  after anes thesia (post 
anesthesia) which includes act ivity, respiration, circulation, consciousness and 
oxygenation.  The scores of each item are summed to obtain a to tal score.  
Information on q ualification, trai ning and approval to rate t his scale will be 
provided separa tely.  Refer to Appendix 4.
10.PAED (Pediatric Anesthesia Emergence Delirium Scale) : A validated 5 -item 
rating scale to measu re emergence delirium (ED) i n children where each item is 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 70scored along a range of “not at all” to “ extreme ly”.  The scores of eac h item are 
summ
ed to obtain a total PAED score where the degree of ED increases directly  
with the total score.   Information on qualification, training and approval to rate 
this scale wi ll be provided sepa rately .  Refer to Appendix 5.
11.PE: includes the following bod y systems: general appearance, head, ears, eyes, 
nose, mouth, throat, neck, lungs, heart, 
abdomen, musculoskeletal, ex tremities, 
skin, ly mph nodes, neurological.  The PE will be conducted b y a ph ysician,
trained ph ysician’s assistant or nurse practitioner as accepta ble according to local 
regulation.  Results must be recorded in the source docum ents and an y 
significant fin dings documented on the approp riate CRF pages. 
12.Prior treatment recordi ng: prior medi cations and non -pharmacologic therapies 
will be collected for t
he 4-week period before randomization and will be 
recorded on the CRF and source documents.
13.PSSS (Pediatric Sedation State Scale) : A validated 6 -point sc ale that is a 
measurement 
of the effecti veness and quali tyof procedu ral sedation in children.  
It is s pecifically designed for evaluating pediatric patients undergoing sedation 
for d iagnostic and therapeutic procedures, and measures aspects of procedural 
sedation relating to the q uality  of seda tion provided, i ncluding the control of 
pain, anxiety , movement , and adverse side effects.  I nformation on qualification, 
training and approval to rate this scale will be provided separatel y.  Refer to
Appendix 6. 
14.Rhythm strip/
12-lead ECG/card iac telemetry monitoring: The 2 -minute 
rhythm strip and/or 12 -lead ECG at Screening should be obtained and hard 
copies retained after the subject has been calm for at least five (5) min utesand 
should be obtained prior tovitalsigns collection.   A phy sicianexperience d in 
pediatric rh ythm interpretation will read and evaluate the tracing for 
abnormalities, which will be documente d on the appropriate CRF.  C linically  
significant abnormal ities on the rh ythmstrip suggestive of AV conduction block 
or sustained cardiac arrhythmia will require th at a 12 -lead E CG be performed.   A 
12-lead E CGwill be required atScreening for subjects with known history  of 
cardiac disease.  If a site does not have the capabil ity to obtain a hard cop y 
rhythm stri p, the 12 -lead ECG may be performed in lieu of the rh ythm strip. The 
investigator is responsible for reviewing, signing and dating the interpretations.  
Cardiac telem etry monitoring is requir ed begi nning just pr iort
o the start of the 
study treatment loading dose and c ontinuing throu gh the post -MRI recovery  
period.  Clinically  significant abnormalities noted on cardiac telemetry  will be 
documented as adverse events.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 7115.Vital si gns: include s heigh t(or length as appr opriate), w eight, temper ature, heart 
rate, respiratory  rate, SpO 2, blood pressure including MAP.  Measurements 
should be obtained with the subject in a supine position as much as possible. 
Height (or Length): in inch es or centim eters, recorde d to one deci malplace. 
The height ( orlength) should be measured with the subject no
t wearing shoes.  
Weight: in pounds or kilograms, recorded to one decimal place will be 
obtained using an electronic scale.  The weight s hould be measured with th e
subje ct not wearin g shoes.
H
eight and weight values will be rounded to 1 dec imal place (the nearest 
tenth) for calculations and documentation. To round a number to the nearest 
tenth (ie, 
1 decimal place) , look at the second number to the right of the 
decim al point (the hundredths place). If that hundredths number is 4 or less, 
remove all numbers to the right of the tenths place . Ifthat hundredths number 
is5 or greater, add 1 to the number in the tenths place, and then remove all 
the 
numbers to the right of the tent hs place .
Heart rat e: whe never possible, the subject should refrain from products 
containing nicotine or caffeine 2 hours before ta king heart rate measurements 
and should rest at least 2 minutes before heart rate is measured.   Onc e the 
l
oading dose is star ted,heart rat e mus tbe m ea sured using the cardiac monitor.  
Blood press ure (SBP, DBP and includes MAP): whenever possible, the 
subject should re frain from products containing nicotine or caffeine 2 hours 
before taking blood pressure me asureme nts and should r est at lea st 2 m inute s 
before blood pressure readings are taken.  The Screening blood pressure may  
be measured using a manual a neroid or mercu ry sphy gmomanometer or by an 
automated method (such as a Dinamap) with a cuff approp riate t o the 
subject’s 
arm or leg girthas appropriate .  Once the DEX lo ading dose is 
started, blo od pressure must be measured using an MRI compatible autom ated 
method tha t will provide BP moni toring throughout the MRI scan.  The site 
will need to re tain documentation of machine c alibration per the 
manufacturer’s suggested cal ibration schedule.   
Temperature: using oral, axillary , temporal scan or ty mpanic m ethod 
measured in degrees Fahrenheit or Centigrade.
Respiratory  rate: respirations per minute.
SpO 2: saturation of periphe raloxygento be measu redas a percentage using 
pulseoximetry .
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 727.1.Pregnancy Te sting
For female subjects of childbearing potential, a uri ne pregnancy te stwith sensitivity  ofat 
least 25 mIU/mL , or a whole -blood pregnancy  test thatcan be done at th e bedside will be 
performed on D ay 1 Peri od 1 (Pre-Rand omization).  S erum qualitative or quanti tative hCG 
pregnancy  testsarenot permitted. 
Anegative pregnancy  testresult is required before the subject may  receive the investigational
product.  Pregnancy  tests may also be repeat ed ifrequested b y institutional review boards 
(IRBs)/ethic s committees (ECs) or if r equire d by local regulations. 
Urine pregnancy  tests mu st be sensitive to a t least 25 mI U/mL and will be conducted with the 
test kit approved b y the spo nsor in accordance with i nstructions provided in its package 
insert.  Subjects who show an indete rminate or po sitive res
ult on the urine test may  not 
further progress in the study .   
7.2.Rater Qualifications
For specific rating asses sments, only  qualified rat ers w ill be allowed toe
valuate and/or rate 
subjects in this study .  The minim um qualifica tions a rater must m eet for ea chstudy  rating 
assessment will be ou tl
ined in the Rater As sessment Manual provided to each participating 
site.  The level of experience with the target popul ation (or equivalent), specific scale 
experience (or equivalent), and certi fication requ ired (if a pplicable) will be listed and used to
determine whether a r ater is approved for a given assessment.  Proposed raters who do not 
meet spe cific criteria but who m
ay be qualified based on unique circumstances may  be 
individually  reviewe d by th e stud y clinical team to determine whether or not a w aiver may  be 
issued.  The rater must become certified to perform selected study  assessments before he or
she can parti cipat ein the conduct of the study .  For specifically  defin ed assessments, rat er 
trai
ning a nd standar dization exercises may  be conducted, andwritten and signed
documentation will be provided by the site for eac h rater’s certification.  In return, each sit e 
willbe provided written and signed documentation outlini ng each rate r’s cer tificat ion for 
specific study assessmen ts.  Recertification ma y be required at per iodic intervals during the 
study .  The raters who a dminister specific study  assessments will be docume nted in a 
centralized location and all site staff who administer ratings will b e veri fied in th e site study  
documentation during the conduct of the stud y.
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table bel ow summarizes the requirem ents 
for recording saf etyevents on the CRF and for 
reporting safety  events on the Clinica l Trial Serious Adve rse Event (C T SAE) Report Form 
to Pfizer Safety . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2)
non-serious adverse event s (AEs); and (3) ex posure to the investigational product under 
study  during pr egnancy  or breastfe eding, and oc cupational exposure.  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 73Safety Event Recorded on the CRF Reported on t he CT SAE 
Report Form to Pfizer 
Safety Within 24 Ho urs of 
Awareness
SAE All All
Non-serious AE All None
Exposure to the 
investigational product 
under st udy during 
pregnanc y or 
breastfe eding, and
occupational ex posure.All AEs/SAEs associated 
with exposure du ring 
pregnancy or breastfeeding.  
Occupationa l exposure is not 
recorded .All (and EDP supp
lemen tal 
form for EDP) .
Note: I nclude al l SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding.  Include all 
AEs/SAEs associated with 
occupational exp osure .
Allobserv ed or volunteere d events regardl ess of d ose group or suspected causal relati onshi p 
to the investigational product(s) will be reported as described in the following paragraphs.
Events listed in the table above that require reportin g to Pfizer Safet y on the CT SAE Report 
Formwithin 24 hours of aw areness of th e event by  the investig atorare to be reported 
regardless of wheth er the event is determined by the investigator to be re lated to an 
investigational product under study .  In par ticular, if the SAE is fat al or life-threa tening, 
notific ation to Pfizer Safety must be made immediate ly, irrespective of the extent of available
event information.  This time fr ame also applies to ad ditional new (follow -up) information on 
previously  forwa rded reports .  In the rare situa tion that the investigato
rdoes no t become 
imme diately aware of the oc curre nce of an event, the investigator must report the event 
within 24 hours after learning of it anddocument the time of his/her first awareness of the 
event.
For e ach eve nt, the inves tigator must pursue and obtain ade quate informa ti on both to 
determine the outcome and to assess whether it meets the criteria for classification a s an SAE 
(see the Serious Adv erseEventssection belo w). In addi tion, t he inve stigat or may  be 
requested b y Pfizer Safety  to obtain specific follow -up informati on in an expedited fashion.  
This information is more detailed than tha t recorded on the CRF .  In general, this will include 
a description of the eve nt in suffic ient de tail to allow for a com pl
ete medical as sessment of 
the case andindependent determination of possible causalit y.  An y informat ion relevant to 
the event, such a s concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a sum mary of avail able autop syfindings mus t be submitted as soon as possible 
to Pfizer Safet y.  An y pertinent additional informati on must be reported on the CT SAE
Report Form; addition al source documents (eg, medical records, CRF, laborator y data) are to 
be sent to Pfizer Safet y ONLYupon request .
As part of ongoing s afety reviews conducted by the sponsor, any  non- serious AE that is
determined b y the sponsor to be 
serious will be report ed by the sponsor as an SAE.  To assist 
in the determina tionof case seriousness, furthe r informat ion may  be reque sted from the 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 74investi gator to provide clarit y andunderstanding of the event in the con text of the clinical 
study .
8.1.1. Addit ional Details On Recor ding Adverse Events on the CRF
All events detailed in the table abov e will be reco rded o n the AE p age(s) of the C RF.  It 
should be note d that the CT SAE Repor t For m for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a con sistent mann er.  AE
s shoul d be r ecorded us ing concise medi cal 
terminology  and t hesame AE term should be us ed on both the CRF and the CT SAE Repo rt 
Form for reporting of SAE information.
8.1.2. Eliciting Adv erse Event Information
The investigator is to record on the CRF all directl y obser ved AEs and all AEs spontaneousl y 
reported b y the stu dysubject/parent(s)/le gal g uardian/legally  acceptable representat ive.  In 
addition, each stud y sub ject/parent(s)/legal g uardian/legally  acceptable representative will be 
questi oned about t he occurrence of AEs in a non -leading manner.
8.1.3. Withdrawal From the S tudy Due to Adverse Eve nts (see also the Subject 
Withdrawal / Early Term inatio nsection)
Withdra waldue to AEs should be distinguished from withdrawal d ue to other causes,
accord ing to the defin ition of AE not ed below, and recorded onthe CRF.  See Section 6.4.1
for adverse events requiring a ssessment for subject withdrawal. 
When a subject wit hdraws from the study  beca use of an SAE, t heSAE must be r ecorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form , in accordance with the 
Requirements section above.
8.1.4.
Time Period for Collecting AE/SAE Information
The time per iod for active ly eliciting and collecting AEs and SAEs (“ active col lection 
period”) for ea ch su bject begins from the time the subject/parent(s)/legal guardian/legall y
acceptable representa tive provides informed consent, which is obtained before the subject ’s 
participati on in the study  (ie, before unde rgoing any  study -relatedprocedure and/or re ceivi ng 
investigational product), through a nd including a minimum of 28 cale ndar day s after the la st 
administration of the investigational product.  At th e Day  29 Lon g-term Follow -up visit (final 
telephone conta ct), the subject/parent( s)/legal guardian/leg ally acceptable representative will 
be cont acted by  telephone to inquire abo ut SAEs, including hos pitalizations ,newly  
diagnosed chronic medical condi
tions and concomitant treatm entssince the prev ious st udy 
Visit.
For s ubjects who are screen fail ures, the ac tive collection period ends when scr een failure 
status is determined.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 758.1.4.1. Repor ting SAEs to Pfizer Safety
All SAEs occurrin g in a subject during the ac tive c ollection period are reported to Pfizer 
Safety  on th e CT SAE Rep ort Form.
SAEs occurring in a subjec t after the active collection period ha s ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasona ble pos
sibility of bein g related to investigationa l 
product mustbe reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after theactive collection period and 
until the event or its sequelae resolve or stabilize at a le vel acc eptable to the investig ator, and 
Pfizer concurs wi th that a ssessment.
8.1.4.2. Recording Non -serious AEs an d SAEs on the CRF
During the active collection period, bot h non-serious AEs and SAE s are recorded on the 
CRF.
Follow -up by  the investigator may  be re quired un til the event or its se quelae resolve or 
stabilize at a lev
el acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assess ment of causalit y must be pr ovided for all AEs (serious and 
non-serious); t he inve stigato r must re cord the causal relationshi p on the CRF,and report such 
an assessment in a ccordance with the SAE reporting requirements, if applicab le.  An 
investigator’s ca usalit y assessment is the de termin ation of whether there exists a re asonabl e 
possi bility  that the investigational product cau sed or co ntri buted to an AE; generall y the facts
(evidence) or arguments to suggest a c ausal relationship sho
uld be provided.  If t he 
investigator does not kno w whet her or not the investigational p roduct ca used th e event, then 
the event will be handled as “related to investigational product” for reporti ng purposes, as 
defined b y the sponsor.   If the investigat or's causality  assessment is “unknown but not 
related ” to i nvestigational product, this sho uld be cl early docum ented on stu dyrecords.  
In addition, 
if the inves t igator determines that an SAE is as sociated with study  procedures, 
the investigator must record this causal relationsh ip in the source documents a nd CRF , and 
report such an assessment inthe de dicated section of the CT SAE Report Form and in 
accordance withthe SAE reporting requirements.
8.1.6. S ponsor’s Reporting Requirements to Regu latory Authorities
AE reporting, including s uspected unexpected serious advers e reactions (SUSAR), will be 
carried out in acco rdance with appl icable local regulations.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 768.2. D efinition s
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study  subject a dministered a produ
ct or 
medical device; the event need not necessaril y have a causal relationship with the tr eatment 
or usage .  Examples of A Esinclude, but are not lim ited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examinati on findings;
Hypersensiti vity;
Progression/worsening 
of und erlying disease ;
Drug abuse;
Drug depende ncy.
Additiona lly, AEs ma y include signs and sy mptoms resul tingfrom:
Drug overdose;
Drug withdraw al;
Drug misuse;
Drug interactions;
Extravasation;
Exposu re during pregnancy  (EDP) ;
Exposure via breastfeeding ;
Medi cation error;
Occupational exposur e.
8.2.2. Abno rmal Te st Findings
Abno rmal objective test fi ndings should be recorded as AEs when an y of the foll owing 
conditions are met: 
Test result is associated with accompan ying symptoms; an d/or
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 77Test result requires ad dition al diagnostic testing or medical /surgical interv ention;
and/or
Test result leads to a change in stud y dos ing (outside of any  protocol -speci fied dose 
adjustments) or discontinuati on from the study , significant additional co ncomitant 
drug treatment, or other therapy ; and/or
Test result is considere d to be an AE by the inve stigator or sponsor.
Merel y repeat ingan abnormal test, in the absence of any of the above conditions, does not 
constitute an AE.  Anyabnormal test result 
that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any untoward m edical occurrence at an y dose that:
Results in death;
Is life -threatening (im mediate risk of dea th);
Requires inpatient h ospitalization or prolongati on of existing hospitalization;
Result s in pers istent or significant d isability /incapacity  (substantial di sruption of the 
ability  to conduct norm al life functions);
Results in congenit al anomaly /birth de fect.
Or that is consider ed to be:
An important medic al eve nt.
Medical and scientific judgm ent is ex ercised in determining 
whether an event is an important 
medi calevent.  An important medical event may not be immediately  life-threatenin g and/or 
result in dea th or hospitalization.   However, if it is determin ed tha t the event may  jeopardize 
the subject or may require interventi on to prevent one of the other AE ou tcomes, the 
important medical event should be reported as serious.
Examples of such events are in ten
sive treatment in an e mergency  room or at home for
allergic bronchospasm; blood dyscrasi asor con vulsion s that do not re sult in hospitalization; 
or developm ent of drug dependency  or drug abuse.
Medical device complaints may  meet the S AE reporting requir ement criteria (see the Medical 
Device Compla int Reporting Requirements section). An incident is any malfunction (ie, the 
failure of a device to meet its performance specif ications or to perform as intended; 
performance specificat ions include all claims m
ade in the labeling for the device ) that, 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 78directly  or indirectl y, might lea d to or might have led tothe death of a subject, or user, or of
other persons, or to a serious de terioration in their state of health.
Aserious injury  that can cause a serious det erioration in state of healt h can include:
A life -threatening illn ess, even if tem porary in nature ;
A permanent impairment of a bod y functi on or permanent damage to a body  
structure;
A condition necessitating med
ical or surgical in tervention to prevent the above 
2bulleted items;
Examples: clinica lly relevant increase in the dura tion of a surgical proc edure; a 
condition that requires hospital ization or significant prolongatio n of existing 
hospitalization;
Any indirect harm as a cons equence of an incorrect d iagnostic or in vitro diagno stic 
device te st results when used wit hin the m anufact urer’s instructi ons for use;
Fetal distress, fetal d eath,or an y congenital abnormality  or birth defects.
8.2.4. Hospitalization
Hospital ization is defined as any initial admission (even less than 24 hours) in a hos pital or
equivalent healthcare f acility, or any  prolongation of anexisting admission.  Admission al so 
includes transfer within the hospita l to an acute/intensive care unit (eg, from the psy chiatri c 
wing to a medical floor , medical floor to a coronar y care unit, o r neurological floor to a 
tubercu losis u
nit).  An emerge ncy room visit does not necessaril y c onstitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed 
formedical importance.
Hospitalization does not include the follow ing:
Rehabilitation faci
lities;
Hospice faci lities;
Respite care (eg, caregiver relief);
Ski
llednursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 79Hospitalization or prolongation of hospital izatio n in the absence of a precipitat ing clini cal 
AE is not in itself an SAE.  Examples include:
Admissi on
for treatment of a preexisting condit ion not associated with the 
development of a new AE or wit
h aworsening of the pree xisting condition (eg, for 
workup of a per sistent pretreatment labor atory  abnormal ity);
Social adm ission (eg, subject has no place to sleep);
Administrative admission (eg, f or yearly physical examination);
Protoc ol-specified admiss ionduring a stud y (eg, f or a procedure required by  the study  
protocol);
Optional admission not associated with a precipita ti ng clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for o bservation without a medical AE;
Prepla nned treatments or surgical procedures.  The se should be noted in the ba seline
documentation for the entire pr otocol and/or fo r the individual subject.
Diagnostic and therapeuti c noninvasive and invasive procedures, s uch as surgery , should not 
be reported as SAEs.  However, 
themedical condition for which the procedure was 
performed should be reported if it meets the defin ition o f anSAE.  For e xample, an acute 
appendicitis that begins during the reporting period shoul d be reported if the SAE 
requirements a re met, and the res ulting appendectomy  shoul d be recorded as treatment o f the 
AE.
8.3.Severity Assessment
If requi red on th
e AE pa ge ofthe CRF, t heinvestigator will use the adject ivesMILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consi stency, these intensity  grades are defined as follows:
MILD Does not interfere with subjec t's usual functi on.
MODERATE Interferes t o some extent with subjec t's usual function.
SEVERE Interferes s ignificantl y with subject's usual function.
Note the dist inction between the sever ity and the seriousness of a n AE. A severe event is not 
necessari lyan SAE .  For exam ple, a heada che may  be severe (interferes signi ficantly with 
the subject's usual functi on) but would not be classified as seri ous un
less it met one of the 
criteria for SA Es, listed above.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 808.4.Special Si tuations
8.4.1. Protocol -Specified Adverse Ev
ents
8.4.1.1. Chan ges in Bloo dPressure a ndHeart Rate
The Investigator will assess changes in supine blood pressure and supine heart rate 
throughout the s tudy. Blood pressure and/or heart rate meas urements exceeding the speci fied 
limits as below will be recorded asadvers e event s, regardless of whether or not they  result in 
discontinuation from the study  or necessitat e therapeutic medical intervention.  
Vital s
ign (HR or BP ) measurements exceeding the specified limits within the indicated time 
periods below a re con sidered AEs:  
Brad ycardia: A de crease in HR of ≥ 30% from Baselin e and/ormeets the criteria 
below .HRmust be sustained for ≥2 consecutive measurements that are s eparated b y 
at least 1minute .If available HRvalues between the sched uled re adings meet the 
criteria for bradycardia , the A Eshould b ereported .A decrease i nHRthatrequires 
intervention should also be report ed as an AE (or SAE as appropriate )of brady cardia .  
Baseline values a re those obtained at Day  1 Period 1 
within approximatel y 5 minut es
before the st art of the DEX loading dose.
Study Criteria for AE of Bra dycardia*
Age HR
≥1month to <3 months <107 bpm
≥3 months to <6 months <104 bpm
≥6 months to <9 months <98 bpm
≥9 months to <12 months <93 bpm
≥12 months to <18 months <88 bpm
≥18 months to < 24 months <82 bpm
≥2 years to <3 years <76 bpm
≥3 yearsto <4 years <70 bpm
≥4 years to <6 years <65 bpm
≥6 years to <8 years <59bpm
≥8 years to <12 years <52 bpm
≥12 y ears to <15 years <47 bpm
≥15 y ears to <18 years <43 bpm
*Based on 1stcentile data from the HR t able in Appendix 7, HR and RR Centile 
Chart Cut- offs for Child ren from Birth to 18 Year s of Age (Fleming et al, Lancet 
2011). 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 81If bradycardia is not responsive to standard treatment (in cluding g lycopyrrolate or
atropine), the DE X infusion should be disco ntinued and t he subject treate d as
clinically  indicated.  This a dverse event should be reported as an SAE.  
Hypotension: A decrease in SBP of 
≥30% from Baseline should be repor ted as an
AE of hypotension.  A decrease in SBP of ≥50% from Baseline should be reported as 
a severe AE.  SBP values must be sustained for ≥2 consecutive measurements at least 
5(±1) m inutesapart.  Ifavailable SBP values between the sched uled readings meet 
the criteria for hypotension , the A Eshould b ereported .A decrease in SBP that
require sintervention should also be reported as an AE(or SAE as appropriate )of 
hypotension. Baseline value s are those obtained at Day  1 Period 1 within 
approximately  5 minutes before the start of the DEX loa ding dose.
If hypo tension is not responsive to standard treatme nt (including fluid 
resuscitation and vasopressor/inotropic support), the DEX infus ion sh ould be 
discontinued and the subject treated as clinic ally indic a
ted.  This adverse event 
shoul d be reported as an SA E. 
Hypertension: The criteria for the definition of an adverse event of h ypertension 
were based on the National High Bl
ood Pressure Educat ion Program Working Group 
on High Blood Pressure in Ch ildren and Adolescents,28the Pedia tric Vital Signs 
Reference Chart (pediatric advanced life support [PAL S] normal blood pressure by  
age guidelines)29and the advice of clinical expert consultan ts. 
For subjects ag es ≥1 month to <1 y ear: Hypertension is defined as supine SBP 
≥104 mm Hg and/or DBP ≥56 mm Hg measurements on ≥2 consecutive 
occasions taken at least 5 (±1) minut esapart and/or requir es intervention.  This 
event should be reported as an AE.
For subject sages ≥1 year to <17 y ears: Hypertension is defined as supine SBP 
and/or DBP measurements that are ≥95th percentile for gender, age, and height 
(stature) on ≥2 cons ecutive occasions taken at least 5 (±1) minutes apart and/or 
requires intervention.  The ta bles for h ypertensi onassessment for this age group 
will be provided separately .  This event should be reported as an AE.  
If hypertension is not responsiv e to standa rd tre atment, the DE X infusion will be 
discontinued and the subject treated as clinicall yindicated.  This a dverse event 
should be reported as an SAE.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 828.4.1.2. Paradoxical Agitation Reactions 
Throughout the Study Drug Infusion Period and extending into the 24-hour post-infusion 
observation period, the Investigator should monitor for the onset of parad oxical agitation 
reactions (eg, rage).  The clinical features may  vary  with age of the subject, but the following 
should be used as a guide:
Age ≥1 month to<8 years: Inconsolable cry ingand/or irritability  that are otherwise 
unexplained by  the subjects’ c urrent medical cond it ion and are unable to be 
controlled with conventional interventions.
Age ≥8 years to ≤17 y ears: Aggressive behavior and/ or excessive emotional out bursts
that are oth erwise unexplained b y the subjects’ current medical condition and are 
unable to be contro ll ed with conventional interventions.  An example of this may  
include a subject that becomes phy sically  violent that may  expose healthcare 
personnel or the mselves to h arm.  
In the event a paradoxical agitation reaction occurs during the study  drug infusio n period, the 
study  drug will be discontinued and the subject treated as clinicall y indicated.  The event 
should be report ed as an AE and an SAE.
8.4.1.3. Changes 
in Respiratory Rate, EtCO 2and SpO 2
The Investigator will assess changes in respira tory rate, changes inmeasurement of carbon 
dioxide (CO 2) concentration and ox ygen saturation throughout the stud y.  Respiratory  rates, 
EtCO 2and/or SpO 2measurement s below the threshold soutlined in the tables below will be 
recorded as adverse events, reg ardless of whether ornot they  result in discontinuation from 
the study  or necessitate therapeutic medical intervention.
Thresholds for Respi ratory Rate Adverse Even ts
Age Respiratory Ra te*
(breaths per minute)Adverse Event Term **
≥1 month to <3 months <25 Brad ypnea
≥3 months to <6 months <24
≥6 months to <9 months <23
≥9 months to <12 
months<22
≥12 months to <18 
months<21
≥18 months to <24 
months<19
≥2years to <3 years <18
≥3 years to <4 years <17
≥4 years to <6 years <17
≥6 years to <8 years <16
≥8 years to <12 years <14
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 83Age Respiratory Ra te*
(breaths per minute)Adverse Event Term **
≥12 y ears to <15 years <12
≥15 y ears to <17 years <11
*Rate must be sustained for at least 2 consecutive measurements that are s eparated by at least one minute 
and/or requires intervent ion in order to meet the criteria for AE .  If available RR value sbetw een the 
scheduled readi ngsmeet the criteria for bradypn ea, the AE s hould be reported .Based on the 1stcentile 
data from the RR table in Appendix 7, HR an dRR Centile Chart Cut -offs for Children from Birth to 18 
Years o f Age (Fleming et al, Lancet 2011) .
**This term shou ld be u sed unless the decreased respiratory rate is part of a l arger con stellation of signs 
and symptoms documented as another adverse even t.
Thresholds for EtO2 and SpO 2Change Adverse Events
Value Adverse Event Term*
SpO 2 <90% for a ny duration Hypoxia
Capn ography EtCO 2 = 0for ≥30 seconds Apnea
*These terms should be u sed unless the EtCO 2and/or SpO 2finding(s) are part of a larger co nstellation of 
signs and symptoms documented as another adverse event.  In determining whether an a pnea or 
hypoxi a AE has oc curred the clinici an should verify the na sal capnograph or SpO2 m onitor is in the 
right location and functioning properly.
Respira tory rate, SpO 2and/or EtCO 2 measurements that do not meet or exceed these values 
will also be reco rded as advers e events if they necessitate therapeutic medical intervention or 
the Investigator considers them t o be adverse events.  The date and time of oc currence and 
any treatment or intervention for all adverse events are to be recorded on the appropr iate 
eCRF.  Ex ampl es of i nterventions that should be re corded to brad ypnea/h ypoxia/apnea a re 
airway  repositionin g, bag
-mask intervention, deepening of sedation, fluid bolus, jaw thrust, 
CPAP, initiation of or increased ox ygen, intubation, etc.
For a decrea se in respirat ory rate in a subject unresponsive to com mands, the Investigator 
will determ ine if study  drug should be discontinued and will treat the subject as clinicall y 
indicated.  All interventions will be recorded in the appropriate section of the eCR F.
8.4.2. Protocol -Specif ied Ser ious Adverse Event s
There are no protocol -specified SAEs in this study .  All SAEs will be reported to Pfizer 
Safety  by the investiga tor as described in previous sections, and will be handled as SAEs in 
the safet y database. 
8.4.3. Potenti al Cases of Dr ug-Induced Liver Injury
Human s exposed to a drug who show no sign of liver i njury  (as determined b y elevations in 
transaminases) are termed “tol erators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some s ubjects, transamin ase ele vations are a harb inger of a m ore 
serious potential outcome.  The se subjects fail to adapt and therefore are "susceptible" to 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 84progre ssive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experienc e a transam inase elevation ab ove 3 times the upper limit of 
normal (× ULN) s hould be monitored mor e frequently  to determine if they are an “ada ptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monito ring procedure in this 
study.  However, sho uld an investigator deem it necessary  to assess LFTs because a subjec t 
presents with clinical signs/sy mptoms, such LFT results should be managed and followed as 
described below.
Inthe majority  of DILI cases, elev ations in aspa rtate amino transferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) b y several 
days or wee ks.  The increase in TBili ty picall y occurs while AST/ALT is/are s till elevated 
above 3 × ULN (ie, AST/AL T and TB ili values w ill be elevated w ithin the same lab sample).  
In rare instances, by the time TBili ele vations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DI LI.  Therefore, abnormal 
elevatio ns in either A ST O R AL T in
addition to TBili that meet the criteria outlined below 
are con sidered potential DILI (assessed per Hy ’s law criteria) cases and s hould alway s be 
considered important medical events, even before a
ll other possible causes of liver injury  
have b een exclude d.
The threshold o f laboratory  abnormalities for a potential DILI case depends on the s ubject’s 
individual baseline values and under lying conditions.  Subjects who present with the 
following laborat ory abnormalities should be evalu ated further a s po
tential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laborator y values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2 × ULN wit hno evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBil i values above the ULN, the 
following threshold values are used i n the definition mentioned above, as needed, 
depend ing on w hich values are a bove the ULN at baseline:
Preexisting AST or AL T baseline values abov e the normal range: AST or ALT 
values >2 timesthe baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smal ler).
Preexisting values of TBili above the nor mal range: TBili level increa sed from 
baseline value b y an amount of at leas t 1 × ULN or if the va lue reaches >3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks shou ld be assessed 
individually  based on clinical j udgm ent; an ycase where uncer tainty  remains as to whether it 
represents a po tential Hy’s law case should be reviewed with the sponsor.  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 85The subject should return to the investigator site and be evaluated as s oon as possible, 
preferabl y withi n 48 hours from aw areness of the abnormal r esults.  This evaluation should 
include laborat ory tests, detailed hi story , and physical assessment.    
In additi on to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, cre atine kinase ( CK), direct and indirect bili rubin, gamma- glutam yl 
transferase (GGT), prothr ombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein ad duct levels.  
Consideration shoul d also be give n todrawin g a separate tube of clotted blood and an 
anticoagulated tube of blood for further test ing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to det ermine etiology .  A detailed 
history, including relevant information, such a s review of ethanol, acetaminophen (either b y 
itself or as a coformul ated product in prescription or over- the-coun ter medications) , 
recreational drug, supplement (herbal) use and c onsumption, family  history , sexua l history , 
travel 
history ,history  of conta ct with a jaundiced person, surgery , blood tran sfusion, history  
of liver or allergic disease, and potential occupa tional exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infecti on and live rimaging 
(eg, bil iary tract) may  be warranted. 
All cases demonstrated on repeat testi ng as meeting the laboratory  criteria of AST/ ALT and 
TBili elevation defined above should be considered potenti al DILI (Hy ’s law) cases if no 
other reason for theLFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reporte d as SAEs, irrespective of availability of al lthe results of the 
investigations performed to determine etiolog y of the LFT abnormalities.  
A potential DILI (Hy’s law) 
case becomes a con firmed case onl y after all results of 
reasonabl e investigations have been received and have excluded an alternativ eetiology .
8.4.4. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupati onal Exposure
Expo sure to the investigational product under study during pregnancy  or breastfeeding and 
occupati onal exposure are reportable to Pfizer Safety within 24 hours of investigator 
awareness.
8.4.4.1. Exposure During Pregnancy
For both unapproved/unlicense d products and formarket ed products, an ex posure during 
pregnancy  (EDP) occurs if:
A fema le becomes, or is found to be, pregnant either while receiving or h aving been 
exposed (eg, because of treatment or environment al exposure) to the investigational 
product; or the fe male become s or is found to b e pregnant after discontinuing and/or 
being exp osed to the investigat ional product;
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 86An example of environmental exposure would be a case involving direct contact 
with a Pfiz er product in a pregnant woman (eg, a nu rse reports th at she is p
regnant 
and has be en exposed to chemotherapeutic products).
A mal e has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
dur
ing his partne r’spregnan cy. 
If a subject or subject’s partner becomes or is found to be pregnant during the su bject’s 
treatment with the investigational pr oduct, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supple ment al form ,regardless of 
whether an SAE has occurred.   
In addition, the in vestigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been e xposed to a cy totoxic pro duct b y inhalation or 
spillage) to Pfizer Safety  using the 
EDP supplemental form.  This must be done irrespective 
of whether an AE h as occurred and within 24 hours of awareness of the exposur e.  The 
information submitted should inc lude the antic ipated date of delivery  (see below for 
information related to termination of pregnancy ).
Follow -
upis conducted to obtain general information o nthe pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pr egna ncy until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplementa l form.  In the case of a live birth, the structural 
integr ity of the neonate can be assessed at th e time of birt h.  In the event of a termina tion, the 
reason(s) for termination should be s pecified and, if clinically  possible, the structural 
integrit y of t he terminated fetus should be assessed by  gross visual inspection (unless 
pre-procedure test findin gs are conclus ive 
for a co ngenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnan cy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminate dfetus, an intrauterine fetal demise, or a neonatal death]), the
investigator should f ollow the procedures for reporting SAEs.
Addi tional information about pregnancy  outcomes that are report ed to Pfizer Safet y as SAEs 
follows: 
Spontaneous abor tioninclud es miscarriage and missed abortion;
Neonatal deaths that occur wi thin 1 month of birth should be reported, without regard 
to causali ty, as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investig ator assesses the infant death as related or possibly  related to 
exposure to the investiga tional product.
Additi onal information regarding the EDP may  be req
uested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 87preter minfants to ident ify developmental delay s).  In the case of pate rnal exposure, the 
investigator will provide the subject with the P regnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the sou rce documen ts that the 
subjec t was given the Pregnant Partner Release of Inf ormation Form to provi de to his 
partner.
8.4.4.2. Exposure During Breastfeedi ng
Scenarios of exposure during breastfeeding must be repo rted, irrespective of the presence of 
anassociated SA E, to Pfize rSafet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.   An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for us e in breastfeeding women (eg, vitamins) is administere d in
accord with authorized use.  However, if the infant experiences an SAE associated with such 
adrug’s administration, the SAE is reported to gether with the exposure during breastfeeding.
8.4.4.3. Occupational Exposure
An occupational exposure occu rs when, durin g the perfo rmance of job duti es, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, w hich may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator ’s 
awareness, using the CT SAE Report Form, reg ardless of whether the re is an associated 
SAE.  Since the informati on does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; h owever, a copy of the com pleted CT SAE Report 
Form is maintained in the investigator site file.
8.4.5. Medication Error s 
Other exposures to the investigational pro duct under study  may  occur in clinical trial set tings, 
such as medication errors.
Safety Event Reco rded on the CR F Reported on the CT SAE 
Repo rt Form to Pfizer 
Safety Within 24 Hours of 
Awa reness
Medication err ors All (regardless of whether 
associated wit han AE)Only  if associated with an 
SAE
8.4.5.1. Medication Errors
Medication errors may  result from the administration o r consumpti on of the investig ational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength.   
Medication errors include :
Medication errors involving subj
ect exposure to the investigational product;
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 88Potential medication errors or uses out side of what is f oreseen in the protocol that do 
or do not invol ve the participating s ubject.
Such medication errors occurring to a study  participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
Inthe event of a m edication dosing error, the sponsor should be notified within 24 hour s .
Whether or not the medication error is acco mpanied by  an AE, as determined by  the 
inves tigator, the medication error is recorded on the medication error page o f the CRF a nd, if 
applica
ble,any associated AE(s), serious and non- serious, are recorded on a n AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety  within 24 hours on a CT SAE Report 
Form only when associated with an S AE.
8.5.Medical De vice Complai nt Reporting Requ irements
This section applies onlyto sites in Japan using propof ol pre -filled s yringes.  Please r efer to 
Appendix 9, Propofol Pre -filled Sy ringe Medical Device Reporting in Japan for details.
9. DATA ANALYSIS/STATI STICAL METHO DS
Detailed me thodology  for sum mary  and statistical anal yses of the data colle cted in this study
is outl ined here and further detailed ina statistical anal ysis plan (SAP), which will be 
maintained by  the sponsor.  The SAP may  modify  what is outlined in th e prot ocol w here 
appropriate; h
owever, any  major modifications of the primary  endpoint definitio ns or their 
analyses will also be refle c
ted ina protocol amendment.
9.1.Sample Size Determination
The primary  comparison will be the percent of subject s who do not requi re sup plemental 
PRO in th e high dose group vs. the low do se group in bot h age cohorts comb
ined.  T he 
younger age cohort will be c omprise d o f subjects aged ≥ 1 month to <2 y ears of age and the 
older age cohort will include subjects ≥2 to <17 years of age.  The pri mary efficacy  anal ysis 
population is the Full Analy sis Set (FAS) d efined as all rand omized subjects who receive an y 
amount of DEX ,and for the primar y and key  secondary  anal yses, subjects who do not 
complete the MRI scan will be considered failures, ie, wi ll be counted as receiving 
supplemental PRO.  Assum ing that the pe rcent of subjects 
not requiring PRO are 15% and 
60% in the low and high dose groups respectivel y, a sample size of 40 per dose group would 
provide a 99% power for a 2- sided test with alpha=0.05.  The key  secondary  comparison is 
the percent o f subjects who do not require supplementa l PRO in each of the 2 age coho rts.  
Assuming that the pe rcentage of subjects not requiring supplemental PRO in the older age 
cohort is 17% and 63% for the low and high dose groups respectively , and the percent of 
subjects not req uiring PRO in the younger age cohort is 13% and 57% for t helowandhigh 
dose group s respectivel y, and assuming that equal number of subjects will be enrolled in 
each age cohort, the power = 87% for the older age cohort and 86% for the y oung er age 
cohort. Within the older age coho rt, it is planned to enroll app
roxima tely4 subjects per dose 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 89group for subjects ≥ 12 to <17 y ears of age, since it is expected that these subjects would 
require min imum sedation.  Fort y subjects will be enrolled per each dose leve l, and 20 
subjects for eac h dose group for age cohorts ≥1month to <2 yearsand ≥2 years to <17 years.  
The table below shows the planned enrollment in this study .
Sample Size 
Age Group for Enrollment Low Dose Medium Dose High Dose
≥1 mont h to <2 year 20 20 20
≥2 years t o <12 years 16 16 16
≥12 y ears to <17 years 4 4 4
These assumpt ions were obtained from study  DEX 10-16 and Mason et al publication in 
Pediatric Anesthesia 2008.  I n DEX 10
-16 approximately  30% of subjects who had MRIs did
not require re scue medication; t he dose in study  10-16 is comparable to the middl e dose in 
this study .  In the Mason et al publica tion, approximately  80-90% of patients treated with 2 - 3
mcg/kg loading dose of DEX for MRI scans did not require supplemental anesthesia, 
therefore a conserva tive est imate of 65% was assumed.  Additionall y, in the DEX 
10-16 study , 6% of subjects did no t complete the MRI  scan, so a failure rate of 
approximately  5% was incorporated into the assumptions of patients requiring supple mental 
PRO .
9.2.Ana
lysis Populations
9.2.1. Safety A nalysis Set
The safet y analysis set co nsists of all rando mized subjects who received any amount of DEX.  
Participants will be analyzed according to the intervention they received.  In the event a 
subject receives a loading and/or maintenance dose t hat is different from the dose group to 
which the y were randomize d, the subject will be analy zed in the dose level group that 
corresponds to the lowest dose received .  All safety  analy ses will be performed on the safet y 
analysis set.
9.2.2. Full Analysis Set (FAS )
All ra ndomized subj ects who recei veanyamou nt of DEX will form the FAS.  Participants 
will be anal yzed according to the intervention to which they  were randomized.  This will be 
the primary  population for efficacy  anal ysis.
9.2.3. Efficacy Ev aluable Population (EEP)
All randomized subjects who re ceive anyamount of DEX and complete the MRI  scan will 
form the EEP.  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 909.2.4. Per Protocol Population (PPP)
All subjects included in the FAS and have no major protocol deviations will form the PPP.  
The detai ls of the major pr otocol violation crit eria will be d ocumented i n aseparate 
docume nt prior to the end of the study .
9.2.5. Japanese Population Set (JPS)
All randomized Japanese subjects who receive any amount of DEX will form the JP S
.
The JPS will be used for ef ficacy  endpoints, demographic and baseline characteris ticand 
safety endpoints.  Pa rticipants will be anal yzed according to the intervention to which they  
are randomized for efficacy  and will be analy zed according to the intervention they  receive 
for safet y
.
9.3.Efficacy Analys is
A ran domized subject who received any amount o f DE Xbut does not complete the MRI  scan 
will be considered a treatment failure for the primary  and key  secondary  endpoint analy ses; 
ie, they  will be counted as receiving PRO .
9.3.1. Analysis of t he Primary Endpoin t
The DEX high vs low dose group wil l be compa redby Mantel -Haens zel test, and by  
calculating the odds ratio and 95% confidence intervals on the percent of subjects not 
requiring supplemental PRO.  All age cohorts will be c ombined.  The p rimary  anal ysis wi ll 
be pe rformed based on the FAS.  T he same an alysis will be repe ated on the EEP and PPP. 
9.3.2. Analysis of the Key Secondary Endpoint
The method of analy sis for the primary  endpoint will be repeated for the key  secondary  
endpoi nt for each age cohort based on t he FAS. The same anal ysis will be r e
peated on the 
EEP and PPP.
9.3.3. A nalysis of Other Secondary Endpoints
The method of analy sis for the primary  endpoint will be repeated for the secondary  endpoints 
comparing the low dose to the medium dose a nd the medium dose to the high dose, overall 
and withi n
each age cohortbased on the FAS, EEP and PPP. 
The total amount and the weight and time adjusted amount (per kg per minute) of PRO use 
will be summarized for each dose group with descr iptive statisti cs (N, mean, standard 
deviation [SD], median, minimum, Q1, Q3, a nd maxi mum).  The w eight -and time -adjusted 
difference between treatment groups (high dose and low dose, and medium dose and low 
dose and high dose versus medium dose) will be a ssessed using t wo-way analy sis of varianc e 
(ANOVA) when assumption of
norm al distribution is reaso nable or by  nonparametric tests 
when this assumption is not met.  
Emergence time (defined as the time from the end of the MRI  scan to when the subject meets 
a Modified Aldr ete Score ≥9) will be summ arized and compared between dose groups using
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 91Kaplan Meier methodology. Subjects who are withdrawn or discharged from the recovery 
area without reaching an Aldrete score ≥9, will be considered as having censored time
computed from the end of the MRI scan to the time of the last vital signs assessment.  Zero minute will be used as the censored time if no vital signs are taken during the post-MRIrecovery period.
Additionally, the difference between dose levels in percent of time at the target sedation 
rating scale score (PSSS rating of 2) following the administration of the DEX loading dose and during the DEX maintenance infusion will be assessed using the Wilcoxon test.  
Time (in minutes) from the onset of the DEX infusion to the first dose of PRO will be 
summarized using the Kaplan-Meier method.  Subjects that do not receive any additional PRO will be considered as having a censored time.  The censored time to the first dose of PRO for additional sedation will be computed as the length of time from the onset of the DEX infusion up to the time the DEX infusion is stopped.
Efficacy analyses will be conducted for all age cohorts combined and by each age cohort.
  
 
9.5. Safety Analysis
All safety analyses will be performed on the safety analysis set.
Descriptive statistics (quantitative variables: arithmetic mean, SD, median, minimum, and 
maximum, categorical and ordinal variables: proportion of subjects) will be calculated for quantitative safety data as well as for the change from baseline, when appropriate.  Data analyses will be presented by dose level, overall and within each age cohort.  Baseline values are those obtained at Day 1 Period 1 within approximately 5 minutes before the start of the DEX loading dose.
TEAEs will be analyzed by dose level, overall, and for each age cohort according to the 
Medical Dictionary for Regulatory Activities system organ class and preferred term.  
Additionally, the proportion of subjects with protocol-specified adverse events of bradypnea, hypoxia, apnea, hypotension, hypertension, bradycardia and paradoxical agitation reaction and the proportion of subjects with such events requiring intervention will be summarized for each age cohort and each dose level.  Pre-specified criteria will be used to identify the protocol-defined adverse events mentioned above.  CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 92Theproportion of subjects who c ompleted the MRI scan and required artificial v entilation or 
interv
ention t o restore baseline or normal hemod ynamic status will also be summarized.  The 
incidence of i ndividual adverse event s during MRI sedation will be descriptively  summarized 
foreach dose level, includi ng the total a dverse e vents.
Thetypes of individual inter ventions and the total number of interventions will be 
descriptivel y summarized at each dose level and for each age cohort (ie, airway  
repositioning, bag-mask intervention, deepening of sed ation, fl uid bolus, jaw thrust, CPAP, 
initiation of or incr eased ox ygen, intubation, etc). 
Vital sign measurements and hemod ynamic and respiratory parameters will be summarized 
descriptivel y by dose level and a ge co hort.
Prior and concomit ant medications 
will be s ummarized acco rding to WHODRUG
Dictionary .  The number and percentage of subjects who used prior medications (by  
preferred term) will be tabulated by  dose level and age coho rt.  The number and percentag e 
of subjects who used concom itant medication s will be similarly  tab
ulated. 
DEX wi thdrawal sy mptoms, s uch as a gitation/anxiety , rebound tach ycardia and rebound 
hypertension will be summarized by  each do se level and age cohort .  A descriptive summary  
willbe performed for the inciden ce of DEX withdr awal -related AEs after discontinuation of
the DEX infusion.
Descrip tive ana lyses will be pe rformed for the PAED total score for dose level and by  age 
cohort.
9.6. Interim Analysis 
No for mal interim anal ysis will be conduc ted for this study .
9.7.Data Monitoring Com mittee 
This study  will use an external d ata monitoring com mittee ( E-DMC ). 
The E- DMC will be responsible for ongoing monitoring of the safet y of subjects in t he study  
according to t he charter.  
The E- DMC will be com prised of a group of ex perts externa l to Pfizer who will review 
accumu lated safe ty data from this study onan ongo ing basis.  The E- DMC may  at any  time, 
request additional information from the Spons or including an y inform ation they  feel is 
relevant.  Based on these reviews, the E-DMC will ha ve the capacity to make 
recommenda tions to P fizer that might i mpact the future conduct of the trial.  These may  
include amending safet y-monitoring procedures, modify ing the protocol or consent/assent, 
terminating the stu dy, or continuing the s
tudy as desig ned.
The recomm endations made b y the E- DMC t o alter the conduc t of the study  will be 
forwarded to Pfizer for final decision.  Pfizer will forward such decisions, which may  include 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 93summa ries of aggregate anal yses of endpoint events and of safet y data that a re not endpoint s, 
to regulatory  authorities, as appropriate.  
The Pfi zer stud y team and site personnel involved in the conduct of the study  will remain 
blinded t o any
 unblinded study  data communicated to the E -DMC.  
10.QUALITY CONTROL AND QU ALITY ASSURANCE
Pfizer or its a gent will conduct p eriodic mo nitoring visits du ring stu dy condu ct to ensure tha t 
the protocol and Good Clinical Practices (GCPs) are being followed .  The monitors may  
review source documents to confirm tha t the data recorded on CRFs are accu rate.  The 
investigator and instit ution will allow Pfizer moni tors/aud
itors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.  This 
verification may  also occur after study  comp letion.
Durin g study conduct and/or after stud ycompletio n, the investigato
r site m ay be su bject to 
review by the IRB/EC, and/or to quality  assurance audits performed by  Pfize r, or companies 
working with or on behalf of Pfizer, and/o r to inspection by  appr opriate regul atory  
authoriti es.
The investigato r(s) will notify  Pfizer or i tsagent s immediately  of any  regulatory  inspection 
notification in relation to the study .  Furthermo re, the investigator wi ll cooperate with Pfizer 
or its age nts to prepare the inve stigator site for the inspec tion and will allow Pfizer or its 
agent, whenev erfeasi ble, to be present durin g the inspection.  The investigator site and 
investigator will promp tly resolve any  discrepancies that are identified between the study  
data and the subject's med ical records.  The investigator wi ll promptl y provide copies o f the 
inspection findings to Pfi zer or its agent.  Before response submission to the regulatory  
authorities, the investigat or will provide Pfizer or its agent s with an opportunity  to review 
and comment on responses to any  such f indings.
It is important tha t the in vestigat or(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspec tions and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RECORD KEE PING
11.1. Case Report Forms/Electr onic Data Record
As used i n this protocol, the ter m CRF should be understood to refer to either a paper form or 
an ele ctronic data record or both, depending on the data collect ion method used in this study .
A CRF is required an d should be completed for eac h included subject . The c ompleted
original CRFs a re the sole propert y of Pfizer and should not be made available in a ny form to 
third partie s, except for authorized representa tives of Pfizer or appr opriate re gulato ry 
authorities, without written permission from Pfizer.  Th e invest igator s hall ensure that the 
CRFs are securel y stored at the study  site in encrypted electro nic form and will be pa ssword 
protected to prevent access by unauthorized third parties.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 94The inve stigator has ultimate responsib ility for the collection and r eporti ng of al l clinical, 
safety, and laboratory  data entered on the CRFs and any  other data colle ction forms (source 
documents) and ensuring that they  are accurate, authentic/original, att ributa ble, complet e, 
consistent, legi ble, timel y (contemporaneous), endur ing, and available when required.  The 
CRFs must be signed b y the investigator or b y an auth orized staff member to attest that the 
data contained on t he CRFs are true.  An y correction s to e ntries made in the CRFs or sour ce 
documents must be dated, initiale d, and e xplained (if nec essary ) and should not obscure the 
original entry . 
In most cases, t he source documents are the hospital or the phy sician subj ect chart.  In these 
cases, data collec ted on the C RFs must match the data in th ose charts. 
In so mecases , the CR F may  also serve as the source document.  In these cases, a document 
should be avail able at the investigato r site and at Pfizer that clearl y identifies those data th at 
will be recor ded on the C RF, and for which t he CRF wil l stand as the sou rce docu ment.
11.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all pa rticip ating subjec ts 
(sufficient information to link records, eg, CRFs an d hospit al records), all original signed 
informed consent/assent documents, copies of all CR Fs, safet y reporting fo rms, source 
documents, and detailed records of treatment d isposition , and adequate doc umentation of 
relev ant corres pondence (eg, letters, mee ting min utes, and teleph one call reports).  The 
records should be retained by  the investigator according to the ICH guidelines, according to 
local regulations, or as specifi ed in the clinic al study  agreement (CSA), which ever is longer.  
The investi gator mu st ensur e that the recor ds continue to be stored securel y for so long as 
they are retained.
If the investigator becomes unable for any  reason to conti nue to retain study rec ords for t he 
required period (eg, retirement, r elocation) , Pfizer should be prospec tively notified.  The 
study records must be transferred to a designee acceptable to Pfizer, such as another 
investi gator, another institution, or an i
ndependent third party  arranged b y Pfizer.  
Invest igator records must be kept f or a minimum of 15 years a fter com pletion or 
discontinuation of the study  or for longer if required by  applicable loca l regulations.
The investigator must obtain Pfizer's written permission before disposing of any records, 
even if retention req uirements have been met.
12.ETH ICS
12.1. Institutiona l Review Board/E thics Committee
It is the responsibility  of the investigator to have prospective approval o f the study  protocol, 
protocol amendments, informed consent/assent documents, and othe r relevant document s, eg, 
recruitment advertise ments, i f applic able, from the I RB/EC.  All correspondence with the 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 95IRB/EC should be retained in the investigator file.  Co pies of I RB/EC approvals should be 
forwarded to Pfizer.
The only  circumsta nce in which an amendment may  be initiate d prior to IRB/EC ap proval is 
wher e the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the inve stigator must notify  the IRB/EC and Pfizer in writing imme diately  after 
the implementa tion.
12.2. Ethical Condu ct of the Study
The study  willbe co nducted in accordance wi th the protocol, legal and regulatory  
requirements and the general p rinciples set forth in the I nternational Ethical Guideline s for 
Biomedical Resear ch Involvi ng Hum an Subjects (Council for Intern ational Or ganizations of 
Medical Sci ences 2002), ICH Guideli ne for Good Clinical Practice, and the Declaration of 
Helsinki.
12.3. Subj ect Information and Con sent
All parties will comply  with a ll applicable laws, inc luding law s rega rding the implementation 
of org anizationa l and technical me asures t o ensure protection of subject personal data.  Such 
measures will include omitting subject n ames or other directl y identifiable data in an y 
reports, publications, or other disclosures , exce pt where required b y applicable laws. 
The personal data wi llbe stored at the study  site i n encry pted electronic and/or paper form 
and will be password protec ted or secured in a loc ked room to ensure that only  author ized 
study  staff have a ccess.  Th e stud y site will implement appropria te technic al and 
organizatio nal meas ures to ensure that the personal data can be recovered in the event of 
disaster.  In the eve nt of a potential perso nal data breach, the study  site sha ll be responsible 
for d etermining wheth er a persona l data breach has i n fact occ urred and, if so, providin g 
breach notifications as required by  law
To protect the rights and freedoms of natural pers ons with regard to the processing of 
personal data, when study  data are compiled for transf er to Pfizer and other authorized 
parties, subj ect names will be removed and will be replaced by  a single specific numerical 
code based on a numbering s ystem defined by Pfizer.
  All other identifiable data transferred 
to Pf izer or other authorize d parties will b e identified by this single, subject -specific code.
The inves tigato r site w ill maintain a confidential list of subjects who participated in the 
study , linking each subject’s numerica l code to his or her actual identit y.  In case of data 
transfer, Pfizer wi ll maintain high standards of c onfidentia lityand p rotectio n of subjects’ 
personal data con sistent with the Clinical Study  Agreement and applicable privacy  laws.
The informed consent /assent documents and an y subject r ecruitment materials mu st be in 
complia nce with ICH GCP, local regulat ory requir ements, an
d legal requirem ents, including 
applicable privacy  laws.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 96The informed consent/assent documents used during t he informed consent process and an y 
subject recruitment ma terials must be reviewe d and approved b y Pfizer, ap proved b y the 
IRB/EC before u se, and available for inspection.
The investigat or must ensure that each study  subject, or his or her legall y accept able 
representative, or parent(s) or legal guardian if a m inor, is fully  informed about the natur e 
and object ives of the study , the sharin g of data relating to the 
study  and possible risks
associated with participation, including the risks associated with the processing of the 
subject’s personal data. The investi gator further must ensu re that each stu dy subject,[ or his or 
her legal ly accepta ble repres entative , or par ent(s) o r legal guardian if a minor,] is fully  
informed about his or her right to access and correct his or her per sonal data and to withdraw 
consent for the processing of his or her personal data.  
Whenever consent is obtained f rom a subj ect’s le gally acceptable representative/ parent(s) or 
legal guardian, the subject’s assent (affirmative agree ment) must subsequently be obtained 
when the subject has t he capacity  to provide assent, as deter mined by  theIRB/EC.  If the 
investigator determine s that a subject ’s decis ional capacity  is so limited he/she cannot 
reasonabl y be consulted, then, as permitted b y the IRB/EC and co nsistent with local 
regulatory  and legal requirements, the subject’s assen t may  be wai ved with source 
documentation of the re ason ass ent was not obta ined.  If the st udy subject does not provide 
his or her own consent, the source docu ments must record wh y the subject did not provide 
consent (eg, minor, decisionall y impaired adult ), how the i nvestigator determi ned that t he 
person signing th e consent was the subject’s le gally  acceptable representative, the consent 
signer’s relationship t o the study  subject (eg , parent, spouse), and that the sub ject’s assent 
was obtai ned or waived.  If assent is obtained verbally ,it must b e document ed in the source
documen
ts.
If the stud yincludes minor subjects who reach the age of majorit y during the st udy, as 
recognized unde r local law, they  must reconsent as adults to remain in the study .  If the
enrollment of emancipated mino rs is perm itted by  the study age cri teria, t he IRB/EC, and 
local law, they  must provide documentation of legal status to give co nsent without the 
permi ssion of a parent or legal guardian .  
The investigator, o r a person desig nated by  theinvestigator, will obtain wr itten info rmed 
consent fro
m each s ubject or the su bject's legall y acceptable representative, parent(s) or legal 
guardi an and the subject’s assent, when applicable, before an y study-specific activity  is 
performed, un
less a waive r of informed conse nt has bee n granted by  an IRB/EC.  T he 
inves tigator will ret ain the original of each subject's signed consent/assent document.
Precedex is commercially available, however it is not approved for use in pediatri cs.
12.4. Reporting of Safety Issu es and Serious Brea ches of th e Protocol or ICH GCP
In the event of any  prohibit ion or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the inves tigator is aware of any new 
information that might influence the evalu ation of t he benefit s and ri sks of t he inves tigational 
produ ct, Pfizer should be informed immediately .  
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 97In addition, the investigator will inform Pfiz er immediately of an y urgent safet ymeasures 
taken b y the investigator to protect the study  subjects agai nst an y immediate ha zard, and of 
anyserious breaches of thi s protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TR IAL
End of trial in all participating countries is defined as last subject la st visit (LS LV).
14.SPONSOR DISCON TINUATION CRITERIA
Premature termina tion of this study  may  occur because of a regulatory  authority  decision, 
change in opinion o f the IRB/EC, or investigational product safety  problems, or at the 
discretion of Pfizer.  In add
ition, Pfize r retains the right to discontinue development of
inves tigational product at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.   After 
notification, the investiga tor must contact all pa rticipating subj ects and the hospital pha rmacy  
(if applic able) within 7 day s.  As directed by Pfizer, all s tudy materials must be collected and 
all CRFs completed to the great est extent possible.
15.PUBLICATION OF STUDY R
ESULTS
15.1. Communic ation of Results by Pfi zer
Pfizer fulfi lls its comm itment to publicly  disclose c linical trial resu lt s thro ugh post ing the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the Europ ean Clinical Trials 
Database (EudraCT), and/or www.pfizer. com, and other public r egistries in acc ordance with
applicable l ocal l aws/regula tions. 
In all cas es, stud y result s are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner an d are reported regardle ss of the outcome of the study  or the country  in 
which the study  was condu cted.
www.cl inicaltrials. gov
Pfizer posts clinical trial US Basic R esults on www.clinicaltr ials.gov for Pfizer -sponsored 
interventional studies (conducted in p atients) that evaluate the safet y and/or efficacy of a 
Pfizer product, regardless of the geograph ical locatio n in which the stud y is condu cted.  US 
Basic Re sults ar e submit ted for posting within 1 year of the primary  completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
population s.
PCD is define d as the dat e that the fi nal subject was examined or receiv edan interventi on for 
the purposes of final collection of data for the primary  outcome, whether the clinical study  
concluded according to the prespecified protocol or was terminated.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 98EudraCT
Pfize r posts European Union (E U) Bas ic Results on EudraCT for al l Pfizer -sponsor ed 
interventiona l studies that are in scope of EU requirements.  EU Basic Results ar e submitted 
for posting within 1 y ear of the PCD for studi es in adult populations or within 6 months of 
the P CD for studie s in p ediatric p opulations.
www.pf izer.com
Pfizer posts Public Dis closure Synopses (clinical study report synopses in which an y data 
that could be used to id entify  individual patients has been removed) on www.pfizer .com for 
Pfizer -sponsored interventional studie s at the s ame time the US Ba sic Resu lts document is 
posted t o www.clinicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of ac ademic freedom and has no objection to publication by  the 
PIof the result s of the study  based on informa tion colle cted or g enerated by the P I, whether 
or not the results are favorable to the Pfizer product.  However, to ensure again st inadvertent 
disclosure of confidential information or u nprotected inventions, the investigator will provide 
Pfizer an opportu nity to re view an y proposed publica tion or other t ype of disclosure of the 
results of the study  (collectively , “publication”) be fore it is submitted or otherwise disclosed.
The investiga tor will provide any  publi cation to Pfi zer at least 30 day s before it is submitt ed 
for pu blication or othe rwise disclosed.  If any  patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a peri od not to exceed an 
additional 60 day s.
The investigator will, on requ est, remov e any pre viously  undisclosed confidential 
information before disclosure, except for an y study -or Pfizer product -related information 
necessar y to the appropriate scientific pre sentation or understand ingof the study results.
If the stud y is part of a multi center st udy, the investi
gator agrees that the first publication is 
to be a joint publication covering all investigato r sites, and that an y subsequent publications 
by the PI wi ll reference that prima ry publication. However, if a joint manuscript has not 
been submi tted for publicat ion within 12 months of completion or termination of the study  at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this section.
For all publications relating to the study , the i nstitutio n will comply  with recognized ethical 
standards concerning publications and authorship, including Se ction II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requi rements for 
Manuscripts Submitt ed to Biom edical Jo urnals, http://w ww.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 99Publicati on of study  results is also provide d for in the CSA betwee n Pfizer and the
institution.  I n this section entit led Publications by  Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict betw een t his proto col and t he CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CS A will control as to all other 
issues.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 10016.REFERENCES
1. Petroz G C, Sikich N, James M, van Dyk H, Shafer SL, et al. A phase I, two -center 
study of the pha rmacokine tics an dpharmacod ynamics of dexmedetomidine in children. 
Anesthesiology. 12 2006; 105:1098–1110.
2. Potts AL , Anderson BJ, Ho lford NH, Vu TC, Warman GR. Dexmede tomidine 
hemody namics i n children after cardiac surgery . Pediatr Anest h.2010; 20:425 –33.
3. Mason KP , Lerma n J. Dexmedetomidine in Children: Current Knowledge and Future 
Applications. Anesth & Analg. 2011 Nov; 113:1129-1142.
4. Mason KP, Zurakowski D, Zgleszews ki S, Prescilla R, Font aine PJ, Dinardo JA. 
Incidence and predictors o f hyperten sion duri ng high-dose dex medetomidine sedation 
for pediatric MRI. Pediatr Anesth. 2010; 20:516–523.
5. Venn RM, Hell J, G rounds RM. Respiratory  effects of dexmedetomidine in the s urgical 
patient requiri ng intensive car e. Critical Care. 2000 Jul; 4:3 02-30 8.
6. Sandler AN. The role of clo nidine and alpha 2- agonists for postoperative analgesia. Can 
J Anaesth. 1996 Dec; 43(12):1191 -1194.
7. Kamibay ashi T, Ma ze M. Clinical uses of alpha2-adren ergic agonists. Anesthe siology.
2000 Nov; 93(5):1345 -1349.
8. Ebert TJ, H all JE, Ba rney JA, et al. Th e effec ts of increasing plasma concentrations of 
dexmedetomidine in humans. Anesthesiology. 2000 Aug ; 93(2):382-394.
9. Jooste EH, Hammer GB, Reyes CR, Katkade V , Szmuk P. Phase IV, Op en-Label, 
Safety Study  Evaluating the Use of De xmede tomid ine in Pe diatric P atients Undergoing 
Procedure -Type Sedation. Front Pharmacol. 2017; 8:529.
10. Sulton C, McCracken C, Sim on HK, et al. Pediatric Procedural Sedation Using 
Dexmedet omidine: A Report from thePediatric Se dation Research Consortium. 
Hospital Pediatrics. 2016; 6(9) :536-44.
11. Siddappa R, Riggins J, Kariy
anna S, et al. High -dose dexmedetomidine sedation for 
pediatric MRI. Pediatr Anesth. 2011; 21(2):153 -158.
12. Schulte -Uentrop L, Goepfert MS. Anaest hesia or sedatio n for MRI in children. Current 
Opini on in Anaesthe siolog y. 2010; 2
3(4):513 -517.
13. Vilo S, Rautianinen P, Kaisti K et al. Pharmacokinetics of intravenous 
dexmedet omidine in children und er 11 yr of age. Br J Anaesth. 2008; 100(5):697 -700.
14. Farag E,Argalious M, Abd-Elsay ed A, et al. The use of de xmede tomidine in anesth esia 
andintensive care: a review. Current Pharmaceutical Design. 2012;18(38):6257-65.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 10115. Mason KP, Zur akowski D, Zgleszewski SE, et al. High dose dexmedetomidin e as the 
sole sedative forpediatric MR I. Pediatr Anesth. 2008; 18(5): 403-411.
16.
Pestieau S R, Quezado ZMN, J ohnson YJ, et al. High -dose dexmedetomidine increases 
the opioid -free interval and decreases opioid requirement aft er tonsillectomy in 
children. Can J Anesth. 2011; 58(6):540-550.
17. Tirotta C F, Ngu yen T, Fishberger S, et a l. De xmede tomidine use in pa tients undergoing 
electroph ysiological study  for supraventricular tachy arrhy thmias. 
Pediatr Anesth. 2017; 
27(1):45-51.
18. Dego s V, Le charpentier T, Chhor V, et al. Neuroprotective eff ects of dexmedet omidine 
against glutamate agoni st-induced neuronal cell dea th are related to increased astrocy te 
brain -derived neurotrophic factor expression. Anesthesiology . 2013; 118(5):1123 -1132.
19. Janke EL , Samra S. Dexmedetomidine and neuroprotection. Semi nars in Anest hesia, 
Perioperative Medicine a nd Pa
in. 2006; 25(2):71-76.
20. Berkenb osch JW, Wankum PC, Tobias JD. Prospective evaluation of dexmedetomidine 
for noninvasive proc edural sedation in children. Pediatr Crit Care Med . 2005; 6(4):435-
439.
21. Välitalo, PA, Ahtola -Sätilä T, Wighton A, et al. Population pharma cokinetic s of 
dexmedetomi dine in critica lly ill patients. Clin Drug Investig . 2013; 33(8):579-587.
22. Potts, AL , Anderson BJ, Warman GR, et al. Dexmedetomidine pharmacokinetics in
pediatric intensive ca re -a pooled anal ysis. Pediatr Anesth. 2009; 19(11) :1119 -1129.
23. Koroglu A, Teksan H, Sagr O, et a l. A comparison of the sedative, hemodynamic, and 
respiratory  effects of dexme detomidine and propofol in children undergoing magnetic 
resonance imaging. Anesth & Analg. 2006; 103(1): 63 -67.
24. Boriosi JP, Eickhoff JC, K lein KB, Hollman G A. A re trospective com parison of 
propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI 
sedati on. Pediatr Anesth . 2017; 27(1):52 - 59.
25. Precedex™ [Package Insert]. Hospira Inc., Lake Forest, IL; May  2016.
26. Constan
tin JM, M omon A, M antz J, Payen JF, De J onghe B, Perbet S, et al. Efficacy 
and safet y of sedation with dexmedetomidine in critical care patie nts: a meta -analysis of 
randomized controlled trials.  Anaest h Crit Care & Pain Med. 2016; 35(1):7 –15.
27. Cravero JP, Askins N, Sriswasd
i P, et al. Validation of the Pediatric Sedation State 
Scale. Pediatrics. 2017; 139(5): e20162897.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 10228. National High Blood Press ure Education Program Working Group on High Blood 
Pressure inChildren and Adolescents.  The Fourth Repor t on the Diagnosis, Evaluat ion, 
andTreatment of H igh Blood Pressure in Children and Adolescents .  Pediatrics. 2004; 
114: 555-578.
29. Pediatric Vital Sign s Reference Chart. http://www.pedsc ases.com/pediatric- vital-signs-
referen ce-chart; April 2016.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 103Appendix 1. Abbreviat ions 
This following is a l ist of a bbreviations th at may  be used in the protocol.  
Abbreviation Term
AE adverse event
ALT alanine aminotransferase
ANOVA analysis of variance
ASA Ame rican Societ y of Anesth esiologists
AST aspartate aminotransferase
AV atrioventricular
BP bloodpressur e
BPM beats per minu te
CHOP Children’s Hospital of Philadelphia
CK creatine kinase
CNS Central nervous s ystem
CO 2 carbon dioxide
COVID -19 coronavirus disease 2019
CPAP continuous pos itive airway  press ure
CRF case report fo rm
CRL complet eresponse letter
CSA clinical study agreement
CT computed tomogr aphy
CT SAE clinical trial serious adverse event
DBP diastolic blood pressure
DEX dexmedet omidine
DILI drug-induced liver injury
DM diabetes melli tus
DMC data monitorin g committee
DU dispensabl e unit(s)
EC ethics commi ttee
ECG electrocardiogram
ED emergence delirium
E-DMC external data monitoring committee 
EDP exposure during pregnanc y
EEG electroencephalo gram
EEP Efficac y evaluable popula tion
ET End tidal
EtCO2 end-tidal ca rbon dioxid e
EU European Union
Eudr aCT European C linical Trials D atabase
FAS Full anal ysis set
FI Fractional Inspiratory
FIO 2 Fractional Inspiratory  Oxygen
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 104Abbreviation Term
FSH follicle -stimulat ing hormone
GCP Good Clinical Prac tice
GGT Gamma -glutam yl transferase
hCG Human chorionic gonadotropin
HR heart rate
HTN hypertension
ICH International Conference on Harmonisation
IB Investigator brochure
ICU intensive care u nit
ID identification
IEC Independent Ethics Committee
IM intramuscular
IND investigational newdrug ap plication
INR international normalized ratio
IP investig ational product
IRB Institutional Review Board
IRT interactive response technology
IUD intrauterine device
IV intravenous
IWR interactive web re sponse
J-PI Japan Pack age Insert
JPS Japan population set
KG kilogram
LFT liver func tion test
LMA laryngeal mask airwa y
LSLV last subject last visit 
MAP mean arterial pressure
MCG microgram
mIU/mL milli internat ional units per m illiliter
mL milliliter
MM HG millimete rs of mercury
MRI magneti c resonance imaging
N/A not applicabl e
NI-MDS non-intubated, spontaneous breathing, moderate to deep sedati on
N-PASS Neonatal Pain, Agitation and Sedation Scale
O2 oxygen
PACU post-anesthesia care unit
PAED Pediat ric A nesthe sia Emergence Delirium Sca le
PCD primary  completion da te
PD Pharmacodynamics(s)
PE physical exami nation
PI principal investigator
PICC peripherally  inserted (or percutan eous indwelling) centra l catheter
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 105Abbreviation Term
PICU pediatric intensiv e care unit
PK pharmaco kinetic
PO per orum (oral )
PPP Per protocol populatio n
PPS pediatric procedura l sedation
PT prothrombin time
PREA Pediatric Resear ch Equity  Act
PRO propofo l
PSSS Pedia tric Sedation State Sca le
PWR Pediatric Written Request
RR respirator y rate
SAE serious adver se event
SAP statistical analy sis plan
SBP systolicblood pressur e
SD standard deviation
SOP standard operating proce dure
SpO 2 saturation of p eripheral oxy gen
SRSD single refere nce safet ydocument
SubI sub-inves tigator
SUSA R suspected unexpected se rious advers e reaction
TBili total bilir ubin
TEA E treatment -emerg ent adverse eve nt
TTE transthoracic echocardiogram
UGT Uridine 5' -diphospho -glucuronos yltransferase
ULN upper lim it of norm al
UMSS University  of Mi chigan Sedati onScale
US United State s
U/S ultrasound
USPI United States Pac kage Insert
Vd volume of distribution
Vdss Steady -state volume of distribution
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 106Appendix 2.Simulated Pharmacokine tic Profiles of Dexmedetomidine in P ediatric 
Subjects Undergoing Proced ural Se dation
Back ground
The pharmaco kin
etics (PK ) of dexmedetomidine (DEX) ha s been well characterized in adult 
intensive care unit (I CU) patients.  I n adult s, following intravenous ( IV) administr ation, DEX 
exhibits a r apid distr ibution phase with a distribution half -life(t½) of approximate ly 
6minutes; a terminal elimination t ½of appr oximately2 hours; a steady -state v olume of 
distribution (Vd ss) of approxi mately  118 L, and an estim ated clearanc e of approximately  
39 L/hour.  DE X exhibits linear PK in a dults i n the dosag erange of 0.2 to 0. 7 µg/kg/hour
when administered b y IV infusion f or up to 24 hours. DEXundergoes ex tensive hepatic 
metabolism to inactive 
metabolites, with 85% unde rgoing glucur onidation by  
UDP -glucur onyltransf erase (UGT) and 15% b y cytochrom e P450 2A6.
ThePK of DEX has also been characterized in 5 clinical st udies in pediatric populat ion 
mainly  in ICU patients.  Linear PK was observed in these studies within the dosage ranges
(0.2 to 2 µg/kg/hour) 
evaluated.   A population PK (Pop PK ) model has b een d eveloped to 
characte rize the PK and disposition of DEX in ped iatric ICU pati ents.   In this model, a total 
of 1372 plasma DEX concentration re cords from 131 pediatric I CU patients o f age range 
0.01 to 17 years enrolled in 4 studies (Study  DEX -09-08, CH OP st udy, Study DEX - 08-01, 
and Study  DEX -
11-01) were used for the analyses.The final popul ation PK model was a 
2-compartment model with inter in dividual variability  estim ated on clear ance (CL), 
inter-compar tmental cl
earance (Q), volume of th e centr al com partm ent (V c), and volume of
the peripheral compartment (Vp) using expon ential error models, fixed allometr ic exponents 
on the clearance (0.75 for CL and Q) and volume of distribution ( 1.0 for Vc and Vp) 
parameters.  
Limited information is av ailable about the P K of DEX in pediatr ic procedural sedation (PPS) 
patients.  However, ba sed on the known clearance path ways of DEX, the disposition of DEX 
in PPS patients is assumed to be similar t o that in pediatric ICU patients, which seems to be 
suppor ted by  the re porte dPK p arameters of D EX by Vilo et al (2008)13in PPS patie nts 
compared to the PK parameters (CL a nd Vd ss) obtained from ped iatric ICU po pulation PK 
model, as s hown in Ta ble 1 below.  As such, th e PK pr ofiles of DEX in PPS patients a t the 
proposed doses in this study  are si mulate d b
y using the pedia tric ICU popula tion PK model 
(Cognigen Corporation.  P opulation Pharmacokinetic Evaluation of Dexmedetomidine 
Infusion in Mechanically Ventilated Pedia tric Subjects . Jun e 6, 2012, Report on file) .  These 
simulation results are pro vided for information purp oses only .
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 107Table 1. Reported DEX PK Parameters in Pe diatric ICU Patients and P ediatric 
Proc edural Sedation Patient s
Pediatr ic Patients Median Age (years) CL (L/h /kg) V
dss(L/kg)
ICU* 1.31 1.11 2.42
Procedural Sedation130.6 1.04 3.8
4.2 1.04 2.2
Source: *Cognigen Pop-PK model 
Abbreviations: CL =Clearance; DEX =Precedex; ICU =Intensive Care Unit; Vd ss=Volum e of 
Distr ibution at Steady State
Methods
Assumptio ns
Similar PK profil es of DEX between PICU patients and PPS p atient s.
LinearPK of DEX in the dose ran ge from 0.5 to 2.0 µg/kg when administe red vi a 
IV infusion.
Softw are
The PopPK simulations were conducted using the software packages NONMEM, v ersion 7.2
(ICON Development So lutions, Hanover, MD) .  A statistical sof tware package Rversion 
3.2.2 (R Developm ent Core Team) and R studio (RStudio, I nc.) w asused for generati on of 
simulat ion input da tasets, sta tistical a nalysisand creation of simulati on out put g raphs for this 
protocol .  Non -compartmental anal ysis to estim ate th e PK parameters were conducted usin g 
Phoenix WinNonlin, version 6.4 (Certa ra USA , Inc., Princeton, N J).  
Input D atasets
Individual PK parameter a nd demographic informat ion (age, body  weigh tand sex) from the 
pediatric ICU population PK model were us ed as input parameters for the simulation s.  There 
were total 124 pediatric subj ects i n the final ICU popu
lation PK model.  Out of those 
124 s ubjects, 28 subjects were less th an1 month old and w ere thus excluded fr om simulation 
input file.  Age and bod y weight distribution for the remaining 96 subjects based on age 
category  proposed in protocol C0801039 are provided in Ta ble 2 below.  The proposed 
loadin g and maintenance doses f or each age g roup (Table 3 and Table 4 below) were used as 
dose level inputs fo r the simulatio ns employ ing the final ped iatric ICU population PK model. 
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 108Table 2. Demographics of Input D ataset by Age Group
Dem ographics Group-1 (
1 month to < 
2 years)Group -2 (2 to ≤ 12 
years )Group -3 (12 to ≤ 17 
years)
N 42 44 10
Age Range (Years) 0.099 –1.766 2.07 -11.63 12.07 -16.97
Mean Body Weight (Kg) 7.78 19.95 45.63
Body  Weight Range (Kg) 3.15 –13.5 9.98 -61.6 23.59 -72.3
Source: ePharm Artifact ID:14554510
Table 3. Dose levels for Subjects >2years of age
Loading Dose (µg/kg)
Maintenance Infusion Dose 
(µg/kg/hour)
Low dose 0.5 0.5
Middle dose 1.2 1.0
High dose 2.0 1.5
Table 4. Dose level s for Subjects ≥1month to ≤2 years of a ge
Loading Dose ( g/kg) Maint enanc eInfusion Dose 
(g/kg/hour)
Low dose 0.5 0.5
Middle dose 1.0 1.0
High dose 1.5 1.5
Results 
Simulation Output s
The simulated plasma DEX concentration -time profile s for each age group at low , mid and 
high dose levels are presented in Figure 1, Figur e 2, and Figure 3, r espectively .  The PK 
profiles of DEX via either a 5 -
minute or 10- minute loading dose infusion are also graphicall y 
presented side -by-side in the same graph for comparison.  The PK profiles of DEX via 5 min 
and 10 min infu sion are genera lly similar within e achage group at same dose except th at the 
peak levels of DEX are slightly  higher via 5 min loadi ng infusion than that via 10 min 
loading infusion.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 109Figure 1. Simulated Plasma Dexmedetomidine Concentr ation vs Time Profiles in 
Different Age Groups following Low Dose Infusion
Red line : Mean concentration 
Shaded gray area: 90 % confidence interval.
Source data: ePharm Artifact ID: 14067909
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 110Figure 2.Simulated Plasma Dexmedetomidine Concentration vs Time Profiles in 
Different Age Groups following M edium Dose Infusion
Red line : Mean concentration 
Shaded gray area: 90 % confidence interval.
Source data: ePharm Artifact ID: 140 68066
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 111Figure 3. Simulated Plasma Dexmedetomidine Concentration vs Time Profiles in 
Different Age Groups following High Dose Infusion
Red line : Mean c oncentration 
Shaded gray area: 90 % confidence interval.
Source data: ePharm  Artifact ID: 14068080
Simulated PK Paramete rs
PK para meters including area u nder plasma concentration time curve ( AUC) and m aximu m
plasma concentrations (Cmax ) for simulated DEX data were estimated b y noncompartmental 
PK analysis of simulation output.  Summary  of PK parameters for each age group at low, 
medi um and high dose levels are presented in Table 5.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 112Table 5. Dexmedetomid ine P KParameters for Sim ulated Da ta by Dose and Age 
Group
Dose 
LevelAge Group PK Param eters 5 Minute Loading 
Infusion10 Minute Loading 
Infusion
N Mean (SD) N Mean (SD)
Low Dose 1 Month to ≤2 
YearsAUC0-t (ng*h/mL) 42 0.381(0.154) 42 0.352 (0.142)
Cmax(ng/mL) 42 0.453 (0.259) 42 0.408 (0.242)
2 to ≤ 12 Years AUC 0-t (ng*h/mL) 44 0.513 (0.285) 44 0.475 (0.264)
Cmax(ng/mL) 44 0.517 (0.291) 44 0.496 (0.292)
12 to ≤17 Years AUC 0-t (ng*h/mL) 10 0. 621 (0.223) 10 0.574 (0.206)
Cmax(ng/m L) 10 0.603 (0.248) 10 0.595 (0.248)
Medium 
Dose1 Month to ≤2 
YearsAUC 0-t (ng*h/mL) 42 0.761 (0.309) 42 0.704 (0.283)
Cmax(ng/mL) 42 0.906 (0.517) 42 0.816 (0.484)
2 to ≤ 12 Years AUC 0-t (ng*h/mL )44 1.14 ( 0.631) 44 1.05 (0.584)
Cmax(ng/mL) 44 1.22 ( 0.703 ) 44 1.17 (0.711)
12 to ≤17 Years AUC 0-t (ng*h/mL) 10 1.38 (0.491) 10 1.27 (0.454)
Cmax(ng/mL) 10 1.43 (0.607) 10 1.41 (0.614)
High 
Dose1 Month to ≤2 
YearsAUC 0-t (ng*h/mL) 42 1.14 (0. 463) 42 1.06 (0.425)
Cmax(ng/mL) 42 1.36 (0.7 76) 42 1.22 (0.726)
2 to ≤ 12 Years AUC 0-t (ng*h/mL) 44 1.82 (1.01) 44 1.69 (0.932)
Cmax(ng/mL) 44 2.01 (1.18) 44 1.94 (1.20)
12 to ≤17 Years AUC 0-t (ng*h/mL) 10 2.20 (0.783) 10 2.04 (0.724)
Cmax(ng/mL) 10 2.37 (1.02) 10 2.35 (1.04)
Abbreviatio ns: N =Number of subjects; SD =Standard deviation; Cmax =Maximum plasma concentration; 
AUC 0-t=Area under plasma concentration time curve from time zero to time t where t= 1.5 hr.
Source: ePharm Artifact ID:140678 88
PF-00914730
C0801039
Final Protocol Amendment 2, 11 March 2021
PFIZER CONFIDENTIAL
Page 113 
 
 
 
 
 
 CCI
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 114Appendix 4.Modified Aldrete Score
The Modifi ed Aldrete S core is an observational scale allowing verbal prompts.  The total 
score is the sum of all values.
Modified Aldrete Score
ACTIVITY Able to move 4 extremities voluntarily or on command 2
Able to move 2 extremities voluntarily or on comman d 1
Unab le to move extremities voluntarily or on command 0
RESPIRATION Able to breathe deeply and cough freely 2
Dyspnea or limited breathing 1
Apneic 0
CIRCULATION BP ± 20% of pre -anesthetic level 2
BP ± 20% to 49% of pre -anesthetic level 1
BP± 50% of pre-anesthetic level 0
CONSCIOUSNESS Fully awake 2
Arousable on calling 1
Not responding 0
O2SATURATION Able to maintain O 2saturation >92 % on room air 2
Needs O 2inhalation to maintain O 2saturatio n >90% 1
O2saturation <90 % even w ith O2supplem ent 0
Reference: Aldrete JA. The post -anesthesia recovery score revisited. Journal of Clinical Anesthesia. 1995;7:89 -
91
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 115Appendix 5.Pediatric Anesthesia Emergence Delirium Scale (PAED)
The total PAED sco re is the sum of all values.
Behavior Not at 
allJust a 
littleQuite 
a bitVery 
muchExtremely
The child makes ey e contact with the 
caregiv er4 3 2 1 0
The child’s actions are purposeful 4 3 2 1 0
The child is aware of his/her 
surroundings4 3 2 1 0
Thechild is restless 0 1 2 3 4
The child is incon solable 0 1 2 3 4
Reference s: Sikich N, Lerman J. Development and Psychometric Evaluation of the Pediatric Anesthesia 
Emergence Delirium Scale. Anesthesiology 2004; 100:1138 –45and Bajwa S, F anzca D, Cyna A .A 
Comparison of Emergence Delirium Scales Following General Anesthesia in Children. Pediatric
Anesthesia . 2010; 20(8):704-711.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 116Appendix 6. Pediatric Sedation State Scale (PSSS)
State Behavior
5 Patient is moving (pu rposefully or nonpurposefully) in a manner that impedes th e proceduralist and 
requires forceful i mmo biliza tion.  This incl udes crying or shouting during the procedure, but 
vocalization is not required.  Score is based on movement.
4 Moving during the proc edure (aw ake or sedated) that requires gentle i mmobilizati on for 
positioning.  May verbalize some discomfo rt orstress, bu t there is no crying or shouting that 
expresses stress or objection.
3 Expression of pain or anxiety on face (m ay verbalize discomfor t), but not moving or impeding 
completion of th e procedure .  May require help positioning (as wit h alumbar puncture) but does 
not require restraint to stop movement during the procedure.
2 Quiet (asleep or aw ake), not moving during procedure, and no frow n (or brow  furrow) indicating 
pain or anxiety. No verbali zation of any complaint.
1 Deeply asle ep with normalvital sign s, but requiring airway intervention and/or assistance (eg, 
central or obstructive apnea, etc).
0 Sedation associated with abnormal p hysiologic parameters that require acute interv ention (ie,
oxygen saturation <90%, blood pressure is30% l owerthan baseli ne, bradycardia receiving 
therapy).
Reference : Cravero JP, Askins N, Sriswasdi P, et al. Validatio n of the Pediatric Sedation State S cale. 
Pediatrics. 2017; 139(5):e20162897
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 117Appendix 7. HR and RR Centi le Chart Cut -offs for Children from Birth to 18 Year sof 
Age
Source: Fleming S, Thompson M, Stevens R, et al. Normal ranges of HR and RR in children 
from birth to 18 y ears of age: a s ystematic review of observational studies. Lancet.  2011; 
377:1011- 18, We b appendix.

PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 118Appendix 8.Normal Vital Signs Acco rding to Age
    Table 67- 1, Nelson Textbook of Pediatrics
AGE HEART RATE 
(beats/min)BLOOD PRESSURE 
(mm Hg)RESPIRATORY RATE 
(breaths/min)
Premature 120 – 170* 55-75 / 35 - 45† 40-70‡
0-3months 100-150* 65-85 / 45-55 35-55
3-6months 90-120 70-90 /50-65 30-45
6-12 months 80-120 80-100 / 55 -65 25-40
1-3years 70-110 90-105 / 55 -70 20-30
3-6years 65-110 95-110 / 60 -75 20-25
6-12 years 60-95 100-12 0 / 60 -75 14-22
12+ years 55-85 110-135 / 6 5 - 85 12- 18
Source: Nelson Textbook of Pediatrics, 20thEd, 2016
*In sleep, infant heart rates may drop significantly lower, but if perfusion is 
maintained, no intervention is required.
†A blood pressure c uffshould cover approximately two -thirds of the arm; too sma ll a 
cuff yields spuriously high blood pressure readi ngs, and too large a cuff yields 
spuriously low pressure readings.
‡Many premature infants require mechanical ventilatory support, making thei r 
spontaneous respiratory rate less relev ant.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 119Appendix 9. Pr opofol Pre -filled Syringe Medical Device Reportin g inJapa n
Propofol pre -filled s yringe medical device incidents in Japan including those resulting from 
malfunctions of the device, must be detected, docu mente d, and reported b y the investigator to 
the S pons or through out the study .
The detection and docum e
ntation proce dures described in this protocol apply  only to sites in 
Japan using Propofol pre -filled sy ringes in the study .  
The specific reporting proc edure process for medical device incidents will b e provided to the 
sites in Japan under separate cover .
Definitions of a Medical Device Incident
Medical Device Incident Definition
A medical device incident is any  malfunction or deterioration in the charac teristics and/or 
performance of a device as well as any inadequ acy in the labeling or the instructions for
use which , directly  or indirectly , might lead to or m ight have led to the death of a 
participant/user/other person or to a serious deterioration in h is/he r
state of health.
Not all incidents lead to death or seri ous deterioration in health.  The nonoc currence of 
such a result might have been due to other for tunate circumstances or to the intervention 
of healthcare personnel.
It is sufficient that:
Anincident associated with a device happened.
AND
Theincident was such that, if it occurred again, mig ht lead t o dea th or a serious 
deterioration in health.
A serious deterioration in state of health can include an y of the following:
Life-threatening illne ss;
P
ermanent impairment of body  function or permane nt damage to body  structure;
Condition necessitati ng medica l or surgical intervention to prevent one of the above;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
PF-00914730
C0801039
Final Protocol Amendment 2,11March2021
PFIZER CONFIDENTIAL
Page 120Examples of Incide nts
A participant, user, caregiver, or healthc are profess
ional is injured as a result of a 
medic al device failure or its misuse.
A participant’s stud
y intervention is interrupted or compromised by a medical device 
failure.
A misdiagnosis due to medic al device failure leads to inappropriate trea tment.
Aparticipant’s health deteriorates due to medical device f ailure.
Documenting Medical Device Incidents
Medical Device Incident Documentation
Any medical device incident occurring during the study  will be doc umented in the 
participant’s medical records, in accordance with the investigator’s normal clinic al
pract ice.
For medical device incidents meeting the definition of an AE or an SAE, the appropriate 
AE CRF page will be completed. An SAE will also require completion of the CT SAE 
form which will be for warded to Pfizer Safet y as per S ec tion 8.1 of the pro tocol.
All m edical device incidents must be reported to the manufacturer b y the site.
The results from the manufacturer ’s investigation of the medical devic
eincident must 
also be reported to the sponsor as an append ixto the original report , as appropri ate.
It is very  important that the investigator provides his/her assessment of causality  
(relationship to the medical device provided b y the sponsor) at the ti me of the initial AE 
or SAE report and describe s any corrective or remedial actions taken to prev ent 
recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a medical 
device where suc h action is nece ssary  to prevent recurrence of an incident.  This 
includes an y amendment to the device design t o preven
t recurr ence.